{"PMC7152134": [["As mentioned in the previous chapter, owing to the supportive policy environment, export-oriented FDI as an important source of private capital has been, to a great extent, contributing to the growth of Chinese manufacturing.", [["Chinese manufacturing", "TREATMENT", 203, 224], ["great extent", "OBSERVATION_MODIFIER", 159, 171]]], ["A large number of FDI projects built production hubs for export, helping increase employment of migrant workers and poverty reduction in coastal cities in China.Manufacturing FDI and China's Economic Growth ::: IntroductionHowever, evidence indicates that FDI into China has started to shift preference from manufacturing to service sectors after the exchange rate of US dollar to RMB became lower than seven, as this implies squeezed profit margins in manufacturing and the booming growth of consumption in service industries in local markets.", [["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["As shown in Fig. 3.1, the 2008 global financial crisis further accelerated this trend.", [["global financial crisis", "PROBLEM", 31, 54]]], ["As addressed in Chapter 1, while manufacturers in China have been facing unfavourable conditions, some FIEs conducted upgrading strategies to transform themselves from traditional \u2018sweatshops\u2019 to modern innovation-oriented production bases for higher economic returns.Manufacturing FDI and China's Economic Growth ::: IntroductionNevertheless, given a variety of inherent risks hiding in global value chain (GVC) upgrading, DE firms may not be able to ensure the success of implementing upgrading strategies despite generally being equipped with more sophisticated technology than local firms.", [["unfavourable conditions", "PROBLEM", 73, 96], ["upgrading strategies", "TREATMENT", 487, 507]]], ["This chapter therefore introduces two diverse cases of studies depicting how foreign-invested manufacturers carried out upgrading strategies in China.", [["studies", "TEST", 55, 62]]], ["The first case incorporates the \u2018Dynamic Capabilities\u2019 perspective (Teece, Pisano, & Shuen, 1997) into the GVC framework, demonstrating how two Singapore-invested OEMs successfully upgraded along the GVC.", [["OEMs", "CANCER", 163, 167], ["GVC", "CANCER", 200, 203]]], ["The second case delineates how a British entrepreneurial OEM suffered a great failure in the Chinese context.Introduction ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaExports are commonly viewed as the main driver of China's economic growth over the past three decades (Gao, Murray, Kotabe, & Lu, 2010).", [["a great failure", "PROBLEM", 70, 85], ["great", "OBSERVATION_MODIFIER", 72, 77], ["failure", "OBSERVATION", 78, 85]]], ["The increasing inflow of FDI is responsible for the majority of China's exports (Wielemaker & Gedajlovic, 2011), promoting its annual GDP and enabling it to become the world's second largest economy in 2010.", [["GDP", "CHEMICAL", 134, 137], ["GDP", "SIMPLE_CHEMICAL", 134, 137], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["inflow", "OBSERVATION", 15, 21], ["responsible for", "UNCERTAINTY", 32, 47]]], ["In terms of the industrial distribution of FDI, about 50% of FDI went into manufacturing sectors since the 1990s, particularly into OEM (National Bureau of Statistics of China, 2012).", [["industrial distribution", "OBSERVATION", 16, 39]]], ["Following the emergence of GVCs (Gereffi et al., 2005), these foreign-invested OEMs capitalized on China's abundant supply of low-wage labour to manufacture products for developed-country buyers.Introduction ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaHowever, China has seen annual wage increases and a 23% appreciation of the currency over the past 5 years and the trend looks set to continue for the next 5 years.", [["GVCs", "PATHOLOGICAL_FORMATION", 27, 31], ["foreign", "OBSERVATION", 62, 69]]], ["The low-cost advantages of FDI OEMs are disappearing and exports may not be sufficient for these firms to remain financially successful in the future.", [["low", "OBSERVATION_MODIFIER", 4, 7]]], ["If well-implemented, functional upgrading enables OEM firms to overcome the unequal distribution of profits by engaging in more value-added activities (Humphrey & Schmitz, 2004).Introduction ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaSince China became the largest consumer market for autos, television sets, and cell phones and the second largest for luxury goods during the worldwide recession, its growing domestic market thus symbolizes one bright point on the horizon for OEMs to implement this upgrading strategy for value creation.", [["cell", "ANATOMY", 325, 329], ["cell", "CELL", 325, 329], ["this upgrading strategy", "TREATMENT", 507, 530]]], ["However, the Chinese mass market demonstrates remarkable heterogeneity and is expected to morph into differentiated and multitiered segments over the next 10 years.", [["remarkable heterogeneity", "PROBLEM", 46, 70], ["mass", "OBSERVATION", 21, 25], ["remarkable", "OBSERVATION_MODIFIER", 46, 56], ["heterogeneity", "OBSERVATION", 57, 70], ["differentiated", "OBSERVATION_MODIFIER", 101, 115], ["multitiered", "OBSERVATION_MODIFIER", 120, 131], ["segments", "OBSERVATION_MODIFIER", 132, 140]]], ["China's domestic market is actually a conglomeration of separate regional markets protected by provincial barriers and segmented by a variety of economic and industrial factors (Tse, 2010).", [["regional", "OBSERVATION_MODIFIER", 65, 73], ["markets", "OBSERVATION", 74, 81], ["variety", "OBSERVATION_MODIFIER", 134, 141]]], ["Therefore, this multimarket conception inevitably raises problems for foreign investors to compete in China's huge but disordered domestic market.", [["domestic market", "OBSERVATION", 130, 145]]], ["As far as the FDI OEMs go, the prominent question is: what are the specific capabilities these OEMs require for changing to adapt to the dynamic Chinese market and uncertainties?Introduction ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaConsidering the foregoing arguments, this chapter incorporates the dynamic capabilities perspective (Teece et al., 1997) into the GVC framework and centres its analysis on the premise that manufacturers must invest to build necessary organizational capabilities to ensure success of functional upgrade along the GVC.", [["GVC", "CANCER", 558, 561], ["prominent", "OBSERVATION_MODIFIER", 31, 40]]], ["Despite numerous studies investigating the value creation of FDI firms in emerging economies (EEs) (Horng & Chen, 2008; Li, Wei, & Liu, 2010; Lin & Hou, 2010; Liu, Wang, & Wei, 2009), there is a dearth of reliable and timely studies focusing on the key value creation processes of functional upgrading by foreign-invested OEMs in China.", [["numerous studies", "TEST", 8, 24], ["functional upgrading", "OBSERVATION", 281, 301]]], ["To fill this research gap, we use a multiple-case study to address the functional upgrading trajectory by FDI OEMs in the Chinese context.Introduction ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaAdditionally, since functional upgrading involves high risks associated with system-wide changes and there is no guarantee of success, the vision and persistency of top leadership is vital for pursuing functional upgrading.", [["a multiple-case study", "TEST", 34, 55], ["no", "UNCERTAINTY", 316, 318]]], ["Then we employ a multiple-case study with a pattern-matching analysis investigating two Singapore-invested OEMs to examine the assumed model.", [["Singapore-invested OEMs", "CELL_LINE", 88, 111], ["a multiple-case study", "TEST", 15, 36]]], ["This study makes three unique contributions.", [["This study", "TEST", 0, 10]]], ["First, it presents the evolutionary upgrading strategies of FDI OEMs in China in the face of the new global economy.", [["face", "ANATOMY_MODIFIER", 85, 89], ["new", "OBSERVATION_MODIFIER", 97, 100], ["global", "OBSERVATION_MODIFIER", 101, 107], ["economy", "OBSERVATION", 108, 115]]], ["Further, conducting in-depth interviews with top management in both parent companies in Singapore and their subsidiaries in China, this research responds to a recent call for collecting first-hand timely data to investigate FDI issues in EEs (Lau & Bruton, 2008).", [["top management", "TREATMENT", 45, 59], ["FDI issues", "PROBLEM", 224, 234]]], ["Finally, the results offer fresh and critical insights into the practical implications for FDI OEMs to grow and prosper in the Chinese market.Functional Upgrading ::: Theoretical Foundations ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaGlobalization has given many OEM firms in developing countries opportunities to participate in international markets by targeting external markets to gain economies of scale and scope, as well as further technological expertise (Kaplinsky, Readman, & Memedovic, 2009).", [["ChinaGlobalization", "CHEMICAL", 241, 259], ["scope", "TEST", 424, 429]]], ["This phenomenon is characterized by the concept of the GVC (Gereffi et al., 2005; Humphrey & Schmitz, 2004; Morrison et al., 2008).", [["GVC", "DISEASE", 55, 58]]], ["Drawing on the GVC system to coordinate global production and distribution, DE exporters are able to manufacture products based on designs supplied by international buyers or just produce small parts of final products.", [["global", "OBSERVATION_MODIFIER", 40, 46], ["production", "OBSERVATION", 47, 57], ["distribution", "OBSERVATION_MODIFIER", 62, 74], ["small", "OBSERVATION_MODIFIER", 188, 193]]], ["This GVC approach has provided a primary path for Chinese manufacturers to initiate international businesses via offering OEM services to large MNCs and foreign buyers since the reform and opening-up policy over 30 years ago (Li, Wei, et al., 2010; Lin & Hou, 2010).", [["MNCs", "ANATOMY", 144, 148], ["MNCs", "CELL", 144, 148], ["MNCs", "CELL_TYPE", 144, 148], ["large MNCs", "PROBLEM", 138, 148], ["foreign buyers", "OBSERVATION", 153, 167]]], ["The GVC view reveals not only a holistic map of the global production network and market, but also a comprehensive and integrated approach explaining industrial development and innovation in emerging countries (Morrison et al., 2008).", [["The GVC view", "TEST", 0, 12]]], ["Echoing this, an increasing number of OEM manufacturers have augmented per-unit value of products by carrying out functional upgrading to shift their business functions from competing on low cost production to competing on innovation pertaining to design and marketing activities in GVCs.", [["GVCs", "CANCER", 283, 287], ["increasing", "OBSERVATION_MODIFIER", 17, 27], ["number", "OBSERVATION_MODIFIER", 28, 34]]], ["It is because functional upgrading changes the mix of activities within and between links in the GVC that can be used as an effective means to transform production organizations to design, marketing, and branding corporations.", [["GVC", "CANCER", 97, 100]]], ["More specifically, research highlights the hierarchy mechanism of functional upgrading in which developing country firms transform from original equipment assembling under contract to global buyers to OEM (producing goods under a buyer's name), to ODM (involving design activities), to OBM (producing own brand products and participating in marketing activities) (Gereffi et al., 2005; Humphrey & Schmitz, 2004).Functional Upgrading ::: Theoretical Foundations ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaAs far as China is concerned, evidence shows that many OEMs, including both local and FIEs, have followed the path of functional upgrading, successfully upgrading to OBM status, such as Taiwan's Acer and China's TCL and Lenovo (Lin & Hou, 2010).", [["Taiwan's Acer", "TREATMENT", 702, 715]]], ["Despite the successful precedents, some large manufacturers in China may still choose to continuously provide OEM services to overseas clients after upgrading to OBM as mature market buyers are usually profitable and reliable clients.", [["large", "OBSERVATION_MODIFIER", 40, 45], ["manufacturers", "OBSERVATION", 46, 59]]], ["Through strategic cooperation, OEMs could rapidly learn about international technology, practices, and standards from advanced economy MNCs (Horng & Chen, 2008; Liu et al., 2009).", [["MNCs", "ANATOMY", 135, 139], ["MNCs", "CELL", 135, 139], ["MNCs", "CELL_TYPE", 135, 139]]], ["In this sense, knowledge and technology transfers between OEMs and their developed country clients are of great importance to facilitating their functional upgrading.Dynamic Capabilities and Functional Upgrading ::: Theoretical Foundations ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaIn terms of competitive advantage, the resource-based view (RBV) states that a firm's competitive advantage is based on ability to leverage its valuable resources (Barney, 1991).", [["a firm's competitive advantage", "PROBLEM", 372, 402]]], ["Linking resources to capabilities, Makadok (2001) defines a capability as an organizationally embedded, nontransferable firm-specific resource whose purpose is to improve the productivity of the other resources possessed by the firm.", [["firm", "OBSERVATION", 228, 232]]], ["In terms of an organization, the internal capabilities, combined with external partnerships, are seen as a flexible innovation system (Su, Peng, Shen, & Xiao, 2012).Dynamic Capabilities and Functional Upgrading ::: Theoretical Foundations ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaOriginating from RBV, dynamic capabilities are the \u2018abilities to integrate, build, and reconfigure internal and external competences to develop new resources and capabilities\u2019 (Teece et al., 1997: p.", [["RBV", "CHEMICAL", 311, 314], ["RBV", "TREATMENT", 311, 314], ["organization", "OBSERVATION", 15, 27], ["internal", "OBSERVATION_MODIFIER", 33, 41], ["capabilities", "OBSERVATION_MODIFIER", 42, 54]]], ["Dynamic capabilities thus reflect a firm's ability to achieve new and innovative forms of competitive advantage, reconfiguring its capabilities according to its environmental changes (Malik & Kotabe, 2009; Su et al., 2012; Teece et al., 1997).", [["a firm's ability", "PROBLEM", 34, 50]]], ["An organizational capability refers to the set of activities performed by the firm which produces outputs that determine its survival and prosperity within its current strategic setting; such outputs will not change the strategic direction of the firm (Sun & Anderson, 2010).", [["organizational capability", "OBSERVATION", 3, 28], ["firm", "OBSERVATION", 78, 82], ["firm", "OBSERVATION_MODIFIER", 247, 251]]], ["In contrast, an organization's dynamic capability should reflect its ability to build new and unique capabilities that help identify new opportunities under turbulent conditions and make strategic responses to situational changes more quickly (Weerawardena, Sullivan Mort, Liesch, & Knight, 2007).", [["an organization's dynamic capability", "PROBLEM", 13, 49]]], ["In other words, a strategic set of dynamic capabilities does not accrue from the firm, but is built consciously and systematically by the leader's wilful decision-making and actions.", [["firm", "OBSERVATION", 81, 85]]], ["Following this logic, scholars argue that corporate profitability may not be sustained by the control over the market (e.g. by using quasimonopolistic practices), but rather by the development of dynamic capabilities to adapt to changing external networks and global situations (Kaplinsky et al., 2009).", [["external networks", "MULTI-TISSUE_STRUCTURE", 238, 255]]], ["Viewed from this angle, the dynamic capabilities theory is indeed closely related to the concept of the GVC analytical framework.Dynamic Capabilities and Functional Upgrading ::: Theoretical Foundations ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaConsidering the foregoing discussion, our research focuses on discussing the mechanisms between the dynamic capabilities possessed by OEMs and the implementation of functional upgrading.", [["functional upgrading", "TREATMENT", 423, 443]]], ["Both acquisitions and access are dynamic in nature because a shift towards an upper specification/function represents a shift in strategic direction.", [["a shift", "PROBLEM", 59, 66], ["a shift in strategic direction", "PROBLEM", 118, 148], ["dynamic", "OBSERVATION", 33, 40], ["upper", "ANATOMY_MODIFIER", 78, 83], ["shift", "OBSERVATION", 120, 125]]], ["Following this logic, functional upgrading can be seen as a competitive and innovative strategy that requires OEMs to develop bundles of capabilities that help them to overcome the barriers and difficulties in crossing different functions and ultimately increasing economic performance.", [["difficulties in crossing different functions", "PROBLEM", 194, 238], ["increasing", "OBSERVATION_MODIFIER", 254, 264]]], ["Taken together, we assume that to ensure successful functional upgrading, firms must possess certain dynamic capabilities that help them react agilely to the uncertainties and complexities in today's world.Manufacturing Capabilities ::: Conceptual Framework for Pattern Analysis ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaThese are a significant facilitator for functional upgrading (Chin et al., 2016; Chin, Tsai, et al., 2016).", [["Chin", "ANATOMY", 415, 419]]], ["In the beginning, when collaborating with large MNCs in a developed country, OEMs typically manufacture simple products and are weak in high-end production processes.", [["MNCs", "ANATOMY", 48, 52], ["MNCs", "CELL", 48, 52], ["MNCs", "CELL_TYPE", 48, 52], ["weak in high-end production processes", "PROBLEM", 128, 165], ["large", "OBSERVATION_MODIFIER", 42, 47], ["MNCs", "OBSERVATION", 48, 52], ["weak", "OBSERVATION_MODIFIER", 128, 132]]], ["However, in order to survive, OEMs must have a broader range of manufacturing functions at their disposal to meet the dynamic requirements of the outsourcers from mature markets (Chin et al., 2016; Chin, Tsai, et al., 2016; Lin & Hou, 2010).", [["Chin", "ANATOMY", 198, 202]]], ["For instance, lean manufacturing methods have been widely implemented to increase operation efficiency and manufacturing flexibility (Malik & Kotabe, 2009).", [["lean manufacturing methods", "TREATMENT", 14, 40], ["increase operation efficiency", "TREATMENT", 73, 102]]], ["Hence, the evolution of manufacturing capabilities by OEMs, ranging from varying product mixes and production volumes to reducing manufacturing process inventories, is expected.Technological Capabilities ::: Conceptual Framework for Pattern Analysis ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaThese pertain to the intensity of R&D and innovation and are widely viewed as critical strategic assets, whereby firms can create the competitive advantages that determine the success of upgrading by OEMs (Morrison et al., 2008; Su et al., 2012).", [["OEMs", "TEST", 54, 58], ["production volumes", "PROBLEM", 99, 117], ["manufacturing capabilities", "OBSERVATION", 24, 50], ["varying", "OBSERVATION_MODIFIER", 73, 80], ["product mixes", "OBSERVATION", 81, 94], ["production", "OBSERVATION_MODIFIER", 99, 109], ["volumes", "OBSERVATION_MODIFIER", 110, 117], ["manufacturing process", "OBSERVATION", 130, 151]]], ["Technological capabilities are not easy to develop or even to imitate because they are embedded in a firm's operation and, to a certain extent, influence its internal mechanisms (Barney, 1991).", [["a firm's operation", "TREATMENT", 99, 117]]], ["By providing manufacturing and assembly services to advanced economy MNCs, OEMs get abundant learning opportunities for acquiring advanced technical and R&D skills to build technological capabilities, including up-to-date technology and the unique capacity to appropriate, adapt, and transform secondary technology (Liu et al., 2009).", [["MNCs", "ANATOMY", 69, 73], ["MNCs", "CELL", 69, 73], ["advanced economy MNCs", "CELL_TYPE", 52, 73], ["advanced economy MNCs", "TREATMENT", 52, 73]]], ["This reflects the prominent dynamic characteristic in terms of building technological capabilities as the development of such capacity has to cater to the latest need of fast-changing global markets.", [["such capacity", "PROBLEM", 121, 134], ["prominent", "OBSERVATION_MODIFIER", 18, 27], ["dynamic characteristic", "OBSERVATION_MODIFIER", 28, 50]]], ["\u2018Learning from outsourcers\u2019 can be regarded as a vital catalyst that facilitates OEMs to upgrade from low-end to more value-added status along the GVC.", [["GVC", "CANCER", 147, 150], ["a vital catalyst", "TREATMENT", 47, 63]]], ["Accordingly, absorptive capabilities that represent a firm's ability to utilize external knowledge through the sequential processes of exploratory, transformative, and exploitative learning (Sun & Anderson, 2010) are is of great importance in functional upgrading.Leadership in Functional Upgrading ::: Conceptual Framework for Pattern Analysis ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaLeadership is a strategic construct that reflects the extent to which managers are innovative, proactive, and risk-taking in their behaviour and management philosophies (Miller, 1983).", [["absorptive capabilities", "TEST", 13, 36], ["a firm's ability", "PROBLEM", 52, 68], ["firm", "OBSERVATION", 54, 58]]], ["Leadership is especially important for functional upgrading because upgrading is a high-risk endeavour and there is no guarantee of success.", [["no guarantee", "UNCERTAINTY", 116, 128]]], ["In this vein, effective leadership (see Rowley & Ulrich, 2014 for an overview) activities that influence a group of individuals to move towards a common goal play a critical role in driving and propelling the whole organization to accomplish functional upgrading.Leadership in Functional Upgrading ::: Conceptual Framework for Pattern Analysis ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaBy incorporating the arguments above, we develop the logic linking the dynamic capability mechanism to the strategy of functional upgrading and a conceptual framework.", [["vein", "ANATOMY", 8, 12], ["vein", "MULTI-TISSUE_STRUCTURE", 8, 12], ["vein", "ANATOMY", 8, 12]]], ["This is set out in Fig. 3.2.Sample Selection ::: Methodology ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaIn case study research, sample selection is one of the most difficult procedures (Yin, 2003) because the research samples have to be specific and representative of all cases.", [["samples", "CANCER", 230, 237], ["the research samples", "TEST", 217, 237]]], ["This Southern province of nine large cities with proximity to Hong Kong has attracted many foreign firms engaging in assembling and manufacturing for world leading MNCs since the 1980s, producing large economic growth rates for more than two decades and importance nationally.", [["MNCs", "ANATOMY", 164, 168], ["MNCs", "CELL", 164, 168], ["MNCs", "CELL_TYPE", 164, 168], ["large economic growth rates", "PROBLEM", 196, 223], ["large", "OBSERVATION_MODIFIER", 31, 36], ["foreign firms", "OBSERVATION", 91, 104], ["large", "OBSERVATION_MODIFIER", 196, 201]]], ["For example, in 2008 the export volume of processing trade in Guangdong province accounted for nearly two-thirds (64.6%) of China's total exports.Sample Selection ::: Methodology ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaThe choice of Singapore-invested OEMs was due to the following reasons.", [["OEMs", "DISEASE", 267, 271], ["volume", "OBSERVATION_MODIFIER", 32, 38]]], ["Manufacturing contributes significantly to Singapore's economic growth, accounting for about one-third of the country's annual GDP.", [["GDP", "CHEMICAL", 127, 130], ["GDP", "CHEMICAL", 127, 130], ["GDP", "SIMPLE_CHEMICAL", 127, 130]]], ["Taken together, these points make Singapore-invested OEMs suitable samples for this research.Sample Selection ::: Methodology ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaThe criteria for selecting the case OEMs in our study were: (1) the firms located in China are Singapore direct investment companies/subsidiaries; (2) they are subcontracted by large developed country MNCs to manufacture components or parts of final products for them; (3) their names are anonymous in the final products market as there are only brand labels on packaging; (4) they went through functional upgrading processes; (5) they are leading manufacturers in their respective industries.", [["samples", "ANATOMY", 67, 74], ["MNCs", "ANATOMY", 382, 386], ["MNCs", "CELL", 382, 386], ["MNCs", "CELL_TYPE", 382, 386], ["large", "OBSERVATION_MODIFIER", 358, 363]]], ["This selection procedure resulted in identification of the following two cases: Company A (listed on the SGX2), headquartered in Singapore, a leading MNC providing a full spectrum of high value-added, integrated turnkey manufacturing services in the electronics industry (Case #1) and Company B (listed on the SGX), headquartered in Singapore, a famous global company producing and assembling precision-machined components used in auto and machinery industries (Case #2).Data Sources and Informants ::: Methodology ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaData were collected from three sources: (1) face-to-face and phone interviews with their president/CEO; (2) interviews with managers of different departments in the same company; (3) secondary sources: internal documents provided by the companies, information on company websites, product and firm brochures, as well as newspaper articles, journal articles, research papers, and informal observations.", [["MNC", "ANATOMY", 150, 153], ["MNC", "CELL", 150, 153], ["MNC", "CELL_TYPE", 150, 153], ["This selection procedure", "TREATMENT", 0, 24]]], ["Respondents were the president/CEO/COO, manufacturing managers, R&D manager/senior engineers, CFO/financial manager, and marketing managers.Data Collection Methods ::: Methodology ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaTo obtain robust data, a triangulation approach was utilized at the collection stage to ensure that different sources were used when gathering data from each firm.", [["a triangulation approach", "TREATMENT", 258, 282], ["firm", "OBSERVATION", 393, 397]]], ["The triangulation of data collection, including interview records, internal reports, archival data, and literature, can reveal the conditions of enterprises to a maximum extent.", [["archival data", "TEST", 85, 98], ["maximum extent", "OBSERVATION_MODIFIER", 162, 176]]], ["For instance, participants were requested to try their best to provide evidence objectively.", [["participants", "SPECIES", 14, 26]]], ["Interviews were tape-recorded at the same time to avoid omitting information and enhance corroborating evidence.", [["tape", "TEST", 16, 20]]], ["Since both firms are listed companies, a wide range of archival records, such as their annual reports and other public statements, were used as supplements.", [["firms", "OBSERVATION_MODIFIER", 11, 16]]], ["Finally, information and data collected from diverse sources were cross-checked to ensure accuracy and reliability.Empirical Findings ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaThe findings of our case-based empirical analysis are presented as follows.", [["empirical analysis", "TEST", 220, 238]]], ["Next, each firm's implementation and outcomes of functional upgrading are demonstrated.", [["each firm's implementation", "TREATMENT", 6, 32], ["functional upgrading", "TREATMENT", 49, 69], ["firm", "OBSERVATION_MODIFIER", 11, 15]]], ["Finally, the pattern-matching approach is applied to further examine the hypothetical conceptual framework, as displayed in Table 3.1.Case #1 ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaCompany A, founded in 1984, is a well-known contract manufacturer producing a wide range of high-mix, high-value, and complex electronic products for global leading MNCs, such as IBM and HP.", [["MNCs", "ANATOMY", 362, 366], ["MNCs", "CELL", 362, 366], ["MNCs", "CELL_TYPE", 362, 366], ["complex electronic products", "TREATMENT", 315, 342], ["global leading MNCs", "PROBLEM", 347, 366], ["IBM", "PROBLEM", 376, 379], ["HP", "PROBLEM", 384, 386]]], ["In 1990, Company A first established two plants in Shanghai bonded areas (i.e. the government-appointed tariff-free areas) following the trend of FDI inflow into China in the 1990s and merely offered OEM services for electronic products to global leading companies.", [["electronic products", "TREATMENT", 217, 236]]], ["This company advanced to the next level of the GVC later, namely providing ODM for foreign buyers.", [["GVC", "CANCER", 47, 50]]], ["Exploiting a broad range of low-cost advantages, including labour, operations, and land rent, the group augmented its revenue very quickly and thus went public on the SGX in 2002.", [["low-cost advantages", "TREATMENT", 28, 47], ["operations", "TREATMENT", 67, 77], ["land rent", "TREATMENT", 83, 92], ["broad", "OBSERVATION_MODIFIER", 13, 18], ["low", "OBSERVATION_MODIFIER", 28, 31]]], ["Since then, the firm has put more emphasis on developing technological capabilities, such as engaging in a variety of R&D activities and building a world-class R&D team.", [["firm", "OBSERVATION", 16, 20]]], ["In the pursuit of incorporating design and technology, the firm obtained critical know-how and intellectual property with domain expertise in printing, imaging, instrumentation, radio frequency communication, networking, and data storage used in the electronics industry.", [["imaging", "TEST", 152, 159], ["instrumentation", "TREATMENT", 161, 176]]], ["Through leveraging and reconfiguring existing and new technologies, the firm generated dynamic technological capabilities and made significant strides in providing ODM solutions.", [["ODM solutions", "TREATMENT", 164, 177], ["firm", "OBSERVATION_MODIFIER", 72, 76]]], ["Moreover, the firm continued to improve its customers\u2019 point-of-sale (POS) products, ranging from updating designs to delivering an exceptional combination of reliability and energy efficiency.", [["firm", "OBSERVATION_MODIFIER", 14, 18], ["energy efficiency", "OBSERVATION", 175, 192]]], ["This enables it to be a primary turnkey supplier, as well as strategic partner to manufacture cash registers for IBM.", [["IBM", "PROBLEM", 113, 116]]], ["In addition, Company A's technological capabilities are also supported by its effective enterprise resource planning (ERP) system that facilitates information flow and provides an IT infrastructure linking it with its business partners all over the world in a real-time basis.Case #1 ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaAs far as manufacturing capabilities are concerned, this firm continually strengthens its manufacturing capabilities to meet global leading MNCs\u2019 latest requirements.", [["MNCs", "ANATOMY", 479, 483], ["MNCs", "CELL", 479, 483], ["MNCs", "CELL_TYPE", 479, 483]]], ["The constant evolution and improvement of manufacturing capabilities allows Company A to adapt rapidly to sharp fluctuations and declines in demand in advanced economies after the 2008 global financial crisis.", [["sharp fluctuations", "PROBLEM", 106, 124], ["constant", "OBSERVATION_MODIFIER", 4, 12], ["evolution", "OBSERVATION_MODIFIER", 13, 22], ["improvement", "OBSERVATION_MODIFIER", 27, 38], ["financial crisis", "OBSERVATION", 192, 208]]], ["More specifically, Company A is highly proficient and cost-effective in manufacturing both high-volume and low-volume yet high-mix, more complex products.", [["more complex", "OBSERVATION_MODIFIER", 132, 144]]], ["To make sure that it had the necessary manufacturing capabilities for the upgrade, the firm established a comprehensive quality control system to meet the requirements of international standards such as ISO 9001:2008, ISO 13485: 2003, ISO 14001:2004, the ODS (Ozone-Depleting Substances), and RoHS (restriction of hazardous substance).Case #1 ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaIn terms of absorptive capabilities, Company A always looks at commercial relationships as mutually beneficial partnerships and encourages a corporate culture of learning from their strategic partners, particularly from global leading electronic firms.", [["ISO 13485", "CHEMICAL", 218, 227], ["ISO 14001:2004", "CHEMICAL", 235, 249], ["Ozone", "CHEMICAL", 260, 265], ["RoHS", "CHEMICAL", 293, 297], ["Ozone", "CHEMICAL", 260, 265], ["Ozone", "SIMPLE_CHEMICAL", 260, 265], ["ISO", "TEST", 218, 221], ["ISO", "TEST", 235, 238], ["the ODS", "TEST", 251, 258], ["a corporate culture", "TEST", 537, 556], ["firm", "OBSERVATION_MODIFIER", 87, 91]]], ["For example, top management supports job rotation and enrichment and provides professional training, as well as a wide range of opportunities for employees to acquire, assimilate, and acquire knowledge from their colleagues and business partners.", [["top management", "TREATMENT", 13, 27], ["professional training", "TREATMENT", 78, 99]]], ["The top management team places great premium on talent and innovation, such as attracting experts with special skills to the company's board, hiring outside professional managers with expertise and experience, and adjusting the salary structure of core personnel.", [["top", "OBSERVATION_MODIFIER", 4, 7], ["great", "OBSERVATION_MODIFIER", 31, 36], ["premium", "OBSERVATION_MODIFIER", 37, 44]]], ["In the transformation process of upgrading from OEM to ODM status, the top management team withstood uncertainties and showed high flexibility and adaptability to external changes, which enabled the company to survive the 2008 global financial crisis and seize emerging market opportunities.", [["high flexibility", "PROBLEM", 126, 142], ["high flexibility", "OBSERVATION_MODIFIER", 126, 142]]], ["Overall, this study illustrates the significance of critical dynamic capabilities in executing the strategy of functional upgrading and highlights the significance of leadership in guiding the upgrading process.", [["this study", "TEST", 9, 19]]], ["Given that the capabilities are dynamic, management should not wait until they are in place before initiating the upgrade.", [["management", "TREATMENT", 41, 51]]], ["Instead, they can adopt the approach of building the necessary capabilities from the inception or during the process of upgrading.Discussion ::: Case #2 ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaOur study makes three unique contributions.", [["ChinaOur study", "TEST", 203, 217]]], ["More specifically, our study explores how Singapore-invested OEMs exploit the dynamic capabilities developed via collaboration with global leading MNCs to implement functional upgrading, whereby they further cultivate China's huge domestic market.", [["MNCs", "ANATOMY", 147, 151], ["MNCs", "CELL", 147, 151], ["MNCs", "CELL_TYPE", 147, 151], ["our study", "TEST", 19, 28]]], ["Second, since in-depth interviews with top management were conducted in both parent companies in Singapore and their subsidiaries in China, our study echoes the appeal for collecting more timely, first-hand data, including raw and informal forms, by which we can better capture reality (Lau & Bruton, 2008).", [["top management", "TREATMENT", 39, 53], ["our study echoes", "TEST", 140, 156]]], ["Third, on the basis of documenting functional upgrading, our study presents a context-specific dynamic capability mechanism by foreign-invested OEM firms in China, responding to calls for the investigation of dynamic capabilities in specific contexts (Weerawardena et al., 2007).Discussion ::: Case #2 ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaOur findings also provide insightful managerial implications for FDI OEMs operating in China, perhaps helping them to grow further and prosper.", [["our study", "TEST", 57, 66]]], ["Evidence reveals that creating own brands is likely to cause animosity from main buyers and GVC leaders towards their OEM suppliers (Morrison et al., 2008) because OEMs may leapfrog them to compete against their initial outsourcers in international arenas after developing sufficient capabilities (Matthews, 2006).", [["animosity", "PROBLEM", 61, 70], ["likely to cause", "UNCERTAINTY", 45, 60]]], ["Despite this, a large number of Chinese manufacturers still view OEM partnerships with global brands as a springboard to learn about creating own brands (Chin et al., 2016; Chin, Tsai, et al., 2016).", [["Chinese manufacturers", "TREATMENT", 32, 53], ["large", "OBSERVATION_MODIFIER", 16, 21], ["Chin", "ANATOMY", 173, 177]]], ["As such, Singapore OEMs usually endeavour to upgrade to ODM status, but hesitate to proceed to upgrade to OBM status.", [["OBM", "CANCER", 106, 109]]], ["In this vein, Singapore-invested OEMs in China reflect an idiosyncrasy to establish thicker linkages and dense interactions with GVC partners rather than to build own brands.", [["vein", "ANATOMY", 8, 12], ["vein", "MULTI-TISSUE_STRUCTURE", 8, 12], ["vein", "ANATOMY", 8, 12], ["dense", "OBSERVATION_MODIFIER", 105, 110]]], ["Following this logic, it is plausible to claim that both foreign-invested and domestic OEMs in China may view the outsourcing trends concerning functional upgrading along the GVC differently.Limitations and Recommendations ::: Case #2 ::: Upgrading Strategies by Singapore/FDI OEMs in ChinaThis exploratory study offers some avenues for future research.", [["GVC", "CANCER", 175, 178], ["exploratory study", "TEST", 295, 312], ["foreign", "OBSERVATION", 57, 64]]], ["First, in terms of research methodology, a two-case study may not be able to offer sufficient evidence to examine our assumed model.", [["case study", "TEST", 47, 57]]], ["On the basis of the foregoing arguments, it is also recommended that future research could conduct a comparative study including firms that did not engage in functional upgrading\u2014which may reveal a more comprehensive picture of FDIs and their upgrading strategies in China.Introduction ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaGlobal start-up firms that exploit the opportunities of globalization to achieve superior performance in international markets from their inception, or shortly thereafter, have generated significant research in the field of entrepreneurship (Jones, Coviello, & Tang, 2011; Kiss, Danis, & Tamer Cavusgil, 2012; Oviatt & McDougall, 2005).", [["OBM", "DISEASE", 303, 306], ["FDIs", "CANCER", 228, 232], ["a comparative study", "TEST", 99, 118], ["significant", "OBSERVATION_MODIFIER", 536, 547]]], ["Owing to poor intellectual rights protection and weak legal enforcement coupled with the very complex bureaucratic systems in EEs, global start-up firms with less resources deciding to venture into EEs may face more intricate problems than those internationalizing their business in other developed economies (DEs) with more sound market infrastructures.", [["poor intellectual rights protection", "PROBLEM", 9, 44]]], ["However, in recent years, there have been an increasing number of entrepreneurial firms from DEs that prefer to enter large EEs such as China at an early stage given the large populations and attractive consumer markets (Jones et al., 2011; Kiss et al., 2012).", [["increasing", "OBSERVATION_MODIFIER", 45, 55], ["number", "OBSERVATION_MODIFIER", 56, 62], ["entrepreneurial firms", "OBSERVATION", 66, 87], ["large", "OBSERVATION_MODIFIER", 118, 123], ["EEs", "OBSERVATION", 124, 127], ["large", "OBSERVATION_MODIFIER", 170, 175], ["populations", "OBSERVATION", 176, 187]]], ["While the literature still tends to explain how large enterprises from DEs compete in EEs (Lyles & Park, 2013; Yamakawa, Khavul, & Peng, 2013), there has been a scarcity of literature demonstrating why some DE global start-up firms choose to venture into EEs with higher uncertainty instead of into other mature markets with more familiarity.Introduction ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaTo fill this research gap, our study uses the Chinese manufacturing sector as a research background because China is the world's largest EE and manufacturing FDI plays a crucial role in its economic growth.", [["OBM", "DISEASE", 372, 375], ["EE", "CHEMICAL", 555, 557], ["our study", "TEST", 445, 454]]], ["Notwithstanding a large body of research that has addressed the upgrading strategies conducted by world class manufacturers from DEs in China (Chin et al., 2015; Herrigel, Wittke, & Voskamp, 2013), the development trajectories of small, entrepreneurial foreign OEMs in this context have been much less covered in the literature.", [["small, entrepreneurial foreign OEMs", "PROBLEM", 230, 265], ["large", "OBSERVATION_MODIFIER", 18, 23], ["small", "OBSERVATION_MODIFIER", 230, 235], ["foreign OEMs", "OBSERVATION", 253, 265]]], ["As such, our study employs a case-study approach, investigating how a British OEM accelerated its internationalization process by setting up a plant in China.", [["our study", "TEST", 9, 18]]], ["This study elucidates how a small foreign OEM was willing and daring to bear the high risks of upgrading to OBM status in China by collaborating with Chinese SOEs.Introduction ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaGiven that global start-up OEMs as a unique form of international new ventures derive from GVC theory (Chin et al., 2016; Chin, Tsai, et al., 2016), our study takes the GVC framework as the departure point to illustrate how global start-up OEMs from DEs enhanced China's economic development (Gereffi, 2009; Ivarsson & Alvstam, 2011).", [["OBM", "DISEASE", 108, 111], ["OBM", "DISEASE", 193, 196], ["This study", "TEST", 0, 10], ["our study", "TEST", 388, 397], ["small", "OBSERVATION_MODIFIER", 28, 33], ["Chin", "ANATOMY", 361, 365]]], ["Seeing that the entrepreneur or SME in general has full authority to make big decisions (Oviatt & McDougall, 2005), we also incorporate the international entrepreneurship view to characterize the unique internationalization and corresponding entrepreneurial behaviours of the case\u2014namely how a British entrepreneur observed, evaluated, and exploited the cross-border opportunities in an unfamiliar Chinese context.Introduction ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaThe outline of this study is as follows.", [["SME", "CHEMICAL", 32, 35], ["OBM", "DISEASE", 444, 447], ["this study", "TEST", 505, 515]]], ["Finally, we demonstrate how our empirical findings contribute to the literature.International Entrepreneurship and GVCs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaThe label of \u2018born global firms\u2019 or \u2018global start-ups\u2019 refers to early internationalizing firms that span international borders almost at birth (Chin et al., 2016; Chin, Tsai, et al., 2016; Jones et al., 2011; Oviatt & McDougall\u2019s, 2005, 1994).", [["OBM", "DISEASE", 164, 167], ["Chin", "ANATOMY", 355, 359], ["Chin", "ANATOMY", 374, 378]]], ["The traditional Uppsala model of internationalization (Johanson & Vahlne, 1977) argues that firms\u2019 internationalization should be a gradual process that needs sufficient experience and knowledge to reduce the \u2018liability of foreignness\u2019 (Zahra, 2005) and risks.", [["foreignness", "DISEASE", 223, 234]]], ["However, Oviatt and McDougall's (1994) theory of international new ventures draws attention to the fact that some small and young ventures may not actually own such experiences and resources, but use their remarkable resourcefulness to compete internationally from their inception.", [["some small and young ventures", "PROBLEM", 109, 138], ["small", "OBSERVATION_MODIFIER", 114, 119]]], ["This rapid internationalization framework explains the emergence of the rising power of young, small firms in the global marketplace.International Entrepreneurship and GVCs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaThe major difference between these models resides in the choices of entry and operation modes firms adopt for internationalization.", [["OBM", "DISEASE", 217, 220], ["operation modes firms", "TREATMENT", 341, 362], ["small", "OBSERVATION_MODIFIER", 95, 100], ["firms", "OBSERVATION_MODIFIER", 101, 106], ["global", "OBSERVATION_MODIFIER", 114, 120], ["major", "OBSERVATION_MODIFIER", 267, 272], ["difference", "OBSERVATION_MODIFIER", 273, 283]]], ["In other words, the learning trajectories for internationalization by global start-ups and established firms may be varied\u2014which highlights the pivotal role of international entrepreneurship in determining the timing, scope, and scale of internationalizing firms.", [["scope", "TEST", 218, 223]]], ["It is also worth further study whether the learning form and content of global start-ups will change as they reach the mature stage of development in host countries.International Entrepreneurship and GVCs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaIn sum, as noted earlier, it requires further elaboration as to why some DE global start-ups choose to confront an environment (i.e. EE) that is more volatile, uncertain, and complex and structurally different from their original countries (i.e. DE).", [["OBM", "DISEASE", 249, 252], ["EE", "CHEMICAL", 428, 430], ["further study", "TEST", 17, 30]]], ["Owing to the multidisciplinary nature of the global start-up phenomenon (Oviatt & McDougall, 2005), our research incorporates the international entrepreneurship view into the GVC framework to delve into relevant issues.Global Start-Up OEMs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaGlobal start-ups have been classified as one of the four typical types of international new ventures (Oviatt & McDougall, 1994): export/import start-up; multinational trader; geographically focused; and global, according to the differences in the possessions of unique knowledge.", [["OBM", "DISEASE", 284, 287], ["global", "OBSERVATION_MODIFIER", 533, 539]]], ["However, owing to increasing global complexities, it is highly possible that the internationalizing patterns of global start-ups may vary under different combinations of industry, market, corporation, and entrepreneur-related conditions.", [["increasing global complexities", "PROBLEM", 18, 48], ["highly possible", "UNCERTAINTY", 56, 71]]], ["There might be more kinds of international new ventures than that presented in the existing literature.", [["more kinds", "OBSERVATION_MODIFIER", 15, 25], ["new", "OBSERVATION_MODIFIER", 43, 46], ["ventures", "OBSERVATION", 47, 55]]], ["For instance, one predominant but previously ignored type is the \u2018global start-up OEM\u2019 that focuses on low cost production and assembly functions within GVCs (Chin et al., 2016; Chin, Tsai, et al., 2016)\u2014yet this is actually a typical and representative type of global start-up firm in the manufacturing industry of DE and EE with large amounts of cheap labour, such as China.Global Start-Up OEMs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaSince the 1990s, in order to reduce costs, quite a few DE MNCs have started to position their core business primarily in brand management and outsourced low value-added production to OEM suppliers in China (Herrigel et al., 2013).", [["EE", "CHEMICAL", 323, 325], ["OBM", "DISEASE", 441, 444], ["MNCs", "CELL", 545, 549], ["DE MNCs", "CELL_TYPE", 542, 549], ["low cost production", "PROBLEM", 103, 122], ["outsourced low value", "PROBLEM", 629, 649], ["one predominant", "OBSERVATION_MODIFIER", 14, 29], ["Chin", "ANATOMY", 178, 182], ["firm", "OBSERVATION", 278, 282], ["large", "OBSERVATION_MODIFIER", 331, 336], ["amounts", "OBSERVATION_MODIFIER", 337, 344], ["cheap labour", "OBSERVATION", 348, 360]]], ["This cross-border outsourcing trend has encouraged not only big but also small and medium-sized OEMs from DEs to follow their key buyers\u2019 strategic options venturing into China (Chin, Tsai, et al., 2016).", [["small", "OBSERVATION_MODIFIER", 73, 78], ["Chin", "ANATOMY", 178, 182]]], ["Compared with domestic OEMs in China, DE global start-up OEMs often have a relatively broader knowledge base in international marketing and modern technology, despite the weakness of local market knowledge and social networks (Chin & Liu, 2017; Chin et al., 2015).", [["the weakness", "PROBLEM", 167, 179], ["Chin", "ANATOMY", 227, 231]]], ["Following this logic, the DE global start-up OEMs in China still possess certain comparative advantages against domestic OEMs when competing in the export and international arenas.Global Start-Up OEMs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaFollowing the discussion above, it is conspicuous that internationalization by DE global start-up OEMs in China seems to be resource\u2014rather than market-seeking as they position China as a production hub or sourcing platform to acquire low-cost advantages.", [["OBM", "DISEASE", 245, 248], ["low-cost advantages", "TREATMENT", 526, 545]]], ["Yet continuously rising labour costs and sharp currency fluctuations have been squeezing OEM's profit margins in China.", [["continuously rising labour costs", "PROBLEM", 4, 36], ["sharp currency fluctuations", "PROBLEM", 41, 68], ["continuously", "OBSERVATION_MODIFIER", 4, 16], ["rising", "OBSERVATION_MODIFIER", 17, 23], ["labour costs", "OBSERVATION", 24, 36], ["sharp", "OBSERVATION_MODIFIER", 41, 46]]], ["Meanwhile, China has grown to be the biggest consumer market for automobiles, televisions, cell phones, and luxury goods (Chin & Liu, 2017).", [["cell", "ANATOMY", 91, 95], ["cell", "CELL", 91, 95], ["Chin", "ANATOMY", 122, 126]]], ["As such, China, in the eyes of many countries and MNCs, has become a very promising market rather than just a low-cost production base.", [["eyes", "ANATOMY", 23, 27], ["MNCs", "ANATOMY", 50, 54], ["eyes", "ORGAN", 23, 27], ["MNCs", "CELL", 50, 54], ["MNCs", "CELL_TYPE", 50, 54], ["a low-cost production base", "PROBLEM", 108, 134], ["eyes", "ANATOMY", 23, 27], ["base", "ANATOMY_MODIFIER", 130, 134]]], ["Its fast-growing local demand symbolizes one silver cloud on the horizon\u2014which motivates DE global start-up OEMs, especially those with years of experience in China, to upgrade from OEM to OBM status or to diversify their business activities apart from manufacturing for better returns.Global Start-Up OEMs ::: Theoretical Foundation ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaNevertheless, it remains unknown how and why DE global start-up OEMs conduct their upgrading strategies and increase their commitments in China, as China's FDI policy is often more in favour of supporting large MNCs.", [["MNCs", "ANATOMY", 608, 612], ["OBM", "DISEASE", 351, 354], ["silver", "CHEMICAL", 45, 51], ["MNCs", "CELL", 608, 612], ["MNCs", "CELL_TYPE", 608, 612], ["growing", "OBSERVATION_MODIFIER", 9, 16], ["silver", "OBSERVATION_MODIFIER", 45, 51], ["cloud", "OBSERVATION_MODIFIER", 52, 57]]], ["In response, our study integrates the international entrepreneurship and GVC perspectives to demonstrate the 10-year internationalization trajectory of a small British OEM venturing into China, articulating how contextual variables of EE shape DE global start-ups\u2019 entrepreneurial behaviours in the process of adapting to the changing competitive context of emerging markets.Data Collection ::: Methodology ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaThe main form of data collection was regular in-depth interviews (monthly) with the managers of several key departments.", [["EE", "CHEMICAL", 235, 237], ["OBM", "DISEASE", 424, 427], ["our study", "TEST", 13, 22], ["Data Collection", "TEST", 375, 390], ["small", "OBSERVATION_MODIFIER", 154, 159]]], ["Therefore, data could be triangulated between real-time observations and retrospective investigations of firm records\u2014which enables the establishment of a chain of evidence (Eisenhardt & Graebner, 2007).", [["retrospective investigations", "TEST", 73, 101], ["firm records", "TEST", 105, 117]]], ["To ensure the robustness of data, all interviews were tape-recorded and undertaken with a three-person team, where one researcher handled the interview questions and two researchers were responsible for noting down all the responses.Data Collection ::: Methodology ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaTo verify the reliability and validity of data, the recorded data were transcribed within 24 h of the interviews.", [["OBM", "DISEASE", 282, 285], ["Data Collection", "TEST", 233, 248]]], ["Given a participatory action research, we requested the firm to allow us to participate in some decision-making meetings regarding the enactment and implementation of their new internationalization strategies in China.", [["their new internationalization strategies", "TREATMENT", 167, 208]]], ["Hence, we attended quite a few meetings discussing their most important strategic move on upgrading to OBM in China\u2014namely building a strategic alliance with an SOE to produce own-brand products\u2014over a period of 16 months (September 2012 to December 2013).", [["OBM", "DISEASE", 103, 106]]], ["Although top management asked us to provide suggestions at the meeting, we strictly adhered to the role of observation and did not voice any opinions during the course of discussion until critical decisions were made.Data Collection ::: Methodology ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaIn the following section, we detail the firm's 10-year internationalization journey.", [["OBM", "DISEASE", 266, 269], ["Data Collection", "TEST", 217, 232]]], ["This journey is categorized into six stages: (1) The beginning; (2) from 2003 to 2004; (3) from 2005 to 2007; (4) from 2008 to 2011; (5) from 2012 to 2013; (6) from 2014.The Beginning: The SARS Crisis ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaIn January 2003, Chris arrived in GZ.", [["SARS", "DISEASE", 189, 193], ["OBM", "DISEASE", 272, 275], ["Crippled", "OBSERVATION", 220, 228]]], ["He selected a young Chinese woman who was proficient in English, Spanish, Cantonese, and the Shanghai dialect of Mandarin as his manager and another woman as her assistant.", [["woman", "ORGANISM", 28, 33], ["woman", "ORGANISM", 149, 154], ["woman", "SPECIES", 28, 33], ["woman", "SPECIES", 149, 154]]], ["Thus, a three-person company was set to go in February 2003.The Beginning: The SARS Crisis ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaHowever, owing to the sudden outbreak of severe acute respiratory syndrome (SARS) in Southern China, the World Health Organization (WHO) issued a global alert.", [["SARS", "DISEASE", 79, 83], ["OBM", "DISEASE", 162, 165], ["acute respiratory syndrome", "DISEASE", 256, 282], ["SARS", "DISEASE", 284, 288], ["severe acute respiratory syndrome", "PROBLEM", 249, 282], ["Crippled", "OBSERVATION", 110, 118], ["severe", "OBSERVATION_MODIFIER", 249, 255], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["respiratory syndrome", "OBSERVATION", 262, 282]]], ["Chris followed the British Embassy's suggestion to fly back to Britain at the end of May and left the office in the hands of the newly hired manager that he barely knew.", [["left", "ANATOMY_MODIFIER", 93, 97]]], ["The WHO continued to issue advisories against travel to China and, therefore, for the next 3 months Chris was compelled to run his business by remote control using the internet and telephone.The Beginning: The SARS Crisis ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaChris flew back to GZ immediately the WHO lifted the restrictions on travel to China in August 2003.", [["SARS", "DISEASE", 210, 214], ["OBM", "DISEASE", 293, 296], ["Crippled", "OBSERVATION", 241, 249]]], ["From this dramatic incident, Chris learned a valuable lesson.", [["dramatic", "OBSERVATION_MODIFIER", 10, 18]]], ["In late 2003, a new manager, Julia, was recruited.", [["Julia", "ANATOMY", 29, 34]]], ["With her outstanding performance and dedication, she soon became Chris's right-hand person, deputy managing director as well as business partner.", [["right-hand", "ANATOMY", 73, 83], ["person", "SPECIES", 84, 90]]], ["Since then, Chris has been able to concentrate on looking for new clients.From 2003 to 2004: Early Success ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaWhile most major rivals in China were domestic firms that implemented a low-cost strategy, Chris decided to highlight his particular comparative advantages in engineering technologies, locating the competitive position of TECHSAVVY as \u2018Western quality, China prices\u2019.", [["OBM", "DISEASE", 178, 181], ["Crippled", "OBSERVATION", 126, 134]]], ["Thus, \u2018Chinese people were saying we should buy cheap and sell it at a lower price than our competitors, but to me quality is more important than price\u2019, Chris said.", [["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21]]], ["This impressive market positioning enabled TECHSAVVY to successfully obtain purchase orders from two important DE buyers.From 2003 to 2004: Early Success ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaUsing his strong social networks, Chris quickly approached two big European customers after settling the company problems noted above in late 2003.", [["OBM", "DISEASE", 225, 228], ["Crippled", "OBSERVATION", 173, 181]]], ["One was a global leader in the manufacture of kitchen and bath products, while the other was a large MNC famous for producing highly sophisticated engines for commercial vehicles.", [["MNC", "ANATOMY", 101, 104], ["MNC", "CELL", 101, 104], ["MNC", "CELL_TYPE", 101, 104], ["bath products", "TREATMENT", 58, 71], ["global", "OBSERVATION_MODIFIER", 10, 16], ["large", "OBSERVATION_MODIFIER", 95, 100], ["MNC", "OBSERVATION", 101, 104]]], ["Both companies were suffering from price pressures at about that time and thus keen to outsource the production of plastic parts and metal components to China to reduce costs.", [["price pressures", "TREATMENT", 35, 50]]], ["However, both companies had high expectations regarding product quality that required advanced manufacturing technologies and practical engineering skills.", [["advanced manufacturing technologies", "TREATMENT", 86, 121], ["practical engineering skills", "TREATMENT", 126, 154]]], ["The two firms continued to buy products from TECHSAVVY for more than 9 years.", [["two", "OBSERVATION_MODIFIER", 4, 7], ["firms", "OBSERVATION", 8, 13]]], ["Owing to the increasing orders placed by the two key clients, TECHSAVVY's annual sales exceeded US$1 million for the first time at the end of 2004 (see Fig. 3.3).From 2005 to 2007: Fast Growth Via Innovative Keyword Marketing ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaGiven that corporate websites were becoming one of the main sales channels around the world, Chris decided to redesign his website in 2005.", [["OBM", "DISEASE", 297, 300], ["Crippled", "OBSERVATION", 245, 253]]], ["Despite a website overhaul, Chris could not see any significant improvement in the number of online inquiries to their firm at the beginning.", [["significant", "OBSERVATION_MODIFIER", 52, 63], ["improvement", "OBSERVATION", 64, 75]]], ["Without hesitation, Chris made a telephone call to him.", [["hesitation", "PROBLEM", 8, 18]]], ["\u2018We had to discover the actual words our clients use when they search for information online about our content topic\u2019, he said.From 2005 to 2007: Fast Growth Via Innovative Keyword Marketing ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaFollowing the tactics suggested by the American consultant, he rearranged and reorganized the content on his firm's web pages.", [["OBM", "DISEASE", 262, 265], ["Crippled", "OBSERVATION", 210, 218]]], ["After 3 months\u2019 hard work, the number of keywords in TECHSAVVY's website had been added up to about 180 on the first page of Google results without advertising.From 2005 to 2007: Fast Growth Via Innovative Keyword Marketing ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaWithout doubt, the firm's operational effectiveness and efficiency were greatly enhanced by advanced information technology.", [["OBM", "DISEASE", 295, 298], ["Crippled", "OBSERVATION", 243, 251], ["firm", "OBSERVATION_MODIFIER", 360, 364]]], ["When a new enquiry came in, Chris was immediately informed by email on his iPhone anywhere in the world.", [["new", "OBSERVATION_MODIFIER", 7, 10]]], ["In 2007, TECHSAVVY tripled its revenue to US$4 million (see Fig. 3.3).From 2008 to 2011: Global Financial Crisis Hit ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaSuddenly, the 2008 financial crisis and subsequent global recession swept the world, leading to sharp declines in demand in mature markets.", [["OBM", "DISEASE", 188, 191], ["sharp declines", "PROBLEM", 330, 344], ["Crippled", "OBSERVATION", 136, 144], ["global", "OBSERVATION_MODIFIER", 285, 291], ["recession", "OBSERVATION", 292, 301], ["sharp", "OBSERVATION_MODIFIER", 330, 335], ["declines", "OBSERVATION", 336, 344], ["mature markets", "OBSERVATION", 358, 372]]], ["This severely impacted on China's OEM industry (Chin et al., 2015).", [["severely", "OBSERVATION_MODIFIER", 5, 13], ["impacted", "OBSERVATION_MODIFIER", 14, 22]]], ["To offset lost high-volume orders from large MNCs, Chris decided to make better use of keyword marketing, striving to get more low-volume orders from SME buyers via the company website.", [["MNCs", "ANATOMY", 45, 49], ["MNCs", "CELL", 45, 49], ["MNCs", "CELL_TYPE", 45, 49], ["high-volume orders", "TREATMENT", 15, 33]]], ["Gradually, TECHSAVVY's sales returned to growth, reaching US$3.2 million in 2010 and US$4 million in 2011 (see Fig. 3.3).From 2012 to 2013: Upgrading to OBM ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaThough Chris started to see sales coming back, the severe pressures of continuous currency appreciation and rising operation costs shrank the profit margin of China's OEM industry.", [["OBM", "DISEASE", 228, 231], ["the severe pressures", "PROBLEM", 321, 341], ["rising operation", "TREATMENT", 382, 398], ["Crippled", "OBSERVATION", 176, 184], ["severe", "OBSERVATION_MODIFIER", 325, 331], ["pressures", "OBSERVATION_MODIFIER", 332, 341], ["rising", "OBSERVATION_MODIFIER", 382, 388], ["margin", "OBSERVATION_MODIFIER", 423, 429]]], ["It seemed to become increasingly difficult for TECHSAVVY to manufacture at low prices with superior quality OEM products in this context.", [["TECHSAVVY to manufacture at low prices", "TREATMENT", 47, 85]]], ["Considering how TECHSAVVY's technological and engineering capabilities developed over the past years had equipped the firm with essential technical know-how to create its own-brand products in related industries, Chris decided to make a bold, brave, and aggressive move, upgrading TECHSAVVY from OEM to OBM status for higher profits.From 2012 to 2013: Upgrading to OBM ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaIn early 2011, through an old British friend's introduction, Chris encountered an opportunity to collaborate with CMM, a large Chinese mining SOE that had been urgently searching for a strategic partner with sophisticated engineering technologies in plastic and metal moulding, casting, and the like.", [["OBM", "DISEASE", 440, 443], ["sophisticated engineering technologies", "TREATMENT", 694, 732], ["plastic and metal moulding", "TREATMENT", 736, 762], ["Crippled", "OBSERVATION", 388, 396], ["metal moulding", "OBSERVATION", 748, 762]]], ["He thus persuaded CMM to form a 5-year strategic alliance with TECHSAVVY.From 2012 to 2013: Upgrading to OBM ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaIn this contract, CMM allowed TECHSAVVY to refer to CMM's existing but out-of-date and somewhat invalid products and to develop new PPEs under TECHSAVVY's brand name, while TECHSAVVY agreed to use one patented chemical material for generating oxygen supplied by CMM's coal mines in its products.", [["OBM", "DISEASE", 180, 183], ["oxygen", "CHEMICAL", 469, 475], ["CMM", "CHEMICAL", 488, 491], ["oxygen", "CHEMICAL", 469, 475], ["coal", "CHEMICAL", 494, 498], ["oxygen", "SIMPLE_CHEMICAL", 469, 475], ["CMM", "SIMPLE_CHEMICAL", 488, 491], ["CMM's", "TEST", 278, 283], ["generating oxygen", "TREATMENT", 458, 475], ["Crippled", "OBSERVATION", 128, 136]]], ["However, the decisions of selecting, developing, launching, and pricing collaborative products needed to be made through discussion and approved by both sides.From 2012 to 2013: Upgrading to OBM ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaAfter intensive communication back and forth, TECHSAVVY and CMM finally agreed to overhaul two PPEs of CMM as their strategic objectives for 2012.", [["OBM", "DISEASE", 266, 269], ["pricing collaborative products", "TREATMENT", 64, 94], ["Crippled", "OBSERVATION", 214, 222]]], ["These were Self-Rescuer (SCSR) and methane gas detector (MGD) products.", [["methane", "CHEMICAL", 35, 42], ["methane", "SIMPLE_CHEMICAL", 35, 42], ["methane gas detector (MGD) products", "TREATMENT", 35, 70]]], ["With CMM's support, the refurbishment process went smoothly.", [["CMM's support", "TREATMENT", 5, 18]]], ["The samples of the two renewed products had been successively completed in late 2012 and soon after were sent to be thoroughly tested at national and international standards.From 2012 to 2013: Upgrading to OBM ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaThe new cooperative products looked good, perfectly refurbished in appearance and technologies.", [["samples", "ANATOMY", 4, 11], ["OBM", "DISEASE", 281, 284], ["The samples", "TEST", 0, 11], ["Crippled", "OBSERVATION", 229, 237]]], ["Drawing on this strategic alliance with CMM as a stepping stone, Chris felt that TECHSAVVY had successfully transformed from an OEM to an OBM firm.", [["a stepping stone", "PROBLEM", 47, 63], ["stone", "OBSERVATION", 58, 63], ["OBM", "ANATOMY", 138, 141], ["firm", "OBSERVATION", 142, 146]]], ["However, at the end of 2014, the two sides were still unable to reach consensus, and yet there was zero income coming from own-brand products for TECHAVVY (see Fig. 3.3).From 2014: Unexpected Difficulties and Challenges Ahead ::: Background and Crippled Start-Up ::: Key Findings ::: Upgrading to OBM by an Entrepreneurial British OEM in ChinaAccording to the original plan, the renewed SCSR and MGD products under the brand name TECHSAVVY should have been released in early 2013.", [["OBM", "DISEASE", 297, 300], ["the renewed SCSR", "TREATMENT", 375, 391], ["MGD products", "TREATMENT", 396, 408], ["Crippled", "OBSERVATION", 245, 253]]], ["Based on the interviews with Chris, the key problems between TECHSAVVY and CMM are summarized into the following trio.1.Cultural differences between British and Chinese decision-making", [["CMM", "CANCER", 75, 78]]]], "PMC7404895": [["AbbreviationWhen the novel coronavirus COVID\u201019 crossed over to humans in late 2019, it led to a rapid worldwide spread of the virus and developed into a devastating pandemic.", [["coronavirus", "ORGANISM", 27, 38], ["humans", "ORGANISM", 64, 70], ["coronavirus", "SPECIES", 27, 38], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["the novel coronavirus COVID", "TEST", 17, 44], ["the virus", "PROBLEM", 123, 132], ["a devastating pandemic", "PROBLEM", 152, 174], ["devastating", "OBSERVATION_MODIFIER", 154, 165], ["pandemic", "OBSERVATION", 166, 174]]], ["As of the time of the writing of this commentary, there were more than 8.9 million confirmed cases along with an increasing number of fatalities over 468,000.", [["fatalities", "DISEASE", 134, 144], ["increasing", "OBSERVATION_MODIFIER", 113, 123], ["number", "OBSERVATION_MODIFIER", 124, 130]]], ["So far, more than 2,600 clinical trials are being conducted, including many observational and interventional studies to for better understanding its pathophysiology as well as trying novel treatments.", [["interventional studies", "TEST", 94, 116], ["novel treatments", "TREATMENT", 183, 199]]], ["Among suggested therapeutic modalities, stem cell\u2010based therapies have also been proposed for alleviation or treatment of COVID\u201019.AbbreviationCOVID\u201019 is a betacoronavirus with a positive\u2010sense single\u2010stranded RNA genome.", [["stem cell\u2010based", "ANATOMY", 40, 55], ["COVID", "DISEASE", 122, 127], ["stem cell\u2010based", "CELL", 40, 55], ["betacoronavirus", "CANCER", 157, 172], ["positive\u2010sense single\u2010stranded RNA genome", "DNA", 180, 221], ["therapeutic modalities", "TREATMENT", 16, 38], ["stem cell\u2010based therapies", "TREATMENT", 40, 65], ["treatment of COVID\u2010", "TREATMENT", 109, 128], ["RNA genome", "OBSERVATION", 211, 221]]], ["Recent genome sequencing data indicates that almost 80% of the COVID\u201019 genome is similar to well\u2010known members of other coronaviruses, such as SARS\u2010CoV.1In addition, the virus uses the same route for adhesion and entry into human cells by adhering to the angiotensin\u2010converting enzyme II (ACE2).1After cell entry, viral transcription leads to the production of polyproteins as well as other structural and nonstructural proteins such as different proteases, spikes, envelope, and nucleocapsids.", [["cells", "ANATOMY", 231, 236], ["cell", "ANATOMY", 303, 307], ["nucleocapsids", "ANATOMY", 481, 494], ["SARS", "DISEASE", 144, 148], ["coronaviruses", "ORGANISM", 121, 134], ["CoV.1In", "GENE_OR_GENE_PRODUCT", 149, 156], ["human", "ORGANISM", 225, 230], ["cells", "CELL", 231, 236], ["angiotensin\u2010converting enzyme II", "GENE_OR_GENE_PRODUCT", 256, 288], ["ACE2", "GENE_OR_GENE_PRODUCT", 290, 294], ["cell", "CELL", 303, 307], ["nucleocapsids", "CELLULAR_COMPONENT", 481, 494], ["COVID\u201019 genome", "DNA", 63, 78], ["human cells", "CELL_TYPE", 225, 236], ["angiotensin\u2010converting enzyme II", "PROTEIN", 256, 288], ["ACE2", "PROTEIN", 290, 294], ["polyproteins", "PROTEIN", 362, 374], ["structural and nonstructural proteins", "PROTEIN", 392, 429], ["proteases", "PROTEIN", 448, 457], ["human", "SPECIES", 225, 230], ["human", "SPECIES", 225, 230], ["Recent genome sequencing data", "TEST", 0, 29], ["the COVID\u2010", "TEST", 59, 69], ["other coronaviruses", "PROBLEM", 115, 134], ["the virus", "PROBLEM", 167, 176], ["adhesion", "PROBLEM", 201, 209], ["cell entry", "TEST", 303, 313], ["viral transcription", "TREATMENT", 315, 334], ["polyproteins", "PROBLEM", 362, 374], ["other structural and nonstructural proteins", "PROBLEM", 386, 429], ["different proteases", "PROBLEM", 438, 457], ["spikes", "PROBLEM", 459, 465], ["nucleocapsids", "PROBLEM", 481, 494], ["polyproteins", "OBSERVATION", 362, 374], ["nonstructural proteins", "OBSERVATION", 407, 429]]], ["These proteins have important roles in virulence and pathophysiology in humans.", [["humans", "ORGANISM", 72, 78], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78]]], ["For instance, spikes bind the virus to the host cells by adhesion into ACE2 receptors.2Other proteins such as the envelope are needed for virus assembly and replication in host cells.", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 177, 182], ["cells", "CELL", 48, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["host cells", "CELL", 172, 182], ["host cells", "CELL_TYPE", 43, 53], ["ACE2 receptors", "PROTEIN", 71, 85], ["host cells", "CELL_TYPE", 172, 182], ["spikes bind the virus", "PROBLEM", 14, 35], ["Other proteins", "PROBLEM", 87, 101], ["the envelope", "PROBLEM", 110, 122], ["virus", "PROBLEM", 138, 143], ["host cells", "OBSERVATION", 172, 182]]], ["After infecting the host, the clinical presentation can vary from asymptomatic to severe cases with pneumonia (14%) and respiratory failure, which can lead to multiorgan dysfunction and septic shock.3Based on the recent data, the progress to severe disease and pneumonia typically happens a week after the onset of the symptoms and is manifested by dyspnea and hypoxia.AbbreviationThe pathogenic mechanism of pneumonia and its delayed onset is currently being studied and seems quite complex.", [["respiratory", "ANATOMY", 120, 131], ["multiorgan", "ANATOMY", 159, 169], ["pneumonia", "DISEASE", 100, 109], ["respiratory failure", "DISEASE", 120, 139], ["multiorgan dysfunction", "DISEASE", 159, 181], ["septic shock", "DISEASE", 186, 198], ["pneumonia", "DISEASE", 261, 270], ["dyspnea", "DISEASE", 349, 356], ["hypoxia", "DISEASE", 361, 368], ["pneumonia", "DISEASE", 409, 418], ["pneumonia", "PROBLEM", 100, 109], ["respiratory failure", "PROBLEM", 120, 139], ["multiorgan dysfunction", "PROBLEM", 159, 181], ["septic shock", "PROBLEM", 186, 198], ["severe disease", "PROBLEM", 242, 256], ["pneumonia", "PROBLEM", 261, 270], ["the symptoms", "PROBLEM", 315, 327], ["dyspnea", "PROBLEM", 349, 356], ["hypoxia", "PROBLEM", 361, 368], ["pneumonia", "PROBLEM", 409, 418], ["its delayed onset", "PROBLEM", 423, 440], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["pneumonia", "OBSERVATION", 100, 109], ["respiratory failure", "OBSERVATION", 120, 139], ["multiorgan dysfunction", "OBSERVATION", 159, 181], ["septic shock", "OBSERVATION", 186, 198], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["disease", "OBSERVATION", 249, 256], ["pneumonia", "OBSERVATION", 261, 270], ["dyspnea", "OBSERVATION", 349, 356], ["hypoxia", "OBSERVATION", 361, 368], ["pneumonia", "OBSERVATION", 409, 418], ["delayed", "OBSERVATION_MODIFIER", 427, 434], ["onset", "OBSERVATION_MODIFIER", 435, 440]]], ["Recent studies indicate that the development of acute respiratory distress syndrome (ARDS) in severe cases is accompanied by a massive release of proinflammatory cytokines (such as interferons and interleukins) as well as other chemokines (such as CCLs and CXCLs).", [["respiratory", "ANATOMY", 54, 65], ["acute respiratory distress syndrome", "DISEASE", 48, 83], ["ARDS", "DISEASE", 85, 89], ["interferons", "GENE_OR_GENE_PRODUCT", 181, 192], ["interleukins", "GENE_OR_GENE_PRODUCT", 197, 209], ["CCLs", "GENE_OR_GENE_PRODUCT", 248, 252], ["CXCLs", "GENE_OR_GENE_PRODUCT", 257, 262], ["proinflammatory cytokines", "PROTEIN", 146, 171], ["interferons", "PROTEIN", 181, 192], ["interleukins", "PROTEIN", 197, 209], ["chemokines", "PROTEIN", 228, 238], ["CCLs", "PROTEIN", 248, 252], ["CXCLs", "PROTEIN", 257, 262], ["Recent studies", "TEST", 0, 14], ["acute respiratory distress syndrome", "PROBLEM", 48, 83], ["ARDS", "PROBLEM", 85, 89], ["proinflammatory cytokines", "PROBLEM", 146, 171], ["interferons and interleukins)", "TREATMENT", 181, 210], ["other chemokines", "PROBLEM", 222, 238], ["CXCLs", "TEST", 257, 262], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory distress syndrome", "OBSERVATION", 54, 83], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["massive", "OBSERVATION_MODIFIER", 127, 134], ["proinflammatory cytokines", "OBSERVATION", 146, 171]]], ["This cytokine storm triggers a substantial immune response (hyperinflammation) to the affected organs leading to vascular leakage and edema, tissue inflammation/damage, multiorgan failure, and severe morbidity.", [["organs", "ANATOMY", 95, 101], ["vascular", "ANATOMY", 113, 121], ["edema", "ANATOMY", 134, 139], ["tissue", "ANATOMY", 141, 147], ["multiorgan", "ANATOMY", 169, 179], ["vascular leakage", "DISEASE", 113, 129], ["edema", "DISEASE", 134, 139], ["inflammation", "DISEASE", 148, 160], ["multiorgan failure", "DISEASE", 169, 187], ["organs", "ORGAN", 95, 101], ["vascular", "MULTI-TISSUE_STRUCTURE", 113, 121], ["edema", "PATHOLOGICAL_FORMATION", 134, 139], ["tissue", "TISSUE", 141, 147], ["cytokine", "PROTEIN", 5, 13], ["This cytokine storm", "PROBLEM", 0, 19], ["a substantial immune response", "PROBLEM", 29, 58], ["hyperinflammation", "PROBLEM", 60, 77], ["the affected organs", "PROBLEM", 82, 101], ["vascular leakage", "PROBLEM", 113, 129], ["edema", "PROBLEM", 134, 139], ["tissue inflammation", "PROBLEM", 141, 160], ["damage", "PROBLEM", 161, 167], ["multiorgan failure", "PROBLEM", 169, 187], ["severe morbidity", "PROBLEM", 193, 209], ["organs", "ANATOMY", 95, 101], ["vascular", "ANATOMY", 113, 121], ["leakage", "OBSERVATION", 122, 129], ["edema", "OBSERVATION", 134, 139], ["tissue", "ANATOMY", 141, 147], ["inflammation", "OBSERVATION", 148, 160], ["damage", "OBSERVATION_MODIFIER", 161, 167], ["multiorgan failure", "OBSERVATION", 169, 187], ["severe", "OBSERVATION_MODIFIER", 193, 199], ["morbidity", "OBSERVATION", 200, 209]]], ["Previous studies on Middle East respiratory syndrome patients similarly indicate a strong correlation between elevated serum levels of proinflammatory cytokines such as IL\u20106 and C\u2010reaction protein (CRP) and disease severity.", [["serum", "ANATOMY", 119, 124], ["Middle East respiratory syndrome", "DISEASE", 20, 52], ["Middle East respiratory", "ORGANISM", 20, 43], ["patients", "ORGANISM", 53, 61], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 169, 173], ["C\u2010reaction protein", "GENE_OR_GENE_PRODUCT", 178, 196], ["CRP", "GENE_OR_GENE_PRODUCT", 198, 201], ["proinflammatory cytokines", "PROTEIN", 135, 160], ["IL\u20106", "PROTEIN", 169, 173], ["C\u2010reaction protein", "PROTEIN", 178, 196], ["CRP", "PROTEIN", 198, 201], ["patients", "SPECIES", 53, 61], ["Previous studies", "TEST", 0, 16], ["Middle East respiratory syndrome", "PROBLEM", 20, 52], ["elevated serum levels", "PROBLEM", 110, 131], ["proinflammatory cytokines", "PROBLEM", 135, 160], ["IL\u2010", "TEST", 169, 172], ["C\u2010reaction protein", "TEST", 178, 196], ["CRP", "TEST", 198, 201], ["disease severity", "PROBLEM", 207, 223], ["respiratory syndrome", "OBSERVATION", 32, 52]]], ["Therefore, in addition to targeted antiviral therapies, there has been a lot of attention towards immunomodulatory interventions to mitigate disease progression and severity in critically ill patients.", [["critically ill", "DISEASE", 177, 191], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["targeted antiviral therapies", "TREATMENT", 26, 54], ["immunomodulatory interventions", "TREATMENT", 98, 128], ["disease progression", "PROBLEM", 141, 160], ["antiviral therapies", "OBSERVATION", 35, 54]]], ["Besides using monoclonal antibodies, such as tocilizumab and anakinra to block IL receptors or other anti\u2010inflammatory medications, using stem cells to modify immune response have been also suggested.", [["stem cells", "ANATOMY", 138, 148], ["tocilizumab", "CHEMICAL", 45, 56], ["anakinra", "CHEMICAL", 61, 69], ["tocilizumab", "SIMPLE_CHEMICAL", 45, 56], ["anakinra", "SIMPLE_CHEMICAL", 61, 69], ["IL receptors", "GENE_OR_GENE_PRODUCT", 79, 91], ["stem cells", "CELL", 138, 148], ["monoclonal antibodies", "PROTEIN", 14, 35], ["IL receptors", "PROTEIN", 79, 91], ["stem cells", "CELL_TYPE", 138, 148], ["monoclonal antibodies", "TREATMENT", 14, 35], ["tocilizumab", "TREATMENT", 45, 56], ["anakinra", "TREATMENT", 61, 69], ["block IL receptors", "TREATMENT", 73, 91], ["other anti\u2010inflammatory medications", "TREATMENT", 95, 130], ["stem cells", "TREATMENT", 138, 148]]], ["As mesenchymal stem cells (MSCs) are known to be immune\u2010privileged, safe, and able to have immunomodulatory abilities, they have been tested in limited clinical trials to treat COVID\u201019 patients with pneumonia.AbbreviationMSCs can be isolated from donor bone marrow, placenta, fat or umbilical cord and after expansion, can be administered to severe patients via the IV route to combat that cytokine storm in severe COVID patients suffering from ARDS.", [["mesenchymal stem cells", "ANATOMY", 3, 25], ["MSCs", "ANATOMY", 27, 31], ["AbbreviationMSCs", "ANATOMY", 210, 226], ["bone marrow", "ANATOMY", 254, 265], ["placenta", "ANATOMY", 267, 275], ["fat", "ANATOMY", 277, 280], ["umbilical cord", "ANATOMY", 284, 298], ["COVID", "DISEASE", 177, 182], ["pneumonia", "DISEASE", 200, 209], ["COVID", "DISEASE", 416, 421], ["ARDS", "DISEASE", 446, 450], ["mesenchymal stem cells", "CELL", 3, 25], ["MSCs", "CELL", 27, 31], ["patients", "ORGANISM", 186, 194], ["AbbreviationMSCs", "CELL", 210, 226], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 254, 265], ["placenta", "TISSUE", 267, 275], ["fat", "TISSUE", 277, 280], ["umbilical cord", "TISSUE", 284, 298], ["patients", "ORGANISM", 350, 358], ["patients", "ORGANISM", 422, 430], ["mesenchymal stem cells", "CELL_TYPE", 3, 25], ["MSCs", "CELL_TYPE", 27, 31], ["AbbreviationMSCs", "CELL_TYPE", 210, 226], ["cytokine", "PROTEIN", 391, 399], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 350, 358], ["patients", "SPECIES", 422, 430], ["pneumonia", "PROBLEM", 200, 209], ["donor bone marrow", "TEST", 248, 265], ["the IV route", "TREATMENT", 363, 375], ["cytokine storm", "PROBLEM", 391, 405], ["ARDS", "PROBLEM", 446, 450], ["mesenchymal stem cells", "OBSERVATION", 3, 25], ["pneumonia", "OBSERVATION", 200, 209], ["placenta", "ANATOMY", 267, 275], ["fat", "ANATOMY", 277, 280], ["umbilical cord", "ANATOMY", 284, 298], ["ARDS", "OBSERVATION", 446, 450]]], ["So far, several randomized clinical trials using MSCs (allogenic or autologous from different sources, such as bone marrow, umbilical cord, adipose tissue, etc) for COVID\u201019 patients are in progress worldwide.", [["MSCs", "ANATOMY", 49, 53], ["bone marrow", "ANATOMY", 111, 122], ["umbilical cord", "ANATOMY", 124, 138], ["adipose tissue", "ANATOMY", 140, 154], ["MSCs", "CELL", 49, 53], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 111, 122], ["umbilical cord", "TISSUE", 124, 138], ["adipose tissue", "TISSUE", 140, 154], ["patients", "ORGANISM", 174, 182], ["MSCs", "CELL_TYPE", 49, 53], ["patients", "SPECIES", 174, 182], ["MSCs (allogenic or autologous", "TREATMENT", 49, 78], ["umbilical cord", "ANATOMY", 124, 138], ["adipose tissue", "ANATOMY", 140, 154]]], ["Recently, the FDA also approved their usage in severely affected COVID\u201019 patients under expanded access to compassionate use.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["The main rationale of using MSCs is based on their immunomodulatory effects by secreting different regulatory cytokines such as IL\u2010I RA (cytokine\u2010dependent) or their direct interaction with immune cells (cytokine\u2010independent) and suppressing their activation or proliferation.", [["MSCs", "ANATOMY", 28, 32], ["immune cells", "ANATOMY", 190, 202], ["MSCs", "CELL", 28, 32], ["IL\u2010I RA", "GENE_OR_GENE_PRODUCT", 128, 135], ["immune cells", "CELL", 190, 202], ["MSCs", "CELL_TYPE", 28, 32], ["regulatory cytokines", "PROTEIN", 99, 119], ["cytokine", "PROTEIN", 137, 145], ["immune cells", "CELL_TYPE", 190, 202], ["MSCs", "TREATMENT", 28, 32], ["secreting different regulatory cytokines", "TREATMENT", 79, 119], ["immune cells", "TREATMENT", 190, 202], ["proliferation", "PROBLEM", 262, 275], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["These play key roles for polarizing regulatory T cells and monocytes/macrophages toward the anti\u2010inflammatory phenotype.4,5In addition, MSC entrapment in the lung following IV injection and local secretion of cytokines and growth factors can reduce inflammation, increase alveolar macrophage phagocytosis, regulate capillary permeability, and restore alveolar fluid clearance in inflammatory lung disorders such as severe pneumonia and ARDS.6So far, a limited clinical trial of MSCs in seven COVID patients in China indicated their safety and possible effectiveness to treat pneumonia.7Improvements included reduction of CRP and tumor necrosis factor\u2010\u03b1, increased peripheral lymphocytes and reduction of cytokine\u2010releasing immune cells in treated patients.", [["regulatory T cells", "ANATOMY", 36, 54], ["monocytes", "ANATOMY", 59, 68], ["macrophages", "ANATOMY", 69, 80], ["MSC", "ANATOMY", 136, 139], ["lung", "ANATOMY", 158, 162], ["alveolar macrophage", "ANATOMY", 272, 291], ["capillary", "ANATOMY", 315, 324], ["alveolar fluid", "ANATOMY", 351, 365], ["lung", "ANATOMY", 392, 396], ["MSCs", "ANATOMY", 478, 482], ["tumor", "ANATOMY", 629, 634], ["peripheral lymphocytes", "ANATOMY", 664, 686], ["cytokine\u2010releasing immune cells", "ANATOMY", 704, 735], ["inflammation", "DISEASE", 249, 261], ["lung disorders", "DISEASE", 392, 406], ["pneumonia", "DISEASE", 422, 431], ["ARDS", "DISEASE", 436, 440], ["COVID", "DISEASE", 492, 497], ["pneumonia", "DISEASE", 575, 584], ["tumor", "DISEASE", 629, 634], ["necrosis", "DISEASE", 635, 643], ["T cells", "CELL", 47, 54], ["monocytes", "CELL", 59, 68], ["macrophages", "CELL", 69, 80], ["MSC", "CELL", 136, 139], ["lung", "ORGAN", 158, 162], ["alveolar macrophage", "CELL", 272, 291], ["capillary", "TISSUE", 315, 324], ["alveolar fluid", "TISSUE", 351, 365], ["lung", "ORGAN", 392, 396], ["MSCs", "CELL", 478, 482], ["patients", "ORGANISM", 498, 506], ["CRP", "GENE_OR_GENE_PRODUCT", 621, 624], ["tumor necrosis factor\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 629, 652], ["peripheral lymphocytes", "CELL", 664, 686], ["cytokine\u2010releasing immune cells", "CELL", 704, 735], ["patients", "ORGANISM", 747, 755], ["polarizing regulatory T cells", "CELL_TYPE", 25, 54], ["monocytes", "CELL_TYPE", 59, 68], ["macrophages", "CELL_TYPE", 69, 80], ["MSC", "CELL_TYPE", 136, 139], ["cytokines", "PROTEIN", 209, 218], ["growth factors", "PROTEIN", 223, 237], ["MSCs", "CELL_TYPE", 478, 482], ["CRP", "PROTEIN", 621, 624], ["tumor necrosis factor\u2010\u03b1", "PROTEIN", 629, 652], ["peripheral lymphocytes", "CELL_TYPE", 664, 686], ["cytokine\u2010releasing immune cells", "CELL_TYPE", 704, 735], ["patients", "SPECIES", 498, 506], ["patients", "SPECIES", 747, 755], ["polarizing regulatory T cells", "TEST", 25, 54], ["monocytes", "TEST", 59, 68], ["macrophages", "PROBLEM", 69, 80], ["the anti\u2010inflammatory phenotype", "PROBLEM", 88, 119], ["MSC entrapment in the lung", "PROBLEM", 136, 162], ["IV injection", "TREATMENT", 173, 185], ["local secretion of cytokines", "TREATMENT", 190, 218], ["growth factors", "PROBLEM", 223, 237], ["inflammation", "PROBLEM", 249, 261], ["increase alveolar macrophage phagocytosis", "PROBLEM", 263, 304], ["capillary permeability", "TEST", 315, 337], ["restore alveolar fluid clearance", "PROBLEM", 343, 375], ["inflammatory lung disorders", "PROBLEM", 379, 406], ["severe pneumonia", "PROBLEM", 415, 431], ["ARDS", "PROBLEM", 436, 440], ["MSCs", "TREATMENT", 478, 482], ["pneumonia", "PROBLEM", 575, 584], ["CRP", "TEST", 621, 624], ["tumor necrosis factor\u2010\u03b1", "PROBLEM", 629, 652], ["increased peripheral lymphocytes", "PROBLEM", 654, 686], ["cytokine\u2010releasing immune cells", "TREATMENT", 704, 735], ["MSC entrapment", "OBSERVATION", 136, 150], ["lung", "ANATOMY", 158, 162], ["increase", "OBSERVATION_MODIFIER", 263, 271], ["alveolar macrophage phagocytosis", "OBSERVATION", 272, 304], ["capillary permeability", "OBSERVATION", 315, 337], ["alveolar", "ANATOMY_MODIFIER", 351, 359], ["fluid clearance", "OBSERVATION", 360, 375], ["inflammatory", "OBSERVATION_MODIFIER", 379, 391], ["lung", "ANATOMY", 392, 396], ["severe", "OBSERVATION_MODIFIER", 415, 421], ["pneumonia", "OBSERVATION", 422, 431], ["ARDS", "OBSERVATION", 436, 440], ["pneumonia", "OBSERVATION", 575, 584], ["reduction", "OBSERVATION_MODIFIER", 608, 617], ["CRP", "OBSERVATION_MODIFIER", 621, 624], ["tumor necrosis", "OBSERVATION", 629, 643], ["increased", "OBSERVATION_MODIFIER", 654, 663], ["peripheral lymphocytes", "OBSERVATION", 664, 686], ["reduction", "OBSERVATION_MODIFIER", 691, 700], ["cytokine\u2010releasing immune cells", "OBSERVATION", 704, 735]]], ["Further gene expression profiling of transplanted MSCs indicated their anti\u2010inflammatory and immunomodulatory roles through secretion of a wide range of modulatory cytokines as the possible mechanism of the MSC effectiveness.", [["MSCs", "ANATOMY", 50, 54], ["MSC", "ANATOMY", 207, 210], ["MSCs", "CELL", 50, 54], ["MSC", "CELL", 207, 210], ["MSCs", "CELL_TYPE", 50, 54], ["modulatory cytokines", "PROTEIN", 153, 173], ["transplanted MSCs", "PROBLEM", 37, 54], ["modulatory cytokines", "TREATMENT", 153, 173], ["the MSC effectiveness", "PROBLEM", 203, 224], ["MSC effectiveness", "OBSERVATION", 207, 224]]], ["Although the initial results of this study were promising, the low number of the patients (seven patients), lack of control/placebo group, and heterogeneity of the studied subjects are among major shortcomings, which warrants further research to determine the true effectiveness of MSCs for COVID\u201019 treatment.", [["MSCs", "ANATOMY", 282, 286], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 97, 105], ["MSCs", "CELL", 282, 286], ["MSCs", "CELL_TYPE", 282, 286], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 97, 105], ["this study", "TEST", 32, 42], ["control/placebo group", "TREATMENT", 116, 137], ["MSCs", "TREATMENT", 282, 286], ["COVID\u201019 treatment", "TREATMENT", 291, 309]]], ["Except for pneumonia, other severe complications of the COVID\u201019 infection such as multi\u2010organ failure and sepsis might also benefit from MSC treatment.", [["MSC", "ANATOMY", 138, 141], ["pneumonia", "DISEASE", 11, 20], ["infection", "DISEASE", 65, 74], ["multi\u2010organ failure", "DISEASE", 83, 102], ["sepsis", "DISEASE", 107, 113], ["MSC", "CELL", 138, 141], ["pneumonia", "PROBLEM", 11, 20], ["other severe complications", "PROBLEM", 22, 48], ["the COVID\u201019 infection", "PROBLEM", 52, 74], ["multi\u2010organ failure", "PROBLEM", 83, 102], ["sepsis", "PROBLEM", 107, 113], ["MSC treatment", "TREATMENT", 138, 151], ["pneumonia", "OBSERVATION", 11, 20], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["complications", "OBSERVATION", 35, 48], ["infection", "OBSERVATION", 65, 74], ["failure", "OBSERVATION", 95, 102], ["sepsis", "OBSERVATION", 107, 113]]], ["There are several encouraging studies done on animal models of sepsis and multi\u2010organ failure, which indicate the beneficial effects of MSC treatment in these situations (reviewed in Harok et al8).", [["MSC", "ANATOMY", 136, 139], ["sepsis", "DISEASE", 63, 69], ["multi\u2010organ failure", "DISEASE", 74, 93], ["MSC", "CELL", 136, 139], ["several encouraging studies", "TEST", 10, 37], ["sepsis", "PROBLEM", 63, 69], ["multi\u2010organ failure", "PROBLEM", 74, 93], ["MSC treatment", "TREATMENT", 136, 149], ["sepsis", "OBSERVATION", 63, 69], ["multi\u2010organ failure", "OBSERVATION", 74, 93]]], ["Possible mechanisms of actions include MSC fusion and transdifferentiation into damaged tissue, paracrine effect to inhibit cell death and tissue damage, facilitation of molecule/organelle transportation in damaged tissue, immunomodulatory effects and finally direct antimicrobial effect by secretion of antibacterial peptides (such as LL\u201037 or lipocalin\u20102) or amplification of phagocytosis.", [["MSC", "ANATOMY", 39, 42], ["tissue", "ANATOMY", 88, 94], ["cell", "ANATOMY", 124, 128], ["tissue", "ANATOMY", 139, 145], ["organelle", "ANATOMY", 179, 188], ["tissue", "ANATOMY", 215, 221], ["death", "DISEASE", 129, 134], ["MSC", "CELL", 39, 42], ["tissue", "TISSUE", 88, 94], ["cell", "CELL", 124, 128], ["tissue", "TISSUE", 139, 145], ["organelle", "CELLULAR_COMPONENT", 179, 188], ["tissue", "TISSUE", 215, 221], ["LL\u201037", "GENE_OR_GENE_PRODUCT", 336, 341], ["lipocalin\u20102", "GENE_OR_GENE_PRODUCT", 345, 356], ["lipocalin\u20102", "PROTEIN", 345, 356], ["MSC fusion", "TREATMENT", 39, 49], ["transdifferentiation into damaged tissue", "PROBLEM", 54, 94], ["paracrine effect", "PROBLEM", 96, 112], ["inhibit cell death", "PROBLEM", 116, 134], ["tissue damage", "PROBLEM", 139, 152], ["molecule/organelle transportation", "PROBLEM", 170, 203], ["damaged tissue", "PROBLEM", 207, 221], ["immunomodulatory effects", "PROBLEM", 223, 247], ["direct antimicrobial effect", "TREATMENT", 260, 287], ["antibacterial peptides", "PROBLEM", 304, 326], ["phagocytosis", "PROBLEM", 378, 390], ["MSC fusion", "OBSERVATION", 39, 49], ["tissue", "ANATOMY", 139, 145], ["damage", "OBSERVATION", 146, 152], ["damaged tissue", "OBSERVATION_MODIFIER", 207, 221]]], ["Therefore, MSCs can also be considered as an adjective therapy in complicated and end\u2010stage COVID patients suffering from sepsis or multiorgan failure.AbbreviationAside from the acute phase of the COVID\u201019 disease, the recovery phase of the disease and its long\u2010term side effects such as lung fibrosis and alveolar damage might also be another area of the interest for future stem cell therapies.", [["MSCs", "ANATOMY", 11, 15], ["multiorgan", "ANATOMY", 132, 142], ["lung", "ANATOMY", 288, 292], ["alveolar", "ANATOMY", 306, 314], ["stem cell", "ANATOMY", 376, 385], ["COVID", "DISEASE", 92, 97], ["sepsis", "DISEASE", 122, 128], ["multiorgan failure", "DISEASE", 132, 150], ["fibrosis", "DISEASE", 293, 301], ["alveolar damage", "DISEASE", 306, 321], ["MSCs", "CELL", 11, 15], ["patients", "ORGANISM", 98, 106], ["multiorgan", "ORGAN", 132, 142], ["lung", "ORGAN", 288, 292], ["alveolar", "MULTI-TISSUE_STRUCTURE", 306, 314], ["stem cell", "CELL", 376, 385], ["MSCs", "CELL_TYPE", 11, 15], ["patients", "SPECIES", 98, 106], ["MSCs", "TREATMENT", 11, 15], ["an adjective therapy", "TREATMENT", 42, 62], ["sepsis", "PROBLEM", 122, 128], ["multiorgan failure", "PROBLEM", 132, 150], ["the COVID\u201019 disease", "PROBLEM", 193, 213], ["the disease", "PROBLEM", 237, 248], ["its long\u2010term side effects", "PROBLEM", 253, 279], ["lung fibrosis", "PROBLEM", 288, 301], ["alveolar damage", "PROBLEM", 306, 321], ["future stem cell therapies", "TREATMENT", 369, 395], ["sepsis", "OBSERVATION", 122, 128], ["multiorgan failure", "OBSERVATION", 132, 150], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["phase", "OBSERVATION_MODIFIER", 184, 189], ["disease", "OBSERVATION", 241, 248], ["lung", "ANATOMY", 288, 292], ["fibrosis", "OBSERVATION", 293, 301], ["alveolar damage", "OBSERVATION", 306, 321], ["stem cell therapies", "OBSERVATION", 376, 395]]], ["Although MSCs can also be useful for reducing inflammation and consequently limiting lung fibrosis, other stem cell therapies might also be considered for eventual alveolar regeneration.", [["MSCs", "ANATOMY", 9, 13], ["lung", "ANATOMY", 85, 89], ["stem cell", "ANATOMY", 106, 115], ["alveolar", "ANATOMY", 164, 172], ["inflammation", "DISEASE", 46, 58], ["fibrosis", "DISEASE", 90, 98], ["MSCs", "CELL", 9, 13], ["lung", "ORGAN", 85, 89], ["stem cell", "CELL", 106, 115], ["alveolar", "TISSUE", 164, 172], ["MSCs", "CELL_TYPE", 9, 13], ["MSCs", "PROBLEM", 9, 13], ["reducing inflammation", "PROBLEM", 37, 58], ["consequently limiting lung fibrosis", "PROBLEM", 63, 98], ["other stem cell therapies", "TREATMENT", 100, 125], ["eventual alveolar regeneration", "PROBLEM", 155, 185], ["inflammation", "OBSERVATION", 46, 58], ["lung", "ANATOMY", 85, 89], ["fibrosis", "OBSERVATION", 90, 98], ["stem cell therapies", "OBSERVATION", 106, 125], ["alveolar", "ANATOMY_MODIFIER", 164, 172], ["regeneration", "OBSERVATION", 173, 185]]], ["For this, lung stem cells such as distal airway stem cells and alveolar epithelial type 2 cells might be a good candidate stem cell therapy for alveolar regeneration9in recovered patients suffering from permanent alveolar damage.", [["lung stem cells", "ANATOMY", 10, 25], ["distal airway stem cells", "ANATOMY", 34, 58], ["alveolar epithelial type 2 cells", "ANATOMY", 63, 95], ["stem cell", "ANATOMY", 122, 131], ["alveolar", "ANATOMY", 144, 152], ["alveolar", "ANATOMY", 213, 221], ["alveolar damage", "DISEASE", 213, 228], ["lung stem cells", "CELL", 10, 25], ["distal airway stem cells", "CELL", 34, 58], ["alveolar epithelial type 2 cells", "CELL", 63, 95], ["stem cell", "CELL", 122, 131], ["alveolar", "MULTI-TISSUE_STRUCTURE", 144, 152], ["patients", "ORGANISM", 179, 187], ["alveolar", "TISSUE", 213, 221], ["lung stem cells", "CELL_TYPE", 10, 25], ["distal airway stem cells", "CELL_TYPE", 34, 58], ["alveolar epithelial type 2 cells", "CELL_TYPE", 63, 95], ["patients", "SPECIES", 179, 187], ["this, lung stem cells", "PROBLEM", 4, 25], ["distal airway stem cells", "PROBLEM", 34, 58], ["alveolar epithelial type 2 cells", "PROBLEM", 63, 95], ["stem cell therapy", "TREATMENT", 122, 139], ["alveolar regeneration9in", "PROBLEM", 144, 168], ["permanent alveolar damage", "PROBLEM", 203, 228], ["lung", "ANATOMY", 10, 14], ["stem cells", "OBSERVATION", 15, 25], ["distal", "ANATOMY_MODIFIER", 34, 40], ["airway", "ANATOMY", 41, 47], ["stem cells", "OBSERVATION", 48, 58], ["alveolar", "ANATOMY_MODIFIER", 63, 71], ["epithelial", "ANATOMY_MODIFIER", 72, 82], ["stem cell therapy", "OBSERVATION", 122, 139], ["permanent", "OBSERVATION_MODIFIER", 203, 212], ["alveolar damage", "OBSERVATION", 213, 228]]], ["These cells can be obtained through clonal expansion or iPSC differentiation methods.AbbreviationFinally, as our understanding of COVID\u201019 and its clinical complications increases, there is growing evidence about the involvement of other organs such as heart, liver, and neurological complications during its long clinical course.10These complications might also benefit from specific stem cell therapies targeting affected organs.", [["cells", "ANATOMY", 6, 11], ["iPSC", "ANATOMY", 56, 60], ["organs", "ANATOMY", 238, 244], ["heart", "ANATOMY", 253, 258], ["liver", "ANATOMY", 260, 265], ["neurological", "ANATOMY", 271, 283], ["stem cell", "ANATOMY", 385, 394], ["organs", "ANATOMY", 424, 430], ["heart, liver", "DISEASE", 253, 265], ["cells", "CELL", 6, 11], ["clonal", "CELL", 36, 42], ["iPSC", "CELL", 56, 60], ["organs", "ORGAN", 238, 244], ["heart", "ORGAN", 253, 258], ["liver", "ORGAN", 260, 265], ["stem cell", "CELL", 385, 394], ["organs", "ORGAN", 424, 430], ["clonal expansion", "PROBLEM", 36, 52], ["its clinical complications", "PROBLEM", 143, 169], ["the involvement of other organs", "PROBLEM", 213, 244], ["heart, liver, and neurological complications", "PROBLEM", 253, 297], ["These complications", "PROBLEM", 332, 351], ["specific stem cell therapies", "TREATMENT", 376, 404], ["affected organs", "PROBLEM", 415, 430], ["iPSC differentiation", "OBSERVATION", 56, 76], ["heart", "ANATOMY", 253, 258], ["liver", "ANATOMY", 260, 265], ["neurological", "OBSERVATION_MODIFIER", 271, 283], ["complications", "OBSERVATION", 284, 297], ["complications", "OBSERVATION", 338, 351], ["stem cell", "OBSERVATION", 385, 394]]], ["As new stem cell therapies are emerging to treat COVID\u201019 patients, specific attention must be given to validate their true efficacy and possible side effects.", [["stem cell", "ANATOMY", 7, 16], ["COVID", "DISEASE", 49, 54], ["stem cell", "CELL", 7, 16], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["new stem cell therapies", "TREATMENT", 3, 26], ["side effects", "PROBLEM", 146, 158], ["stem cell therapies", "OBSERVATION", 7, 26]]], ["These can be accomplished by designing appropriately controlled/randomized clinical trials and monitoring for potential side effects such as a lung/other end\u2010organ emboli and signs of cell overgrowth/tumor formation.11", [["lung", "ANATOMY", 143, 147], ["end\u2010organ emboli", "ANATOMY", 154, 170], ["cell", "ANATOMY", 184, 188], ["tumor", "ANATOMY", 200, 205], ["emboli", "DISEASE", 164, 170], ["tumor", "DISEASE", 200, 205], ["lung", "ORGAN", 143, 147], ["cell", "CELL", 184, 188], ["tumor", "CANCER", 200, 205], ["clinical trials", "TREATMENT", 75, 90], ["monitoring", "TEST", 95, 105], ["potential side effects", "PROBLEM", 110, 132], ["a lung/other end\u2010organ emboli", "PROBLEM", 141, 170], ["cell overgrowth", "PROBLEM", 184, 199], ["tumor formation", "PROBLEM", 200, 215], ["lung", "ANATOMY", 143, 147], ["end\u2010organ", "ANATOMY", 154, 163], ["emboli", "OBSERVATION", 164, 170], ["cell overgrowth", "OBSERVATION", 184, 199], ["tumor", "OBSERVATION", 200, 205]]]], "PMC7431021": [["The century witnessed substantial expansion at the college level: The college enrollment rate for 20- to 21-y-olds increased from around 15% for the mid-1920s birth cohorts to almost 60% for cohorts born toward the end of the century.* As Fig. 1 shows, rates of enrollment rose rapidly for cohorts born in the early century to midcentury, and flattened out and even declined for the midcentury birth cohorts, before resuming a steady increase for cohorts born in the later decades of the century.College Enrollment and Completion in the Twentieth CenturyWe see in Fig. 1 a stark reversal of the gender gap in college enrollment; for birth cohorts from the mid-1950s to mid-1990s, the proportion of women enrolled in college grew by around 30 percentage points, while the corresponding increase for men was just under 20 percentage points (16, 17).", [["women", "ORGANISM", 698, 703], ["men", "ORGANISM", 798, 801], ["women", "SPECIES", 698, 703], ["men", "SPECIES", 798, 801], ["birth cohorts", "PROBLEM", 633, 646], ["substantial", "OBSERVATION_MODIFIER", 22, 33], ["expansion", "OBSERVATION_MODIFIER", 34, 43], ["flattened", "OBSERVATION_MODIFIER", 343, 352], ["increase", "OBSERVATION_MODIFIER", 785, 793]]], ["The reversal occurred immediately after the rapid increase in enrollment rates observed for male birth cohorts at risk for service in the Vietnam War (16).", [["reversal", "OBSERVATION", 4, 12], ["rapid", "OBSERVATION_MODIFIER", 44, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58]]], ["A literature in economics has demonstrated that men born in the 1940s and 1950s were unusually likely to attend and graduate from college, although there is disagreement with respect to whether the observed increase in men\u2019s college participation rates should be attributed to draft avoidance or to postservice GI Bill enrollments (ref.", [["men", "ORGANISM", 48, 51], ["men", "ORGANISM", 219, 222], ["men", "SPECIES", 48, 51], ["men", "SPECIES", 219, 222]]], ["While rates of completion of 2-year college are rather flat for cohorts born from the 1950s onward, rates of 4-year college completion have increased considerably.", [["increased", "OBSERVATION_MODIFIER", 140, 149]]], ["As the figure suggests, rates of 4-year college completion are highly correlated with rates of enrollment, but research shows that, over the past half-century, rates of college completion increased less sharply than rates of enrollment, because the college dropout rate increased (6, 20).Materials and MethodAlthough it is relatively straightforward to examine changes in rates of college enrollment and completion over time, it is rather less straightforward to examine income inequalities in collegiate outcomes across the span of the twentieth century, because data on parental income, college enrollment, and college completion are not routinely collected in government surveys.", [["the college dropout rate", "TEST", 245, 269], ["increased", "OBSERVATION_MODIFIER", 188, 197], ["less", "OBSERVATION_MODIFIER", 198, 202], ["sharply", "OBSERVATION_MODIFIER", 203, 210], ["increased", "OBSERVATION_MODIFIER", 270, 279]]], ["We must therefore piece together the trends in collegiate inequalities through the analysis of available sources of nationally representative data.", [["the analysis", "TEST", 79, 91]]], ["We include results from the analysis of both cross-sectional surveys of adults and longitudinal surveys beginning with school-aged children, and, for a number of recent cohorts, we calculate estimates from tax data results in the public domain.", [["children", "ORGANISM", 131, 139], ["tax", "PROTEIN", 206, 209], ["children", "SPECIES", 131, 139], ["the analysis", "TEST", 24, 36], ["tax data", "TEST", 206, 214]]], ["The datasets and their key characteristics are listed in Table 1; detailed descriptions of each dataset are included in SI Appendix.Materials and MethodThe datasets cover cohorts born between 1908 and 1995, and it is only at the beginning and the end of the data series that our birth cohorts are represented by no more than one dataset.", [["Appendix", "ANATOMY", 123, 131]]], ["Although we aim to define cohorts according to year of birth, for some of the datasets we must construct quasi-cohorts based on age or grade, because year of birth was not recorded.Materials and MethodThe biggest constraint that we face in analyzing income inequalities in collegiate attainment relates to gender.", [["biggest", "OBSERVATION_MODIFIER", 205, 212]]], ["This survey was completed by men only, so we lack information on the educational attainment of women in the earliest birth cohorts.", [["men", "ORGANISM", 29, 32], ["women", "ORGANISM", 95, 100], ["men", "SPECIES", 29, 32], ["women", "SPECIES", 95, 100]]], ["By presenting all results separately for men and women, patterns over time can be compared by gender.Materials and MethodThe datasets were prepared to provide consistent measures of family income, college enrollment, and college completion.", [["men", "ORGANISM", 41, 44], ["women", "ORGANISM", 49, 54], ["men", "SPECIES", 41, 44], ["women", "SPECIES", 49, 54]]], ["We produce simple binary variables that capture whether an individual completed a 4-year degree, whether an individual enrolled in (without necessarily completing) a 4-year degree program, and whether an individual enrolled in (without necessarily completing) a college program.", [["simple binary variables", "PROBLEM", 11, 34]]], ["Unfortunately, the tax data results pertain only to college enrollment per se, so we have fewer available data points for the analyses of 4-year completion and enrollment than for the analyses of enrollment in any college program.", [["tax", "PROTEIN", 19, 22], ["the tax data", "TEST", 15, 27]]], ["All samples are restricted to individuals who enrolled in high school, in order to maximize consistency across samples.", [["samples", "ANATOMY", 4, 11]]], ["In SI Appendix, we also include results for a smaller sample restricted to high school graduates (SI Appendix, Fig. S6).Materials and MethodA more difficult variable to harmonize over time is family income.", [["S6", "GENE_OR_GENE_PRODUCT", 116, 118], ["S6", "PROTEIN", 116, 118], ["a smaller sample", "PROBLEM", 44, 60], ["SI Appendix", "ANATOMY", 3, 14], ["Appendix", "ANATOMY", 101, 109]]], ["For these datasets, we employ the method used by Reardon (9) to calculate test score gaps from coarsened family income data; the method uses the proportions in each income category to assign an income rank to all of those in a given category, and income rank is then the explanatory variable in the analysis (SI Appendix, SI Methods).Materials and MethodWe estimate logits predicting college enrollment and completion as a function of family income or income rank.", [["test score gaps", "TEST", 74, 89]]], ["We choose the 90 vs. 10 comparison over other ways of defining inequality because it accords with past assessments and with the main source of trend in income inequality (9).\u2020 From these rates, we calculate log-odds ratios capturing, for example, the log-odds of completing a 4-year college degree for the 90 vs. 10 family income comparison.Materials and MethodWe would be remiss if we did not note the difficulty in measuring family income reliably, particularly using one-shot measures, which are all that are available in almost all of the datasets that we analyze.", [["past assessments", "TEST", 98, 114]]], ["Further worries might arise because some of the income measures are retrospective, or because the questions are asked of children, not parents.", [["children", "ORGANISM", 121, 129], ["children", "SPECIES", 121, 129]]], ["Although we would not minimize the danger of retrospection or of using children\u2019s reports of family income, evidence suggests that child reports of parental socioeconomic characteristics are not substantially worse than parental reports of those characteristics (9, 22).", [["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79]]], ["To address concerns about the varying quality of the family income data, we multiply all log-odds ratios by 1/r, where r is the estimated reliability of the family income measure (see SI Appendix, Table S5 for reliability estimates) (9).Materials and MethodWe recognize that \u201cresearcher degrees of freedom\u201d are of particular concern when presenting results from a large number of datasets (24).", [["large", "OBSERVATION_MODIFIER", 364, 369]]], ["We provide additional results based on alternative specifications, in SI Appendix, and make our analysis code publicly available on Open Science Framework, https://osf.io/jxne5.The Great U-turn in Collegiate InequalityWe now examine collegiate inequalities for cohorts born between 1908 and 1995.", [["Appendix", "ANATOMY", 73, 81], ["Great", "OBSERVATION_MODIFIER", 181, 186]]], ["Given data constraints, we are limited to examining inequalities over the whole period for men only, but we present results for women for a more limited range of birth cohorts.The Great U-turn in Collegiate InequalityIn Fig. 2 we present, for the full male series, the estimated probabilities of completing 4-year college at the 90th and 10th percentiles of family income.\u2021 We see in Fig. 2 that the increase in 4-year college degree attainment over the twentieth century was far from equally distributed across income groups.", [["men", "ORGANISM", 91, 94], ["women", "ORGANISM", 128, 133], ["men", "SPECIES", 91, 94], ["women", "SPECIES", 128, 133], ["increase", "OBSERVATION_MODIFIER", 400, 408]]], ["Men from the 90th percentile of family income were at the leading edge of the expansion; the figure shows a rapid increase in college completion rates through the 1940s birth cohorts, then a tailing off through the 1950s cohorts, followed by a further rapid increase for those cohorts born in the 1960s onward.", [["Men", "SPECIES", 0, 3], ["rapid", "OBSERVATION_MODIFIER", 108, 113], ["increase", "OBSERVATION_MODIFIER", 114, 122]]], ["In contrast, expansion at the bottom of the income distribution was more sluggish; 4-year college completion rates at the 10th percentile were less than 10 percentage points higher for cohorts born at the end of the century than for cohorts born at the beginning.The Great U-turn in Collegiate InequalityFig.", [["expansion", "OBSERVATION_MODIFIER", 13, 22], ["bottom", "ANATOMY_MODIFIER", 30, 36], ["sluggish", "OBSERVATION_MODIFIER", 73, 81], ["InequalityFig", "OBSERVATION", 294, 307]]], ["2 shows that absolute differences in completion rates between income groups increased from the beginning to the end of the century.", [["absolute differences", "PROBLEM", 13, 33], ["absolute", "OBSERVATION_MODIFIER", 13, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33]]], ["Although the probability gap was small at the beginning of the century, the odds of college completion were around 7 times higher for the rich than for the poor, because the rich were able to secure a large proportion of the limited number of college slots.", [["gap", "OBSERVATION_MODIFIER", 25, 28], ["small", "OBSERVATION_MODIFIER", 33, 38], ["large", "OBSERVATION_MODIFIER", 201, 206]]], ["In relative terms, the poor born in the early century were more disadvantaged than their counterparts born in the 1960s, when 90 vs. 10 gaps in the probability of college completion were substantially larger.", [["larger", "OBSERVATION_MODIFIER", 201, 207]]], ["Although both probability gap and odds-ratio measures are informative, we focus from this point forward on odds-ratio measures of educational inequality, which are margin insensitive and thus feature relative\u2014rather than absolute\u2014advantage.", [["margin", "OBSERVATION_MODIFIER", 164, 170]]], ["But, in SI Appendix, we present probability plots for the three collegiate outcomes (SI Appendix, Fig. S1), and include analyses based on probability gaps in SI Appendix, Table S3.", [["analyses", "TEST", 120, 128], ["SI Appendix", "ANATOMY", 8, 19], ["SI Appendix", "ANATOMY", 158, 169]]], ["The key results hold for both types of analysis.The Great U-turn in Collegiate InequalityWe plot, in Fig. 3, the 90 vs. 10 log-odds ratios describing inequalities in collegiate outcomes for each of the datasets in our analyses, with trends estimated from generalized additive models (GAM).", [["analysis", "TEST", 39, 47], ["our analyses", "TEST", 214, 226]]], ["The GAMs are fitted to the plotted data points, with each point weighted by the inverse of the SE for the estimate.\u00a7 In the earlier period covered by OCG, we fit the model to the estimates derived from analyses of single birth cohorts, but present point estimates representing groups of birth cohorts to show the consistency across these specifications.", [["SE", "DISEASE", 95, 97], ["GAMs", "DNA", 4, 8], ["single birth cohorts", "TREATMENT", 214, 234]]], ["Confidence intervals are presented in SI Appendix, Fig. S2; figures showing 90 vs. 50 and 50 vs. 10 inequalities are included as SI Appendix, Figs.", [["figures", "TEST", 60, 67], ["SI Appendix", "ANATOMY", 38, 49], ["Appendix", "ANATOMY", 132, 140]]], ["S3 and S4.The Great U-turn in Collegiate InequalityWe focus first on describing the trends for men, for whom we have results spanning the whole century.", [["S4", "GENE_OR_GENE_PRODUCT", 7, 9], ["men", "ORGANISM", 95, 98], ["S4", "PROTEIN", 7, 9], ["men", "SPECIES", 95, 98], ["S4", "ANATOMY", 7, 9]]], ["It is clear from Fig. 3 that the over-time trends are similar across the various collegiate outcomes and, further, that there is no simple secular trend for any of the outcomes under consideration.", [["simple secular trend", "PROBLEM", 132, 152], ["clear", "OBSERVATION", 6, 11], ["no", "UNCERTAINTY", 129, 131]]], ["There are three key attributes of the trends that should be emphasized.The Great U-turn in Collegiate InequalityFirst, Fig. 3 shows that, toward the middle of the century, there was a great U-turn in collegiate inequality.", [["middle", "ANATOMY_MODIFIER", 149, 155]]], ["The U-turn appears to be more pronounced for 4-year and \u201cany college\u201d enrollment than for completion of a 4-year degree, but it is present for all of the collegiate outcomes under consideration.The Great U-turn in Collegiate InequalityHad we measured collegiate inequalities in but a single dataset, we might be skeptical that our observed trend was on the mark and, in particular, that there was a rapid fall in inequality for the midcentury birth cohorts.", [["a rapid fall", "PROBLEM", 397, 409], ["the midcentury birth cohorts", "TREATMENT", 428, 456], ["more pronounced", "OBSERVATION_MODIFIER", 25, 40], ["rapid", "OBSERVATION_MODIFIER", 399, 404], ["fall", "OBSERVATION", 405, 409]]], ["But this trend is supported across all of the datasets from the period: OCG and National Longitudinal Study (NLS) Young Men show high inequality in the early 1950s; Panel Study of Income Dynamics (PSID), NLS72, and High School and Beyond (HS&B) pick up the lower inequality of the mid-1950s to the mid-1960s; and the subsequent uptick in inequality is captured in PSID, the school cohort surveys, and the National Longitudinal Studies of Youth (NLSY79&97).", [["National Longitudinal Study", "TEST", 80, 107]]], ["Indeed, Fig. 3 demonstrates that there is great consistency across a large number of different data sources.\u00b6 At the trough, inequality in 4-year college completion was reduced to a log-odds ratio of around 1.5, indicating that, even in this low-inequality period, the odds of those at the 90th income percentile completing a 4-year college degree were almost 4.5 times greater than the equivalent odds for those at the 10th percentile.", [["a log-odds ratio", "TEST", 180, 196], ["great", "OBSERVATION_MODIFIER", 42, 47], ["consistency", "OBSERVATION_MODIFIER", 48, 59], ["large", "OBSERVATION_MODIFIER", 69, 74], ["number", "OBSERVATION_MODIFIER", 75, 81]]], ["Inspection of SI Appendix, Fig. S3 suggests that the U-turn observed in Fig. 3 is largely driven by changes in the top half of the income distribution: the U-turn is rather more pronounced for the 90 vs. 50 comparison than for the 50 vs. 10 comparison.The Great U-turn in Collegiate InequalitySecond, if skepticism about a midcentury fall in collegiate inequality were to be sustained, suspicion would also have to fall upon all currently accepted results on over-time trends, which demonstrate a substantial increase in inequalities in college enrollment and completion between cohorts born in the midcentury and late century.", [["S3", "GENE_OR_GENE_PRODUCT", 32, 34], ["a midcentury fall", "PROBLEM", 321, 338], ["SI Appendix", "ANATOMY", 14, 25], ["largely", "OBSERVATION_MODIFIER", 82, 89], ["driven", "OBSERVATION", 90, 96], ["more pronounced", "OBSERVATION_MODIFIER", 173, 188], ["substantial", "OBSERVATION_MODIFIER", 497, 508], ["increase", "OBSERVATION_MODIFIER", 509, 517], ["late", "OBSERVATION_MODIFIER", 614, 618], ["century", "OBSERVATION_MODIFIER", 619, 626]]], ["If we were to impose a simple linear smooth on the century-long data series, this would indicate relatively modest increases in collegiate inequalities over the period taken as a whole (see dashed lines, Fig. 3).# Again, because the trends are mapped using multiple datasets, we are confident that the pattern of a U-turn in collegiate inequality is supported.The Great U-turn in Collegiate InequalityThird, any evidence of a U-turn must bring to mind the pattern of income inequality over the past century.", [["a whole (see dashed lines", "TREATMENT", 177, 202], ["linear", "OBSERVATION_MODIFIER", 30, 36], ["smooth", "OBSERVATION_MODIFIER", 37, 43], ["relatively", "OBSERVATION_MODIFIER", 97, 107], ["modest", "OBSERVATION_MODIFIER", 108, 114], ["increases", "OBSERVATION_MODIFIER", 115, 124]]], ["As Piketty and Saez (27) described, toward the middle of the twentieth century, the share of income going to the top 10% rapidly declined, before rising again over the later decades of the century.", [["middle", "ANATOMY_MODIFIER", 47, 53]]], ["But, despite the obvious similarities, there is at least one clear divergence in the pattern of collegiate inequality and income inequality: The U-turn in collegiate inequality comes very late.", [["clear", "OBSERVATION_MODIFIER", 61, 66], ["divergence", "OBSERVATION", 67, 77]]], ["Men born in the mid-1940s onward were not just born into a period of low inequality, but they spent most of their formative years in a low-inequality society.", [["Men", "SPECIES", 0, 3], ["low inequality", "PROBLEM", 69, 83], ["low inequality", "OBSERVATION_MODIFIER", 69, 83]]], ["Despite this, the evidence shows that collegiate inequality increased substantially for the cohorts born in the 1940s and early 1950s; the log-odds ratios describing inequality are increased by around a third over this short period.The Great U-turn in Collegiate InequalitySome of the same key features are visible in the results for women, shown in Fig. 3, Right, although we only have access to data for women born after 1950.", [["women", "ORGANISM", 334, 339], ["women", "ORGANISM", 406, 411], ["women", "SPECIES", 334, 339], ["women", "SPECIES", 406, 411], ["collegiate inequality", "PROBLEM", 38, 59], ["inequality", "OBSERVATION_MODIFIER", 49, 59], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["increased", "OBSERVATION_MODIFIER", 181, 190], ["Right", "ANATOMY_MODIFIER", 358, 363]]], ["We see a basic similarity with the men\u2019s analyses from the mid-1950s birth cohorts onward: Collegiate inequalities are relatively flat for the 1950s to 1960s birth cohorts, and increase for women born in the 1970s and onward.", [["men", "ORGANISM", 35, 38], ["women", "ORGANISM", 190, 195], ["men", "SPECIES", 35, 38], ["women", "SPECIES", 190, 195]]], ["Just as with men, toward the end of the period we see flat and even declining inequalities in enrollment and completion.", [["men", "ORGANISM", 13, 16], ["men", "SPECIES", 13, 16]]], ["There are perhaps some subtle differences in the pattern by gender\u2014the upturn in collegiate inequality begins, for example, several years later for women than for men\u2014but we have little evidence here to support a conclusion of substantial difference in inequality for men and women over this period.The Great U-turn in Collegiate InequalityThere is one notable difference between the men\u2019s and women\u2019s results, relating to the period when trends in male collegiate inequality substantially diverged from trends in income inequality.", [["women", "ORGANISM", 148, 153], ["men", "ORGANISM", 268, 271], ["women", "ORGANISM", 276, 281], ["men", "ORGANISM", 384, 387], ["women", "ORGANISM", 394, 399], ["women", "SPECIES", 148, 153], ["men", "SPECIES", 268, 271], ["women", "SPECIES", 276, 281], ["men", "SPECIES", 384, 387], ["women", "SPECIES", 394, 399], ["some", "OBSERVATION_MODIFIER", 18, 22], ["subtle", "OBSERVATION_MODIFIER", 23, 29], ["differences", "OBSERVATION_MODIFIER", 30, 41], ["one", "OBSERVATION_MODIFIER", 349, 352], ["notable", "OBSERVATION_MODIFIER", 353, 360], ["difference", "OBSERVATION_MODIFIER", 361, 371]]], ["This exceptional period appears to be exceptional for men, but not for women.", [["men", "ORGANISM", 54, 57], ["women", "ORGANISM", 71, 76], ["men", "SPECIES", 54, 57], ["women", "SPECIES", 71, 76]]], ["Although we cannot track collegiate inequalities for women across the whole midcentury period, the first data points in the female data series (NLS Young Women: 1951\u20131953 birth cohorts) are lower than the nearby estimates for men (NLS Young Men: 1949\u20131951 birth cohorts).** This period of divergence between collegiate inequality and income inequality coincides with the period that we identified above as holding special consequences for men\u2019s educational attainment: Men born in the 1940s and early 1950s were subject to the threat of military service in the Vietnam War.The Great U-turn in Collegiate InequalityThere are no cohort studies of women that would allow us to compare male and female inequalities in college enrollment and completion throughout this period.", [["women", "ORGANISM", 53, 58], ["men", "ORGANISM", 226, 229], ["men", "ORGANISM", 439, 442], ["women", "ORGANISM", 645, 650], ["women", "SPECIES", 53, 58], ["Women", "SPECIES", 154, 159], ["men", "SPECIES", 226, 229], ["men", "SPECIES", 439, 442], ["Men", "SPECIES", 469, 472], ["women", "SPECIES", 645, 650], ["cohort studies", "TEST", 627, 641], ["no", "UNCERTAINTY", 624, 626]]], ["We do, however, have access to data on men who fathered children who were at risk for service during the Vietnam War: The NLS Older Men survey can be used to track collegiate inequalities for the children of men who were aged 45 y to 59 y in 1966.", [["men", "ORGANISM", 39, 42], ["children", "ORGANISM", 56, 64], ["children", "ORGANISM", 196, 204], ["men", "ORGANISM", 208, 211], ["NLS", "PROTEIN", 122, 125], ["men", "SPECIES", 39, 42], ["children", "SPECIES", 56, 64], ["children", "SPECIES", 196, 204], ["men", "SPECIES", 208, 211]]], ["The structure of this dataset is somewhat different from the datasets underlying our time series, but we nevertheless find confirmation, in Fig. 4, that male and female inequalities diverged in the Vietnam years.The Great U-turn in Collegiate InequalityIn the pre-Vietnam period, male and female collegiate inequalities were of similar magnitude.", [["somewhat", "OBSERVATION_MODIFIER", 33, 41], ["different", "OBSERVATION_MODIFIER", 42, 51], ["similar magnitude", "OBSERVATION_MODIFIER", 328, 345]]], ["The log-odds ratio for 4-year enrollment, for example, was 2.3 for men (95% CI: 1.5, 3.1), as compared to 2.4 for women (1.7, 3.2).", [["men", "ORGANISM", 67, 70], ["women", "ORGANISM", 114, 119], ["men", "SPECIES", 67, 70], ["women", "SPECIES", 114, 119], ["CI", "TEST", 76, 78]]], ["But, for the birth cohorts at risk for serving in Vietnam, the male log-odds ratio increased slightly, to 2.5 (1.8, 3.2), while inequality fell substantially for women, to 1.4 (0.8, 2.0) (see SI Appendix, Fig. S8 for a figure with CIs).", [["women", "ORGANISM", 162, 167], ["S8", "PROTEIN", 210, 212], ["women", "SPECIES", 162, 167], ["Appendix", "ANATOMY", 195, 203]]], ["These results provide support for the claim that men\u2019s collegiate inequality was substantially and artificially raised relative to expected levels during this period because of the Vietnam War.", [["men", "ORGANISM", 49, 52], ["men", "SPECIES", 49, 52]]], ["But some evidence can be brought to bear on this question by comparing preservice and postservice inequalities in college participation for the men in OCG (SI Appendix, Fig. S9).", [["men", "ORGANISM", 144, 147], ["S9", "GENE_OR_GENE_PRODUCT", 174, 176], ["S9", "PROTEIN", 174, 176], ["men", "SPECIES", 144, 147], ["Appendix", "ANATOMY", 159, 167]]], ["These data are more consistent with a draft-induced increase in male collegiate inequality than with a GI Bill-induced increase.\u2020\u2020The Great U-turn in Collegiate InequalityBringing the results in Fig. 4 together with what is known about college enrollment and completion patterns during the Vietnam War period, it seems likely that the disproportionate increase in men\u2019s college participation rates observed in Fig. 1 was achieved, at least in part, through a gender-specific change in the effect of family income on college enrollment and completion.The Association between Income Inequality and Collegiate Inequality.We now present a formal statistical test of the strength of the association between income inequality and collegiate inequality.", [["men", "ORGANISM", 364, 367], ["men", "SPECIES", 364, 367], ["a GI Bill", "TREATMENT", 101, 110], ["more consistent with", "UNCERTAINTY", 15, 35], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["seems likely", "UNCERTAINTY", 313, 325], ["disproportionate", "OBSERVATION_MODIFIER", 335, 351], ["increase", "OBSERVATION_MODIFIER", 352, 360]]], ["We regress the log-odds for collegiate inequalities on income inequality, as measured through the share of wages going to the top 10% (27).\u2021\u2021 In addition to the income inequality variable, for the full male series (1908\u20131995), we fit a \u201cVietnam effect,\u201d with a dummy variable that isolates the cohorts at risk from the draft lotteries (i.e., 1944\u20131952 birth cohorts).", [["a dummy variable", "PROBLEM", 259, 275]]], ["A full regression table with coefficients and standard errors is included as SI Appendix, Table S4.\u00a7\u00a7 In Fig. 5, we present estimates of the predicted increase in the log-odds ratios for an eight percentage point increase in the share of wages going to the top 10%; this increase is equivalent to the \u201ctakeoff\u201d in income inequality that occurred between the midcentury and the 1990s.\u00b6\u00b6The Association between Income Inequality and Collegiate Inequality.The regression coefficients describing the associations between income inequality and 90 vs. 10 collegiate inequalities can be straightforwardly decomposed into two parts: an association between income inequality and the 90 vs. 50 log-odds ratio, and an association between income inequality and the 50 vs. 10 log-odds ratio.", [["The regression coefficients", "PROBLEM", 453, 480], ["increase", "OBSERVATION_MODIFIER", 151, 159]]], ["In Fig. 5, the total height of each bar represents the predicted increase in the 90 vs. 10 log-odds ratio for an eight percentage point increase in income inequality, while the dark and light gray bars show the predicted increases in the 90 vs. 50 and 50 vs. 10 log-odds ratios, respectively.The Association between Income Inequality and Collegiate Inequality.Examining first the results for the 90 vs. 10 comparison, we see confirmation of a relatively strong association between income inequality and collegiate inequality over the full sweep of the twentieth century.", [["light gray bars", "TEST", 186, 201], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["increases", "OBSERVATION_MODIFIER", 221, 230]]], ["For women, for example, the model predicts that an increase in income inequality equivalent to that observed in the takeoff period would increase the 90 vs. 10 log-odds ratio by around 1 for 4-year enrollment and completion, and by around 1.3 for enrollment in any college.", [["women", "ORGANISM", 4, 9], ["women", "SPECIES", 4, 9], ["increase", "OBSERVATION_MODIFIER", 51, 59]]], ["Although there is variation in the strength of the association for the different outcome measures, the income inequality effects are large and positive in all of the analyses, indicating substantial support for the income inequality hypothesis.The Association between Income Inequality and Collegiate Inequality.Given that the takeoff in income inequality was largely characterized by the top of the income distribution moving away from the middle and bottom of the distribution, the income inequality hypothesis would predict larger effect sizes for the 90 vs. 50 comparison than for the 50 vs. 10 comparison.", [["the analyses", "TEST", 162, 174], ["the income inequality hypothesis", "PROBLEM", 211, 243], ["variation", "OBSERVATION_MODIFIER", 18, 27], ["large", "OBSERVATION_MODIFIER", 133, 138], ["positive", "OBSERVATION_MODIFIER", 143, 151], ["substantial", "OBSERVATION_MODIFIER", 187, 198], ["support", "OBSERVATION", 199, 206], ["takeoff", "OBSERVATION_MODIFIER", 327, 334], ["top", "OBSERVATION_MODIFIER", 389, 392], ["middle", "ANATOMY_MODIFIER", 441, 447], ["bottom", "ANATOMY_MODIFIER", 452, 458], ["larger", "OBSERVATION_MODIFIER", 527, 533], ["effect", "OBSERVATION_MODIFIER", 534, 540], ["sizes", "OBSERVATION_MODIFIER", 541, 546]]], ["The income inequality effects for the 90 vs. 50 comparisons in all cases outweigh those for the 50 vs. 10 comparisons, particularly in the analyses of 4-year college enrollment and completion.The Association between Income Inequality and Collegiate Inequality.But the results also provide grounds for exercising caution when interpreting differences in effect sizes across the models, as the effect sizes in the full and compressed male series are more similar for the \u201cany college\u201d analyses than for the 4-year analyses, where the sample sizes are smaller.", [["exercising caution", "TREATMENT", 301, 319], ["sizes", "OBSERVATION_MODIFIER", 399, 404], ["sizes", "OBSERVATION_MODIFIER", 539, 544], ["smaller", "OBSERVATION_MODIFIER", 549, 556]]], ["This is even more clear when we extend the models summarized in Fig. 5 to include additional macro-level regressors that social scientists have previously used to predict inequalities at the college level.", [["more clear", "OBSERVATION_MODIFIER", 13, 23]]], ["As shown in SI Appendix, Table S1, estimates from these models are more volatile, particularly for women.The Association between Income Inequality and Collegiate Inequality.The volatility arises because some of our analyses are, like past analyses, limited to more recent cohorts in which the takeoff assumes a monotonically increasing form.", [["women", "ORGANISM", 99, 104], ["women", "SPECIES", 99, 104], ["our analyses", "TEST", 211, 223], ["a monotonically increasing form", "PROBLEM", 309, 340], ["SI Appendix", "ANATOMY", 12, 23], ["Table S1", "ANATOMY", 25, 33], ["volatility", "OBSERVATION_MODIFIER", 177, 187], ["monotonically", "OBSERVATION_MODIFIER", 311, 324], ["increasing", "OBSERVATION_MODIFIER", 325, 335]]], ["This makes it difficult to adjudicate between the large number of monotonically increasing potential causes.", [["large", "OBSERVATION_MODIFIER", 50, 55], ["number", "OBSERVATION_MODIFIER", 56, 62], ["monotonically", "OBSERVATION_MODIFIER", 66, 79], ["increasing", "OBSERVATION_MODIFIER", 80, 90], ["potential causes", "OBSERVATION", 91, 107]]], ["In Fig. 6, we present the results of a simulation exercise, in which we run 1,000 regressions for a range of different model specifications on the full and compressed male series, with each regression including a new variable containing random numbers drawn from a normal distribution (\u03bc = 0; \u03c3 = 1).", [["a simulation exercise", "TEST", 37, 58], ["random numbers", "TEST", 237, 251], ["new", "OBSERVATION_MODIFIER", 213, 216], ["normal", "OBSERVATION", 265, 271]]], ["We examine the stability of the income inequality effects with respect to inequality in college enrollment, for which we have the largest number of data points.", [["largest", "OBSERVATION_MODIFIER", 130, 137]]], ["But Fig. 6 also highlights the extent to which a proper evaluation of the income inequality hypothesis requires researchers to exploit all of the available data.", [["a proper evaluation", "TEST", 47, 66]]], ["Although the bivariate analysis shows a similar effect of the income inequality variable in both the full and compressed series, the effects are a good deal more volatile in the more highly parameterized models in the compressed relative to the full series.*** The substantive implication of this analysis is clear: It is only with the full data series that we obtain relatively precise and reliable estimates of the association between inequality in collegiate outcomes and income inequality.DiscussionWe have examined descriptive evidence on the association between inequality in collegiate attainment and income inequality over the past century.", [["the bivariate analysis", "TEST", 9, 31], ["this analysis", "TEST", 292, 305], ["similar", "OBSERVATION_MODIFIER", 40, 47], ["effect", "OBSERVATION_MODIFIER", 48, 54], ["good", "OBSERVATION_MODIFIER", 147, 151], ["volatile", "OBSERVATION_MODIFIER", 162, 170], ["more highly", "OBSERVATION_MODIFIER", 178, 189], ["parameterized models", "OBSERVATION", 190, 210]]], ["Just as with income inequality, we see evidence of a U-turn in 90 vs. 10 collegiate inequality, and evidence of a substantial takeoff in collegiate inequalities in recent decades.", [["substantial", "OBSERVATION_MODIFIER", 114, 125], ["takeoff", "OBSERVATION", 126, 133]]], ["Taken together, our results offer solid descriptive support for the income inequality hypothesis.DiscussionInequalities in collegiate attainment increased hand in hand with the expansion of college education in the United States.", [["hand", "ANATOMY", 155, 159], ["hand", "ANATOMY", 163, 167], ["hand", "ORGANISM_SUBDIVISION", 155, 159], ["hand", "ORGANISM_SUBDIVISION", 163, 167], ["solid descriptive support", "TREATMENT", 34, 59]]], ["In point of fact, the only time during the twentieth century for which we observe a reduction in educational inequality is during the period when expansion at the college level had paused.", [["a reduction in educational inequality", "PROBLEM", 82, 119]]], ["These distributional questions will take on even greater significance in the context of the economic and social crisis engendered by coronavirus disease 2019, a crisis that is likely to have enduring effects on both the distribution of income and access to the higher education sector.DiscussionOur analyses are not well suited to evaluating the mechanisms generating the association between income inequality and collegiate inequalities.", [["coronavirus disease", "DISEASE", 133, 152], ["coronavirus", "ORGANISM", 133, 144], ["coronavirus disease", "PROBLEM", 133, 152], ["a crisis", "PROBLEM", 159, 167], ["DiscussionOur analyses", "TEST", 285, 307], ["social crisis", "OBSERVATION", 105, 118]]], ["However, given the pattern of collegiate inequality across the century, we suspect that a mechanical effect is likely to be responsible.", [["a mechanical effect", "PROBLEM", 88, 107], ["mechanical effect", "OBSERVATION", 90, 107], ["likely to be", "UNCERTAINTY", 111, 123]]], ["The mechanical effect is therefore a parsimonious account of the trend that we see here (8).", [["mechanical effect", "OBSERVATION", 4, 21]]], ["Nevertheless, there is a period for which we undoubtedly hypothesize an increase in the relational effect of income: the Vietnam War.", [["increase", "OBSERVATION_MODIFIER", 72, 80]]], ["For the war to lead to increased collegiate inequality, the effect of income on educational attainment would have to increase, particularly given that income inequality was low and stable for these birth cohorts.DiscussionWhatever the mechanisms may be, the key descriptive result is that, over the course of the twentieth century, a grand U-turn in collegiate inequality occurred.", [["increased collegiate inequality", "PROBLEM", 23, 54], ["these birth cohorts", "TREATMENT", 192, 211], ["stable", "OBSERVATION_MODIFIER", 181, 187]]], ["Cohorts born in the middle of the century witnessed the lowest levels of inequality in college enrollment and completion seen over the past hundred years.", [["middle", "ANATOMY_MODIFIER", 20, 26]]]], "PMC7277660": [], "PMC7490248": [["Ventilatory effects of restraint ::: IntroductionOne of the first studies supporting the theory of positional asphyxia was published by Reay et al., in 1988.8 The study examined the recovery rate of oxygen saturation and heart rate in subjects placed in the hogtie position after exercise.", [["heart", "ANATOMY", 221, 226], ["hogtie", "ANATOMY", 258, 264], ["positional asphyxia", "DISEASE", 99, 118], ["oxygen", "CHEMICAL", 199, 205], ["oxygen", "CHEMICAL", 199, 205], ["oxygen", "SIMPLE_CHEMICAL", 199, 205], ["heart", "ORGAN", 221, 226], ["the first studies", "TEST", 56, 73], ["positional asphyxia", "PROBLEM", 99, 118], ["The study", "TEST", 159, 168], ["oxygen saturation", "TEST", 199, 216], ["heart rate", "TEST", 221, 231], ["positional asphyxia", "OBSERVATION", 99, 118], ["oxygen saturation", "OBSERVATION", 199, 216], ["heart", "ANATOMY", 221, 226]]], ["The authors witnessed an increased recovery time across both parameters in the hogtie position compared to sitting, concluding that positional restraint may indeed restrict cardiorespiratory function and should be considered as a cause of death when implicated.", [["death", "DISEASE", 239, 244], ["positional restraint", "TREATMENT", 132, 152], ["death", "PROBLEM", 239, 244], ["increased", "OBSERVATION_MODIFIER", 25, 34]]], ["The study was met with controversy.", [["The study", "TEST", 0, 9]]], ["Critics expressed concern about the use of transcutaneous pulse oximetry and its known inaccuracy, as well as the lack of spirometry to measure ventilatory function.", [["transcutaneous pulse oximetry", "TREATMENT", 43, 72]]], ["Most notably however, authors pointed to the fact that Reay observed an initial decrease in oxygen saturation during exercise.", [["oxygen", "CHEMICAL", 92, 98], ["oxygen", "CHEMICAL", 92, 98], ["oxygen", "SIMPLE_CHEMICAL", 92, 98], ["oxygen saturation", "TEST", 92, 109], ["initial", "OBSERVATION_MODIFIER", 72, 79], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["oxygen saturation", "OBSERVATION", 92, 109]]], ["This finding contradicted the fundamental understanding of exercise physiology in which one would expect to see an increase in saturation during exercise.9,10 It was also noted that while in the hogtie position, the subjects in Reay's study actually had an increase in their oxygen saturations back to normal levels.", [["oxygen", "CHEMICAL", 275, 281], ["oxygen", "CHEMICAL", 275, 281], ["oxygen", "SIMPLE_CHEMICAL", 275, 281], ["Reay's study", "TEST", 228, 240], ["their oxygen saturations", "TEST", 269, 293], ["increase", "OBSERVATION_MODIFIER", 115, 123], ["increase", "OBSERVATION_MODIFIER", 257, 265], ["oxygen saturations", "OBSERVATION", 275, 293], ["normal", "OBSERVATION", 302, 308]]], ["In a follow up study, Schmidt et al. attempted to replicate Reay's work, this time finding no significant differences in recovery rate of identically tested parameters.11 Furthermore, desaturation was not observed during exercise as previously found.", [["desaturation", "DISEASE", 184, 196], ["a follow up study", "TEST", 3, 20], ["desaturation", "PROBLEM", 184, 196], ["desaturation", "OBSERVATION", 184, 196]]], ["Many investigators have found fault with the early work of Reay, despite the study's popularity in being the first to support the theory of positional asphyxia.", [["asphyxia", "DISEASE", 151, 159], ["the study", "TEST", 73, 82], ["positional asphyxia", "PROBLEM", 140, 159], ["positional asphyxia", "OBSERVATION", 140, 159]]], ["Efforts were made in the following years to develop a better understanding of respiratory physiology under restraint.Ventilatory effects of restraint ::: IntroductionThe effects of positioning on ventilatory function in healthy subjects were not previously well-understood.", [["respiratory", "ANATOMY", 78, 89]]], ["Common suggestions of potential phenomena included increased intra-abdominal pressure in the supine position restricting lung expansion, anterior rib pressure restricting lung expansion in the prone position, and positioning affecting ventilation/perfusion zones within the lung itself.", [["intra-abdominal", "ANATOMY", 61, 76], ["lung", "ANATOMY", 121, 125], ["anterior rib", "ANATOMY", 137, 149], ["lung", "ANATOMY", 171, 175], ["lung", "ANATOMY", 274, 278], ["intra-abdominal", "ORGANISM_SUBDIVISION", 61, 76], ["lung", "ORGAN", 121, 125], ["anterior rib", "MULTI-TISSUE_STRUCTURE", 137, 149], ["lung", "ORGAN", 171, 175], ["lung", "ORGAN", 274, 278], ["potential phenomena", "PROBLEM", 22, 41], ["increased intra-abdominal pressure in the supine position restricting lung expansion", "PROBLEM", 51, 135], ["anterior rib pressure restricting lung expansion", "TREATMENT", 137, 185], ["potential", "OBSERVATION_MODIFIER", 22, 31], ["phenomena", "OBSERVATION", 32, 41], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["intra-abdominal", "ANATOMY", 61, 76], ["pressure", "OBSERVATION_MODIFIER", 77, 85], ["lung", "ANATOMY", 121, 125], ["expansion", "OBSERVATION", 126, 135], ["anterior", "ANATOMY_MODIFIER", 137, 145], ["rib", "ANATOMY", 146, 149], ["pressure", "OBSERVATION_MODIFIER", 150, 158], ["lung", "ANATOMY", 171, 175], ["expansion", "OBSERVATION", 176, 185], ["prone position", "OBSERVATION_MODIFIER", 193, 207], ["ventilation", "OBSERVATION", 235, 246], ["perfusion zones", "OBSERVATION", 247, 262], ["lung", "ANATOMY", 274, 278]]], ["He found statistically significant decreases in FVC, FEV1, and MVV, although the results were not shown to be clinically significant.12", [["significant decreases in FVC", "PROBLEM", 23, 51], ["FEV1", "TEST", 53, 57], ["MVV", "PROBLEM", 63, 66], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["decreases", "OBSERVATION_MODIFIER", 35, 44]]]], "d86a70957ae5e263b0bc98255561a7cbd88c309e": [["IntroductionThe outbreak of coronavirus disease 2019 , that was first reported by local health facilities in WuhanMethodsStudies for inclusion were identified by querying Pubmed, the China national knowledge infrastructure, the China Science and Technology Journal Database, and Wanfang data.", [["coronavirus disease", "DISEASE", 28, 47], ["coronavirus", "ORGANISM", 28, 39], ["coronavirus", "SPECIES", 28, 39], ["coronavirus disease", "PROBLEM", 28, 47], ["coronavirus disease", "OBSERVATION", 28, 47]]], ["The main mechanisms for the occurrence and development of COVID-19 are immunosuppression and cytokine storm.", [["COVID-19", "CHEMICAL", 58, 66], ["COVID-19", "GENE_OR_GENE_PRODUCT", 58, 66], ["cytokine", "PROTEIN", 93, 101], ["COVID", "TEST", 58, 63], ["immunosuppression", "TREATMENT", 71, 88], ["cytokine storm", "PROBLEM", 93, 107], ["main", "OBSERVATION_MODIFIER", 4, 8], ["cytokine storm", "OBSERVATION", 93, 107]]], ["4 COVID-19 patients with severe symptoms may develop respiratory impairment and need rehabilitation, including respiratory muscle training, whole-body movement and psychological rehabilitation.", [["respiratory", "ANATOMY", 53, 64], ["respiratory muscle", "ANATOMY", 111, 129], ["body", "ANATOMY", 146, 150], ["respiratory impairment", "DISEASE", 53, 75], ["patients", "ORGANISM", 11, 19], ["muscle", "ORGAN", 123, 129], ["body", "ORGANISM_SUBDIVISION", 146, 150], ["patients", "SPECIES", 11, 19], ["severe symptoms", "PROBLEM", 25, 40], ["respiratory impairment", "PROBLEM", 53, 75], ["rehabilitation", "TREATMENT", 85, 99], ["respiratory muscle training", "TREATMENT", 111, 138], ["whole-body movement", "TREATMENT", 140, 159], ["psychological rehabilitation", "TREATMENT", 164, 192], ["respiratory muscle", "ANATOMY", 111, 129]]], ["5 We searched in the above databases using terms to address the potential mechanism of Qigong in the prevention, treatment and rehabilitation of COVID-19, including \"immune function\", \"inflammation\", \"cytokine\", \"respiratory muscle\", \"stress\" , \"mood\" and \"emotion\", combined with terms which address different types of Qigong: \"Qigong\", \"Qi Gong\", \"Tai-Chi\", \"Tai Chi\", \"Taichi\", \"Taiji\", \"Yi Jin Jing\", \"Yijinjing\", \"Wu Qin Xi\", \"Wuqinxi\", \"Liu Zi Jue\", \"Liuzijue\", \"Ba Duan Jin\", \"Baduanjin\", as well as \"abdominal breathing\" and \"abdominal respiration\".", [["respiratory muscle", "ANATOMY", 213, 231], ["abdominal", "ANATOMY", 508, 517], ["abdominal", "ANATOMY", 534, 543], ["inflammation", "DISEASE", 185, 197], ["respiratory muscle", "DISEASE", 213, 231], ["abdominal breathing", "DISEASE", 508, 527], ["muscle", "ORGAN", 225, 231], ["abdominal", "ORGANISM_SUBDIVISION", 508, 517], ["abdominal", "ORGANISM_SUBDIVISION", 534, 543], ["cytokine", "PROTEIN", 201, 209], ["Qigong", "TREATMENT", 87, 93], ["treatment", "TREATMENT", 113, 122], ["rehabilitation", "TREATMENT", 127, 141], ["COVID", "TEST", 145, 150], ["inflammation", "PROBLEM", 185, 197], ["cytokine\"", "PROBLEM", 201, 210], ["stress\"", "PROBLEM", 235, 242], ["respiratory muscle", "ANATOMY", 213, 231], ["abdominal", "ANATOMY", 508, 517], ["abdominal", "ANATOMY", 534, 543]]], ["Given that clinical studies on the intervention of Qigong for COVID-19 are limited, we used the terms \"respiratory infection\" and \"respiratory rehabilitation\", combined with terms mentioned above to search for clinical evidence about the application of Qigong in the treatment and rehabilitation of respiratory infection.", [["respiratory", "ANATOMY", 103, 114], ["respiratory", "ANATOMY", 131, 142], ["respiratory", "ANATOMY", 299, 310], ["respiratory infection", "DISEASE", 103, 124], ["respiratory infection", "DISEASE", 299, 320], ["clinical studies", "TEST", 11, 27], ["Qigong", "TREATMENT", 51, 57], ["COVID", "TEST", 62, 67], ["respiratory infection", "PROBLEM", 103, 124], ["respiratory rehabilitation", "TREATMENT", 131, 157], ["Qigong", "TREATMENT", 253, 259], ["the treatment", "TREATMENT", 263, 276], ["rehabilitation", "TREATMENT", 281, 295], ["respiratory infection", "PROBLEM", 299, 320], ["infection", "OBSERVATION", 115, 124], ["respiratory", "ANATOMY", 299, 310], ["infection", "OBSERVATION", 311, 320]]], ["\"Qi\" refers to the energy that motivates human life activities, and \"Gong\" refers to the regulation of Qi through practice.Understanding Qi and QigongThe concept of Qi in TCM is very broad, and it is involved in nearly all physiological and pathological processes.", [["human", "ORGANISM", 41, 46], ["TCM", "CELL_TYPE", 171, 174], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46]]], ["6 According to its different functions, Qi can be divided into different types, for example defensive Wei Qi, and the organ Qi that regulates the function of each organ.", [["organ", "ANATOMY", 118, 123], ["organ", "ANATOMY", 163, 168], ["organ", "ORGAN", 118, 123], ["organ", "ORGAN", 163, 168], ["Qi", "PROTEIN", 40, 42], ["the organ Qi", "TREATMENT", 114, 126], ["organ", "ANATOMY", 118, 123]]], ["The channels through which Qi moves in the body are called meridians, which are distributed on the surface of the limbs and trunk and extend to the inside organs.Understanding Qi and QigongQigong is a mind-body training skill that can regulate body, breath and mind under the guidance of theory of TCM to guide Qi operation in the meridian, to regulate physical function, and to prevent and treat diseases.", [["body", "ANATOMY", 43, 47], ["surface", "ANATOMY", 99, 106], ["limbs", "ANATOMY", 114, 119], ["trunk", "ANATOMY", 124, 129], ["organs", "ANATOMY", 155, 161], ["body", "ANATOMY", 206, 210], ["body", "ANATOMY", 244, 248], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["surface", "CELLULAR_COMPONENT", 99, 106], ["limbs", "ORGANISM_SUBDIVISION", 114, 119], ["trunk", "ORGANISM_SUBDIVISION", 124, 129], ["organs", "ORGAN", 155, 161], ["body", "ORGANISM_SUBDIVISION", 244, 248], ["Qi", "PROTEIN", 27, 29], ["a mind-body training skill", "TREATMENT", 199, 225], ["Qi operation", "TREATMENT", 311, 323], ["diseases", "PROBLEM", 397, 405], ["body", "ANATOMY", 43, 47], ["surface", "ANATOMY_MODIFIER", 99, 106], ["limbs", "ANATOMY", 114, 119], ["trunk", "ANATOMY", 124, 129], ["inside", "ANATOMY_MODIFIER", 148, 154], ["organs", "ANATOMY", 155, 161]]], ["7 Qigong regulates the body through an adjustment of body movement and posture.", [["body", "ANATOMY", 23, 27], ["body", "ANATOMY", 53, 57], ["body", "ORGANISM_SUBDIVISION", 23, 27], ["body", "ORGANISM_SUBDIVISION", 53, 57], ["body movement", "OBSERVATION", 53, 66]]], ["Qigong's body regulation is aimed at relaxation, so the movements are typically gentle and smooth.", [["body", "ANATOMY", 9, 13], ["body", "ORGANISM_SUBDIVISION", 9, 13], ["Qigong's body regulation", "TREATMENT", 0, 24], ["smooth", "OBSERVATION_MODIFIER", 91, 97]]], ["Regulation of breath involves changes in respiratory movement, rhythm, and pattern.", [["respiratory", "ANATOMY", 41, 52], ["respiratory movement", "OBSERVATION", 41, 61]]], ["Breath in Qigong needs to be slow, long, and deep.", [["Breath", "TREATMENT", 0, 6], ["deep", "ANATOMY_MODIFIER", 45, 49]]], ["Sometimes changes in breath pattern are also required, such as abdominal breathing, and breathing with phonation, both of which are typical patterns of Qigong respiration.", [["abdominal", "ANATOMY", 63, 72], ["abdominal", "ORGANISM_SUBDIVISION", 63, 72], ["Sometimes changes in breath pattern", "PROBLEM", 0, 35], ["abdominal breathing", "PROBLEM", 63, 82], ["phonation", "TREATMENT", 103, 112], ["Qigong respiration", "TREATMENT", 152, 170], ["abdominal", "ANATOMY", 63, 72], ["Qigong respiration", "OBSERVATION", 152, 170]]], ["Abdominal breathing refers to a breathing pattern with obvious abdomen movement, and breathing with phonation is a combination of breath and the production of speech sounds.", [["Abdominal", "ANATOMY", 0, 9], ["abdomen", "ANATOMY", 63, 70], ["abdomen", "ORGANISM_SUBDIVISION", 63, 70], ["Abdominal breathing", "PROBLEM", 0, 19], ["obvious abdomen movement", "PROBLEM", 55, 79], ["speech sounds", "PROBLEM", 159, 172], ["breathing", "OBSERVATION", 10, 19], ["abdomen", "ANATOMY", 63, 70], ["movement", "OBSERVATION", 71, 79]]], ["Regulation of mind includes focusing attention and visualization.", [["visualization", "TEST", 51, 64]]], ["Most operations of mind regulation are similar to meditation, therefore Qigong is also considered a meditative movement.", [["Qigong", "TREATMENT", 72, 78]]], ["According to the first historical record in China \"Shang Shu\", 4000 years ago, ancient Chinese people found that stretching and dancing could release pain.", [["pain", "DISEASE", 150, 154], ["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["release pain", "PROBLEM", 142, 154]]], ["Almost all religions and philosophical schools, such as Taoism, Buddhism, Traditional Chinese medicine, and martial arts, have elements of Qigong practice methods, with different appellations.", [["Traditional Chinese medicine", "TREATMENT", 74, 102], ["Qigong practice methods", "TREATMENT", 139, 162]]], ["In the 1950s, experts and scholars reached a consensus and coined this methodology \"Qigong\", and the first Qigong institute was established in China in 1954.Understanding Qi and QigongMany studies on Qigong have been carried out through modern research methods, including the observation of physiological and psychological changes during or after Qigong practice, along with clinical trials of treating various diseases with Qigong.Understanding Qi and QigongQigong is particularly appropriate for older people due to its gentle and smooth movements, and there are wide applications of Qigong in geriatric medicine, 9 including in the treatment of musculoskeletal disorders, pain relief, and muscle strengthening.", [["musculoskeletal", "ANATOMY", 648, 663], ["muscle", "ANATOMY", 692, 698], ["musculoskeletal disorders", "DISEASE", 648, 673], ["pain", "DISEASE", 675, 679], ["people", "ORGANISM", 504, 510], ["muscle", "ORGAN", 692, 698], ["people", "SPECIES", 504, 510], ["QigongMany studies", "TEST", 178, 196], ["Qigong", "TREATMENT", 200, 206], ["physiological and psychological changes", "PROBLEM", 291, 330], ["Qigong practice", "TREATMENT", 347, 362], ["various diseases", "PROBLEM", 403, 419], ["Qigong", "TREATMENT", 425, 431], ["Qigong in geriatric medicine", "TREATMENT", 586, 614], ["musculoskeletal disorders", "PROBLEM", 648, 673], ["pain relief", "TREATMENT", 675, 686], ["musculoskeletal", "ANATOMY", 648, 663], ["muscle", "ANATOMY", 692, 698]]], ["As a mind-body skill, Qigong has been found to impact internal and psychosomatic diseases, such as asthma, hypertension, peptic ulcers and diabetes.Understanding Qi and QigongQigong is also used as a meditative movement for treating geriatric mental conditions including mood disorders and cognitive impairment.", [["peptic", "ANATOMY", 121, 127], ["internal and psychosomatic diseases", "DISEASE", 54, 89], ["asthma", "DISEASE", 99, 105], ["hypertension", "DISEASE", 107, 119], ["peptic ulcers", "DISEASE", 121, 134], ["diabetes", "DISEASE", 139, 147], ["mood disorders", "DISEASE", 271, 285], ["cognitive impairment", "DISEASE", 290, 310], ["Qigong", "TREATMENT", 22, 28], ["internal and psychosomatic diseases", "PROBLEM", 54, 89], ["asthma", "PROBLEM", 99, 105], ["hypertension", "PROBLEM", 107, 119], ["peptic ulcers", "PROBLEM", 121, 134], ["diabetes", "PROBLEM", 139, 147], ["treating geriatric mental conditions", "PROBLEM", 224, 260], ["mood disorders", "PROBLEM", 271, 285], ["cognitive impairment", "PROBLEM", 290, 310], ["psychosomatic diseases", "OBSERVATION", 67, 89], ["asthma", "OBSERVATION", 99, 105], ["hypertension", "OBSERVATION", 107, 119], ["peptic", "OBSERVATION_MODIFIER", 121, 127], ["ulcers", "OBSERVATION", 128, 134], ["diabetes", "OBSERVATION", 139, 147]]], ["10, 11Classification of QigongAccording to different operations, Qigong techniques can be divided into two groups: Dynamic Qigong is more successful than passive Qigong with regards to physical regulation, therefore it can be more effective in treating musculoskeletal and psychosomatic disease.", [["musculoskeletal", "ANATOMY", 253, 268], ["musculoskeletal and psychosomatic disease", "DISEASE", 253, 294], ["QigongAccording", "TREATMENT", 24, 39], ["different operations", "TREATMENT", 43, 63], ["Qigong techniques", "TREATMENT", 65, 82], ["Dynamic Qigong", "TREATMENT", 115, 129], ["passive Qigong", "TREATMENT", 154, 168], ["treating musculoskeletal and psychosomatic disease", "PROBLEM", 244, 294], ["more successful", "OBSERVATION_MODIFIER", 133, 148], ["musculoskeletal", "ANATOMY", 253, 268], ["psychosomatic disease", "OBSERVATION", 273, 294]]], ["Passive Qigong pays more attention to mind regulation.", [["Passive Qigong pays", "TREATMENT", 0, 19]]], ["Attention training is an important and common technique of mind regulation that asks practitioners to focus attention on an object or on the present, which is similar to mindfulness meditation.", [["Attention training", "TREATMENT", 0, 18]]], ["According to theory of TCM, through extensive practice of focusing attention, practitioners can enter a state of tranquility.", [["TCM", "CELL_TYPE", 23, 26]]], ["Passive Qigong has few requirements for physical strength, as it can be practiced in any posture without movement.", [["Passive Qigong", "TREATMENT", 0, 14], ["few", "OBSERVATION_MODIFIER", 19, 22]]], ["In addition, for those with impaired body movement ability, passive Qigong is a better choice than dynamic Qigong.", [["body", "ANATOMY", 37, 41], ["impaired body movement", "DISEASE", 28, 50], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["impaired body movement ability", "PROBLEM", 28, 58]]], ["A study on mindfulness, conducted by Lacaille et al. 12 , indicated that prolonged mindfulness practice was associated with an increase in mindful responding, which was in turn associated with increased positive affect and with less perceived stress and negative affect.", [["A study", "TEST", 0, 7], ["increased positive affect", "PROBLEM", 193, 218], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["positive affect", "OBSERVATION", 203, 218]]], ["Thus, those who engage in extensive practice of passive Qigong may be likely to experience better psychological outcomes.How Qigong Can Treat Respiratory Infective Disease Utilizing TCM TheoriesRespiratory infectious diseases belong to the category of external pathogens diseases in TCM.", [["Respiratory Infective Disease", "DISEASE", 142, 171], ["infectious diseases", "DISEASE", 206, 225], ["pathogens diseases", "DISEASE", 261, 279], ["passive Qigong", "TREATMENT", 48, 62], ["Respiratory Infective Disease", "PROBLEM", 142, 171], ["TheoriesRespiratory infectious diseases", "PROBLEM", 186, 225], ["external pathogens diseases in TCM", "PROBLEM", 252, 286], ["Respiratory", "ANATOMY", 142, 153], ["Infective", "OBSERVATION", 154, 163], ["pathogens", "OBSERVATION", 261, 270]]], ["Its pathogenesis is that external pathogens invade the human body and produce tension in the balance between \"good and evil\".", [["body", "ANATOMY", 61, 65], ["human", "ORGANISM", 55, 60], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["external pathogens", "PROBLEM", 25, 43], ["external", "OBSERVATION_MODIFIER", 25, 33], ["pathogens", "OBSERVATION", 34, 43], ["human body", "ANATOMY_MODIFIER", 55, 65], ["tension", "OBSERVATION_MODIFIER", 78, 85], ["balance", "OBSERVATION_MODIFIER", 93, 100]]], ["The \"evil\" refers to exogenous pathogens, which can be considered similar to the pathogen of infection.How Qigong Can Treat Respiratory Infective Disease Utilizing TCM Theories\"Good\" refers to the defensive function of the human body.", [["body", "ANATOMY", 229, 233], ["infection", "DISEASE", 93, 102], ["Respiratory Infective Disease", "DISEASE", 124, 153], ["human", "ORGANISM", 223, 228], ["body", "ORGANISM_SUBDIVISION", 229, 233], ["human", "SPECIES", 223, 228], ["human", "SPECIES", 223, 228], ["exogenous pathogens", "PROBLEM", 21, 40], ["infection", "PROBLEM", 93, 102], ["Respiratory Infective Disease", "PROBLEM", 124, 153], ["infection", "OBSERVATION", 93, 102], ["Respiratory", "ANATOMY", 124, 135], ["Infective", "OBSERVATION", 136, 145], ["human body", "ANATOMY", 223, 233]]], ["When exogenous pathogens invade the human body, defensive Wei Qi fights against them.", [["body", "ANATOMY", 42, 46], ["human", "ORGANISM", 36, 41], ["body", "ORGANISM_SUBDIVISION", 42, 46], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["human body", "ANATOMY", 36, 46]]], ["It can be considered that Wei Qi represents immune function from the perspective of modern medicine.", [["modern medicine", "TREATMENT", 84, 99]]], ["The relationship between Wei Qi and exogenous pathogens determines whether the disease will develop and the prognosis of the disease.", [["Wei Qi", "GENE_OR_GENE_PRODUCT", 25, 31], ["exogenous pathogens", "PROBLEM", 36, 55], ["the disease", "PROBLEM", 75, 86], ["the disease", "PROBLEM", 121, 132], ["disease", "OBSERVATION", 79, 86], ["disease", "OBSERVATION", 125, 132]]], ["If Wei Qi is strong enough to defend against the exogenous pathogen, the disease would not occur, or would be easier to heal, and the prognosis would be good.How Qigong Can Treat Respiratory Infective Disease Utilizing TCM TheoriesBecause of a decline in organ function and an increase in chronic medical conditions, older people are considered to be in a state of weakness or insufficient energy, conceptualized as Qi and blood deficiency in TCM.", [["organ", "ANATOMY", 255, 260], ["blood", "ANATOMY", 423, 428], ["Respiratory Infective Disease", "DISEASE", 179, 208], ["weakness", "DISEASE", 365, 373], ["blood deficiency", "DISEASE", 423, 439], ["organ", "ORGAN", 255, 260], ["people", "ORGANISM", 323, 329], ["blood", "ORGANISM_SUBSTANCE", 423, 428], ["TCM", "CELL_TYPE", 443, 446], ["people", "SPECIES", 323, 329], ["the exogenous pathogen", "PROBLEM", 45, 67], ["the disease", "PROBLEM", 69, 80], ["Respiratory Infective Disease", "PROBLEM", 179, 208], ["a decline in organ function", "PROBLEM", 242, 269], ["an increase in chronic medical conditions", "PROBLEM", 274, 315], ["weakness", "PROBLEM", 365, 373], ["insufficient energy", "PROBLEM", 377, 396], ["blood deficiency in TCM", "PROBLEM", 423, 446], ["Respiratory", "ANATOMY", 179, 190], ["Infective", "OBSERVATION", 191, 200], ["decline", "OBSERVATION", 244, 251], ["organ", "ANATOMY", 255, 260], ["increase", "OBSERVATION_MODIFIER", 277, 285], ["chronic", "OBSERVATION_MODIFIER", 289, 296]]], ["Therefore, according to theories of TCM, when encountering infectious diseases such as COVID-19, the elderly are more likely to be affected, and infections are more likely develop into severe diseases with poor prognoses.", [["infectious diseases", "DISEASE", 59, 78], ["infections", "DISEASE", 145, 155], ["encountering infectious diseases", "PROBLEM", 46, 78], ["COVID", "TEST", 87, 92], ["infections", "PROBLEM", 145, 155], ["severe diseases", "PROBLEM", 185, 200], ["poor prognoses", "PROBLEM", 206, 220], ["severe", "OBSERVATION_MODIFIER", 185, 191], ["diseases", "OBSERVATION", 192, 200], ["poor prognoses", "OBSERVATION", 206, 220]]], ["Given that Qigong regulates the function of Qi in the human body, in which Wei Qi is included, it may prevent respiratory infection or promote recovery from respiratory infection in the elderly.Management of Stress and EmotionOutbreaks and illness are a source of stress, and stress reactions or emotional problems can occur in hospital inpatients, people in isolation, and those in the general population.", [["body", "ANATOMY", 60, 64], ["respiratory", "ANATOMY", 110, 121], ["respiratory", "ANATOMY", 157, 168], ["respiratory infection", "DISEASE", 110, 131], ["respiratory infection", "DISEASE", 157, 178], ["Stress and EmotionOutbreaks", "DISEASE", 208, 235], ["illness", "DISEASE", 240, 247], ["Qi", "GENE_OR_GENE_PRODUCT", 44, 46], ["human", "ORGANISM", 54, 59], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["people", "ORGANISM", 349, 355], ["Qi", "PROTEIN", 44, 46], ["human", "SPECIES", 54, 59], ["people", "SPECIES", 349, 355], ["human", "SPECIES", 54, 59], ["Qigong regulates", "TREATMENT", 11, 27], ["Qi in the human body", "TREATMENT", 44, 64], ["respiratory infection", "PROBLEM", 110, 131], ["respiratory infection", "PROBLEM", 157, 178], ["Stress", "PROBLEM", 208, 214], ["EmotionOutbreaks", "PROBLEM", 219, 235], ["illness", "PROBLEM", 240, 247], ["stress", "PROBLEM", 264, 270], ["stress reactions", "PROBLEM", 276, 292], ["emotional problems", "PROBLEM", 296, 314], ["human body", "ANATOMY", 54, 64], ["infection", "OBSERVATION", 122, 131], ["respiratory infection", "OBSERVATION", 157, 178], ["Stress", "OBSERVATION", 208, 214]]], ["Benson et al. 13 observed physiological changes during meditation, and found that meditation can counteract stress response.", [["physiological changes", "PROBLEM", 26, 47], ["stress response", "PROBLEM", 108, 123]]], ["As a meditative movement, Qigong has been studied as a tool for stress management.", [["Qigong", "TREATMENT", 26, 32], ["stress management", "TREATMENT", 64, 81]]], ["Ryu et al. 14 observed changes in stress hormones during Qigong practice, and found that beta-endorphins increased in the middle of training while levels of adreno-cortico-tropic-hormone declined mid and post-practice suggesting decreased stress levels.", [["beta-endorphins", "CHEMICAL", 89, 104], ["beta-endorphins", "SIMPLE_CHEMICAL", 89, 104], ["changes in stress hormones", "PROBLEM", 23, 49], ["Qigong practice", "TREATMENT", 57, 72], ["adreno", "TEST", 157, 163], ["decreased stress levels", "PROBLEM", 229, 252], ["decreased", "OBSERVATION_MODIFIER", 229, 238], ["stress levels", "OBSERVATION", 239, 252]]], ["It has been suggested that Qigong regulates emotion through enhancing nonreactivity to aversive thoughts and impulses by focusing attention, regulating the hypothalamus-pituitary-adrenal axis reactivity and the balance of the autonomic nervous system, and through changing the function of the brain, limbic system, and expression of genes linked to inflammatory responses and stress-related pathways.", [["autonomic nervous system", "ANATOMY", 226, 250], ["brain", "ANATOMY", 293, 298], ["limbic system", "ANATOMY", 300, 313], ["adrenal", "ORGAN", 179, 186], ["autonomic nervous system", "ANATOMICAL_SYSTEM", 226, 250], ["brain", "ORGAN", 293, 298], ["limbic system", "ANATOMICAL_SYSTEM", 300, 313], ["Qigong regulates emotion", "TREATMENT", 27, 51], ["the hypothalamus", "TEST", 152, 168], ["inflammatory responses", "PROBLEM", 349, 371], ["stress-related pathways", "PROBLEM", 376, 399], ["hypothalamus", "ANATOMY", 156, 168], ["pituitary", "ANATOMY", 169, 178], ["adrenal axis", "ANATOMY", 179, 191], ["autonomic nervous", "ANATOMY", 226, 243], ["brain", "ANATOMY", 293, 298], ["limbic system", "ANATOMY", 300, 313], ["inflammatory", "OBSERVATION_MODIFIER", 349, 361]]], ["15 In a meta-analysis on treating chronic obstructive pulmonary disease (COPD) with Qigong, Wu et al. 16Reducing InflammationQigong can reduce both inflammatory factors and inflammatory response.", [["pulmonary", "ANATOMY", 54, 63], ["chronic obstructive pulmonary disease", "DISEASE", 34, 71], ["COPD", "DISEASE", 73, 77], ["InflammationQigong", "CHEMICAL", 113, 131], ["pulmonary", "ORGAN", 54, 63], ["inflammatory factors", "PROTEIN", 148, 168], ["treating chronic obstructive pulmonary disease", "PROBLEM", 25, 71], ["COPD)", "PROBLEM", 73, 78], ["InflammationQigong", "TREATMENT", 113, 131], ["both inflammatory factors", "PROBLEM", 143, 168], ["inflammatory response", "PROBLEM", 173, 194], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["obstructive", "OBSERVATION_MODIFIER", 42, 53], ["pulmonary", "ANATOMY", 54, 63], ["disease", "OBSERVATION", 64, 71], ["COPD", "OBSERVATION", 73, 77], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["inflammatory response", "OBSERVATION", 173, 194]]], ["Irwin et al. 22 examined the cytokines in older adults who had participated in a 6-monthReducing InflammationTai-Chi program, and found reductions in levels of IL-6 in subjects in the intervention group who previously showed high levels of this inflammatory marker.", [["adults", "ORGANISM", 48, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 160, 164], ["subjects", "ORGANISM", 168, 176], ["cytokines", "PROTEIN", 29, 38], ["IL-6", "PROTEIN", 160, 164], ["this inflammatory marker", "PROBLEM", 240, 264], ["reductions", "OBSERVATION_MODIFIER", 136, 146], ["inflammatory", "OBSERVATION", 245, 257]]], ["In another study, Irwin et al. 23 found that in older adults with insomnia, Tai-Chi reduced proinflammatory gene expression and marginally reduced C-reactive protein by the end of the 4-month practice, and reduced monocyte production of proinflammatory cytokines at the end of the program and at the follow-up after 7 and 16 months, when compared to the control group.", [["monocyte", "ANATOMY", 214, 222], ["insomnia", "DISEASE", 66, 74], ["Tai-Chi", "GENE_OR_GENE_PRODUCT", 76, 83], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 147, 165], ["monocyte", "CELL", 214, 222], ["C-reactive protein", "PROTEIN", 147, 165], ["proinflammatory cytokines", "PROTEIN", 237, 262], ["another study", "TEST", 3, 16], ["insomnia", "PROBLEM", 66, 74], ["Chi reduced proinflammatory gene expression", "PROBLEM", 80, 123], ["marginally reduced C-reactive protein", "PROBLEM", 128, 165], ["proinflammatory cytokines", "PROBLEM", 237, 262], ["insomnia", "OBSERVATION", 66, 74], ["-reactive protein", "OBSERVATION", 148, 165], ["monocyte production", "OBSERVATION", 214, 233], ["proinflammatory cytokines", "OBSERVATION", 237, 262]]], ["Additionally, a 12-week program of Tai-Chi has been found to increase levels of the anti-inflammatory cytokine IL-10 in middle-aged adults.", [["Tai-", "CHEMICAL", 35, 39], ["Tai-Chi", "GENE_OR_GENE_PRODUCT", 35, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 111, 116], ["adults", "ORGANISM", 132, 138], ["anti-inflammatory cytokine", "PROTEIN", 84, 110], ["IL", "PROTEIN", 111, 113], ["the anti-inflammatory cytokine IL", "TREATMENT", 80, 113], ["anti-inflammatory", "OBSERVATION_MODIFIER", 84, 101]]], ["24 Chen et al. 25 found that in COPD patients, 60-day Liu Zi Jue practice lowered the level of IL-4\u3001IL-13 and IL-17, and increased the level of IL-10 when compared to a regular treatment control group.Enhancing the Immune FunctionQigong's enhancement of immune function has manifested in both non-specific immune response and specific immune response.", [["COPD", "DISEASE", 32, 36], ["patients", "ORGANISM", 37, 45], ["IL-4\u3001IL-13", "GENE_OR_GENE_PRODUCT", 95, 105], ["IL-17", "GENE_OR_GENE_PRODUCT", 110, 115], ["IL-10", "GENE_OR_GENE_PRODUCT", 144, 149], ["IL-17", "PROTEIN", 110, 115], ["IL", "PROTEIN", 144, 146], ["patients", "SPECIES", 37, 45], ["IL", "TEST", 95, 97], ["IL", "TEST", 110, 112], ["a regular treatment control group", "TREATMENT", 167, 200], ["immune function", "PROBLEM", 254, 269], ["both non-specific immune response", "PROBLEM", 288, 321], ["COPD", "OBSERVATION", 32, 36], ["Immune FunctionQigong", "OBSERVATION", 215, 236], ["non-specific", "OBSERVATION_MODIFIER", 293, 305], ["immune response", "OBSERVATION", 306, 321]]], ["Regarding non-specific immune response, Qigong can increase the amount or activity of immune cells in the body.Enhancing the Immune FunctionYeh et al. 24 found that in middle-aged healthy people, after a 12-week program of TaiApplication of Qigong to the Prevention of Respiratory Infectious DiseasesSome studies have demonstrated the effectiveness of Qigong in preventing respiratory infectious diseases.", [["immune cells", "ANATOMY", 86, 98], ["body", "ANATOMY", 106, 110], ["respiratory", "ANATOMY", 373, 384], ["Respiratory Infectious Diseases", "DISEASE", 269, 300], ["respiratory infectious diseases", "DISEASE", 373, 404], ["immune cells", "CELL", 86, 98], ["body", "ORGANISM_SUBDIVISION", 106, 110], ["people", "ORGANISM", 188, 194], ["immune cells", "CELL_TYPE", 86, 98], ["people", "SPECIES", 188, 194], ["non-specific immune response", "PROBLEM", 10, 38], ["Qigong", "TREATMENT", 40, 46], ["immune cells in the body", "PROBLEM", 86, 110], ["TaiApplication", "TREATMENT", 223, 237], ["Qigong", "TREATMENT", 241, 247], ["Respiratory Infectious Diseases", "PROBLEM", 269, 300], ["Some studies", "TEST", 300, 312], ["Qigong", "TREATMENT", 352, 358], ["respiratory infectious diseases", "PROBLEM", 373, 404], ["amount", "OBSERVATION_MODIFIER", 64, 70], ["immune cells", "OBSERVATION", 86, 98], ["body", "ANATOMY", 106, 110], ["Respiratory", "ANATOMY", 269, 280], ["Infectious", "OBSERVATION", 281, 291], ["respiratory", "ANATOMY", 373, 384], ["infectious", "OBSERVATION", 385, 395]]], ["Hu et al. 34 selected elderly men as experimental subjects and randomly divided participants into either a Qigong intervention group or a control group who performed jogging.", [["men", "ORGANISM", 30, 33], ["men", "SPECIES", 30, 33], ["participants", "SPECIES", 80, 92], ["a Qigong intervention group", "TREATMENT", 105, 132]]], ["Compared with the control group, the experimental group experienced significantly fewer respiratory tract infections after Qigong exercise for two years, and the difference between the two groups increased with exercise time.", [["respiratory tract", "ANATOMY", 88, 105], ["respiratory tract infections", "DISEASE", 88, 116], ["respiratory tract", "ORGANISM_SUBDIVISION", 88, 105], ["significantly fewer respiratory tract infections", "PROBLEM", 68, 116], ["Qigong exercise", "TREATMENT", 123, 138], ["respiratory tract", "ANATOMY", 88, 105], ["infections", "OBSERVATION", 106, 116]]], ["Wright et al. 35 found that in swimmers who practiced Qigong at least once per week, cold and flu symptoms showed a significant non-linear association with frequency of Qigong practice, with a strong, inverse relationship between practice frequency and symptom scores.Use of Qigong in Treating Respiratory Infectious DiseasesThere are few studies on the intervention of Qigong in the acute phase of respiratory infection, but according to limited research results Qigong can be found to shorten the course of infection.", [["respiratory", "ANATOMY", 399, 410], ["flu", "DISEASE", 94, 97], ["Respiratory Infectious Diseases", "DISEASE", 294, 325], ["respiratory infection", "DISEASE", 399, 420], ["infection", "DISEASE", 509, 518], ["cold and flu symptoms", "PROBLEM", 85, 106], ["Qigong practice", "TREATMENT", 169, 184], ["symptom scores", "PROBLEM", 253, 267], ["Qigong", "TREATMENT", 275, 281], ["the intervention", "TREATMENT", 350, 366], ["Qigong", "TREATMENT", 370, 376], ["respiratory infection", "PROBLEM", 399, 420], ["infection", "PROBLEM", 509, 518], ["Respiratory", "ANATOMY", 294, 305], ["Infectious", "OBSERVATION", 306, 316], ["acute", "OBSERVATION_MODIFIER", 384, 389], ["respiratory", "ANATOMY", 399, 410], ["infection", "OBSERVATION", 411, 420], ["infection", "OBSERVATION", 509, 518]]], ["In the two Tai-Chi groups, the levels of IgA and IgG became higher, as compared with the control group.Use of Qigong in Treating Respiratory Infectious DiseasesThere was no difference in the frequency of respiratory tract infection in the three groups, however the duration of each onset became shorter in the Tai-Chi group. improved when compared with the control group who received regular treatment.How to Learn and Practice QigongSome simple Qigong can be learned independently through watching Qigong videos.How to Learn and Practice QigongBefore learning Qigong, consulting with doctors is necessary for safety reasons.How to Learn and Practice QigongLearners can begin with physical movements of the forms.", [["respiratory tract", "ANATOMY", 204, 221], ["Respiratory Infectious Diseases", "DISEASE", 129, 160], ["respiratory tract infection", "DISEASE", 204, 231], ["IgA", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 49, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 204, 221], ["IgA", "PROTEIN", 41, 44], ["IgG", "PROTEIN", 49, 52], ["IgA", "TEST", 41, 44], ["IgG", "TEST", 49, 52], ["Qigong", "TREATMENT", 110, 116], ["respiratory tract infection", "PROBLEM", 204, 231], ["regular treatment", "TREATMENT", 384, 401], ["Practice QigongSome simple Qigong", "TREATMENT", 419, 452], ["Practice QigongLearners", "TREATMENT", 642, 665], ["Respiratory", "ANATOMY", 129, 140], ["Infectious", "OBSERVATION", 141, 151], ["no", "UNCERTAINTY", 170, 172], ["respiratory tract", "ANATOMY", 204, 221], ["infection", "OBSERVATION", 222, 231], ["shorter", "OBSERVATION_MODIFIER", 295, 302]]], ["After practitioners acquire the sequences of both isometric and isotonic segmental movements in upper and lower extremities, they can try to combine breathing techniques and focus their attention on movement, breath and Qi.Recommending Forms of QigongConsidering the physiological characteristics of the elderly, the pathological features of respiratory diseases, and the psychosocial factors in the face of the COVID-19 epidemic, we recommend Ba Duan Jin, Liu Zi Jue, and abdominal breathing.Recommending Forms of QigongAccording to the research results mentioned above, these three kinds of Qigong are often used in the prevention and treatment of respiratory infections, for the movement is smooth with low intensity, and easy to learn.", [["lower extremities", "ANATOMY", 106, 123], ["respiratory", "ANATOMY", 342, 353], ["abdominal", "ANATOMY", 473, 482], ["respiratory", "ANATOMY", 650, 661], ["respiratory diseases", "DISEASE", 342, 362], ["abdominal breathing", "DISEASE", 473, 492], ["respiratory infections", "DISEASE", 650, 672], ["upper", "ORGANISM_SUBDIVISION", 96, 101], ["lower extremities", "ORGANISM_SUBDIVISION", 106, 123], ["abdominal", "ORGANISM_SUBDIVISION", 473, 482], ["breathing techniques", "TREATMENT", 149, 169], ["breath", "TEST", 209, 215], ["respiratory diseases", "PROBLEM", 342, 362], ["the psychosocial factors", "PROBLEM", 368, 392], ["the COVID", "TEST", 408, 417], ["Ba Duan Jin", "TREATMENT", 444, 455], ["Liu Zi Jue", "TREATMENT", 457, 467], ["abdominal breathing", "PROBLEM", 473, 492], ["Qigong", "TREATMENT", 593, 599], ["respiratory infections", "PROBLEM", 650, 672], ["segmental movements", "OBSERVATION", 73, 92], ["upper", "ANATOMY_MODIFIER", 96, 101], ["lower extremities", "ANATOMY", 106, 123], ["respiratory diseases", "OBSERVATION", 342, 362], ["abdominal breathing", "ANATOMY", 473, 492], ["respiratory", "ANATOMY", 650, 661], ["infections", "OBSERVATION", 662, 672], ["low intensity", "OBSERVATION_MODIFIER", 706, 719]]], ["In addition, the range of these threeRecommending Forms of QigongQigong movements is small, and the space requirements are not significant.", [["the space requirements", "TEST", 96, 118], ["small", "OBSERVATION_MODIFIER", 85, 90], ["not", "UNCERTAINTY", 123, 126], ["significant", "OBSERVATION_MODIFIER", 127, 138]]], ["Thus, they are suitable for home practice during the current epidemic.", [["home practice", "TREATMENT", 28, 41]]], ["The type of respiratory pattern of pursed lip breathing performed by expiration to produce six different sounds (xu, he, hu, si, chui, and xi) is similar to the pursed-lips breathing in rehabilitation training for COPD patients 43 .", [["respiratory", "ANATOMY", 12, 23], ["lip", "ANATOMY", 42, 45], ["lips", "ANATOMY", 168, 172], ["COPD", "DISEASE", 214, 218], ["lip", "ORGAN", 42, 45], ["lips", "ORGANISM_SUBDIVISION", 168, 172], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227], ["pursed lip breathing", "PROBLEM", 35, 55], ["the pursed-lips breathing", "PROBLEM", 157, 182], ["rehabilitation training", "TREATMENT", 186, 209], ["COPD patients", "PROBLEM", 214, 227], ["respiratory pattern", "OBSERVATION", 12, 31], ["pursed lip breathing", "OBSERVATION", 35, 55], ["lips", "ANATOMY", 168, 172]]], ["It can modify rapid shallow breathing patterns and retard the expiratory flow rate.", [["rapid shallow breathing patterns", "PROBLEM", 14, 46], ["the expiratory flow rate", "TEST", 58, 82], ["rapid", "OBSERVATION_MODIFIER", 14, 19], ["shallow breathing", "OBSERVATION", 20, 37], ["expiratory flow", "OBSERVATION", 62, 77]]], ["Additionally, the different sounds can produce vibrations with different frequencies, which is commonly used in neurorehabilitation 44 and tension relaxation 45 .", [["tension relaxation", "TEST", 139, 157]]], ["Research indicates that Liu Zi Jue might help tissue and organs in respiratory recovery through these vibrations.", [["tissue", "ANATOMY", 46, 52], ["organs", "ANATOMY", 57, 63], ["respiratory", "ANATOMY", 67, 78], ["tissue", "TISSUE", 46, 52], ["organs", "ORGAN", 57, 63], ["Liu Zi Jue", "TREATMENT", 24, 34], ["respiratory recovery", "OBSERVATION", 67, 87]]], ["Liu ZiRecommending Forms of QigongJue is a good choice for people seeking to recuperate from respiratory dysfunction and sequela of COVID-19 infection.ConclusionsThe available biological and psychological evidence suggest Qigong may be potentially useful for the prevention, treatment, and rehabilitation of respiratory infections, including COVID-19.", [["respiratory", "ANATOMY", 93, 104], ["respiratory", "ANATOMY", 308, 319], ["QigongJue", "CHEMICAL", 28, 37], ["respiratory dysfunction", "DISEASE", 93, 116], ["COVID-19", "CHEMICAL", 132, 140], ["infection", "DISEASE", 141, 150], ["respiratory infections", "DISEASE", 308, 330], ["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["respiratory dysfunction", "PROBLEM", 93, 116], ["COVID-19 infection", "PROBLEM", 132, 150], ["Qigong", "TREATMENT", 222, 228], ["treatment", "TREATMENT", 275, 284], ["respiratory infections", "PROBLEM", 308, 330], ["COVID", "TEST", 342, 347], ["respiratory dysfunction", "OBSERVATION", 93, 116], ["infection", "OBSERVATION", 141, 150], ["respiratory", "ANATOMY", 308, 319], ["infections", "OBSERVATION", 320, 330]]], ["The elderly, in particular, could benefit from Qigong during the ongoing pandemic, for it is easy to practice.", [["Qigong", "TREATMENT", 47, 53]]], ["Future studies are needed to confirm the effectiveness of Qigong in this context and to provide more evidence on this topic.", [["Future studies", "TEST", 0, 14], ["Qigong", "TREATMENT", 58, 64]]]], "80e11b9313e94f26f8c8de8ecefb4d32b9cfc0bc": [["A 35-year-old female patient, without comorbidities, presented to the emergency room with fever, dyspnea, and adynamia over the previous four days.", [["fever", "DISEASE", 90, 95], ["dyspnea", "DISEASE", 97, 104], ["adynamia", "DISEASE", 110, 118], ["female", "ORGANISM", 14, 20], ["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["comorbidities", "PROBLEM", 38, 51], ["fever", "PROBLEM", 90, 95], ["dyspnea", "PROBLEM", 97, 104], ["adynamia", "PROBLEM", 110, 118], ["fever", "OBSERVATION", 90, 95], ["dyspnea", "OBSERVATION", 97, 104]]], ["She also had a complaint of a headache that had started two days before admission.", [["headache", "DISEASE", 30, 38], ["a headache", "PROBLEM", 28, 38], ["headache", "OBSERVATION", 30, 38]]], ["She was lucid and oriented, without focal neurological deficits.", [["neurological", "ANATOMY", 42, 54], ["neurological deficits", "DISEASE", 42, 63], ["focal neurological deficits", "PROBLEM", 36, 63], ["without", "UNCERTAINTY", 28, 35], ["focal", "OBSERVATION_MODIFIER", 36, 41]]], ["During hospitalization, the headache worsened and she became disoriented.", [["headache", "DISEASE", 28, 36], ["the headache", "PROBLEM", 24, 36], ["disoriented", "PROBLEM", 61, 72], ["headache", "OBSERVATION", 28, 36]]], ["Fundoscopy was impaired.", [["Fundoscopy", "TEST", 0, 10], ["impaired", "OBSERVATION", 15, 23]]], ["A cerebrospinal fluid puncture was performed, showing increased pressure (40 cm H2O).", [["cerebrospinal fluid", "ANATOMY", 2, 21], ["H2O", "CHEMICAL", 80, 83], ["H2O", "CHEMICAL", 80, 83], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 2, 21], ["A cerebrospinal fluid puncture", "TEST", 0, 30], ["increased pressure", "PROBLEM", 54, 72], ["cerebrospinal", "ANATOMY", 2, 15], ["fluid puncture", "OBSERVATION", 16, 30], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["pressure", "OBSERVATION_MODIFIER", 64, 72], ["40 cm", "OBSERVATION_MODIFIER", 74, 79]]], ["The cerebrospinal fluid analysis was entirely normal and negative for several pathogens.", [["cerebrospinal fluid", "ANATOMY", 4, 23], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 4, 23], ["The cerebrospinal fluid analysis", "TEST", 0, 32], ["several pathogens", "PROBLEM", 70, 87], ["cerebrospinal", "ANATOMY", 4, 17], ["fluid", "OBSERVATION", 18, 23], ["negative for", "UNCERTAINTY", 57, 69], ["several", "OBSERVATION_MODIFIER", 70, 77], ["pathogens", "OBSERVATION", 78, 87]]], ["Real-time reverse-transcription polymerase chain reaction testing of a nasopharyngeal swab confirmed SARS-Cov-2 infection.", [["nasopharyngeal swab", "ANATOMY", 71, 90], ["infection", "DISEASE", 112, 121], ["nasopharyngeal swab", "CANCER", 71, 90], ["Cov-2", "GENE_OR_GENE_PRODUCT", 106, 111], ["a nasopharyngeal swab", "TEST", 69, 90], ["SARS", "PROBLEM", 101, 105], ["Cov", "PROBLEM", 106, 109], ["2 infection", "PROBLEM", 110, 121], ["nasopharyngeal", "ANATOMY", 71, 85], ["infection", "OBSERVATION", 112, 121]]], ["A brain magnetic resonance imaging scan showed signs of intracranial hypertension characterized by prominent subarachnoid space around optic nerves, vertical tortuosity of the optic nerves, and superior compression of the hypophysis (Figure 1A-C) .", [["brain", "ANATOMY", 2, 7], ["intracranial", "ANATOMY", 56, 68], ["subarachnoid space", "ANATOMY", 109, 127], ["optic nerves", "ANATOMY", 135, 147], ["optic nerves", "ANATOMY", 176, 188], ["hypophysis", "ANATOMY", 222, 232], ["intracranial hypertension", "DISEASE", 56, 81], ["brain", "ORGAN", 2, 7], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 109, 127], ["optic nerves", "MULTI-TISSUE_STRUCTURE", 135, 147], ["optic nerves", "MULTI-TISSUE_STRUCTURE", 176, 188], ["hypophysis", "ORGAN", 222, 232], ["A brain magnetic resonance imaging scan", "TEST", 0, 39], ["intracranial hypertension", "PROBLEM", 56, 81], ["prominent subarachnoid space around optic nerves", "PROBLEM", 99, 147], ["vertical tortuosity of the optic nerves", "PROBLEM", 149, 188], ["superior compression of the hypophysis", "PROBLEM", 194, 232], ["brain", "ANATOMY", 2, 7], ["intracranial", "ANATOMY", 56, 68], ["hypertension", "OBSERVATION", 69, 81], ["prominent", "OBSERVATION_MODIFIER", 99, 108], ["subarachnoid space", "OBSERVATION", 109, 127], ["optic nerves", "ANATOMY", 135, 147], ["vertical", "OBSERVATION_MODIFIER", 149, 157], ["tortuosity", "OBSERVATION", 158, 168], ["optic nerves", "ANATOMY", 176, 188], ["superior", "OBSERVATION_MODIFIER", 194, 202], ["compression", "OBSERVATION", 203, 214], ["hypophysis", "ANATOMY", 222, 232]]], ["Chest computed tomography showed round ground-glass opacities in both lungs ( Figure 1D) .", [["lungs", "ANATOMY", 70, 75], ["lungs", "ORGAN", 70, 75], ["Chest computed tomography", "TEST", 0, 25], ["round ground-glass opacities in both lungs", "PROBLEM", 33, 75], ["round", "OBSERVATION_MODIFIER", 33, 38], ["ground-glass opacities", "OBSERVATION", 39, 61], ["both", "ANATOMY_MODIFIER", 65, 69], ["lungs", "ANATOMY", 70, 75]]], ["The final diagnosis, based on clinical, laboratory, and imaging findings was benign intracranial hypertension (BIH).", [["benign intracranial", "ANATOMY", 77, 96], ["intracranial hypertension", "DISEASE", 84, 109], ["BIH", "DISEASE", 111, 114], ["imaging findings", "TEST", 56, 72], ["benign intracranial hypertension", "PROBLEM", 77, 109], ["benign", "OBSERVATION_MODIFIER", 77, 83], ["hypertension", "OBSERVATION", 97, 109]]]], "PMC7088079": [], "PMC6118186": [["Influenza poses a public health challenge during Hajj.", [["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9]]], ["Published data indicate that influenza virus infection was a common cause of severe respiratory illness in pilgrims returning from Hajj.1 Hajj pilgrimage follows the lunar calendar; thus, it may or may not coincide with wintertime in Saudi Arabia.", [["respiratory", "ANATOMY", 84, 95], ["influenza virus infection", "DISEASE", 29, 54], ["respiratory illness", "DISEASE", 84, 103], ["influenza virus", "ORGANISM", 29, 44], ["influenza virus", "SPECIES", 29, 44], ["influenza virus", "SPECIES", 29, 44], ["influenza virus infection", "PROBLEM", 29, 54], ["severe respiratory illness", "PROBLEM", 77, 103], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["respiratory", "ANATOMY", 84, 95], ["illness", "OBSERVATION", 96, 103]]], ["As pilgrims performing Hajj come from both, the northern and southern hemispheres, some come from areas with active transmission of seasonal influenza.", [["influenza", "DISEASE", 141, 150], ["seasonal influenza", "PROBLEM", 132, 150], ["active", "OBSERVATION_MODIFIER", 109, 115], ["seasonal influenza", "OBSERVATION", 132, 150]]], ["The seasonal availability of the influenza vaccine presents a challenge for the preventive efforts related to Hajj.2", [["influenza", "DISEASE", 33, 42], ["the influenza vaccine", "TREATMENT", 29, 50]]]], "PMC7348297": [["IntroductionCoronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a clinical spectrum ranging from asymptomatic/pauci-symptomatic forms to severe pneumonia leading to respiratory failure, need for mechanical ventilation, and death (1).", [["respiratory", "ANATOMY", 228, 239], ["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 68, 106], ["pneumonia", "DISEASE", 207, 216], ["respiratory failure", "DISEASE", 228, 247], ["death", "DISEASE", 286, 291], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 61, 108], ["SARS-CoV-2", "ORGANISM", 110, 120], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 61, 106], ["SARS-CoV-2", "SPECIES", 110, 120], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 106], ["SARS-CoV", "TEST", 110, 118], ["a clinical spectrum", "PROBLEM", 127, 146], ["asymptomatic/pauci-symptomatic forms", "PROBLEM", 160, 196], ["severe pneumonia", "PROBLEM", 200, 216], ["respiratory failure", "PROBLEM", 228, 247], ["mechanical ventilation", "TREATMENT", 258, 280], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["pneumonia", "OBSERVATION", 207, 216], ["respiratory failure", "OBSERVATION", 228, 247], ["mechanical ventilation", "OBSERVATION", 258, 280]]], ["Severe COVID-19 pneumonia seems to be mediated by a cytokine storm (2, 3).", [["pneumonia", "DISEASE", 16, 25], ["cytokine", "PROTEIN", 52, 60], ["Severe COVID", "PROBLEM", 0, 12], ["pneumonia", "PROBLEM", 16, 25], ["pneumonia", "OBSERVATION", 16, 25], ["cytokine storm", "OBSERVATION", 52, 66]]], ["Therefore, therapies that target hyperinflammation may be effective.Role of IL-1\u03b2 and IL-6 in Hyperinflammation in COVID-19In a recent report, patients with COVID-19 needing intensive care unit (ICU) admission showed a cytokine profile similar to that of secondary hemophagocytic lymphohistiocytosis with increased levels of several inflammatory cytokines [interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor (G-CSF), granulocyte-monocyte stimulating factor (GM-CSF), interferon-\u03b3-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-\u03b1 (MIP1-\u03b1), and tumor necrosis factor-\u03b1 (TNF-\u03b1)] (4).", [["hyperinflammation", "DISEASE", 33, 50], ["Hyperinflammation", "DISEASE", 94, 111], ["hemophagocytic lymphohistiocytosis", "DISEASE", 265, 299], ["necrosis", "DISEASE", 623, 631], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-6", "GENE_OR_GENE_PRODUCT", 86, 90], ["COVID-19In", "CELL", 115, 125], ["patients", "ORGANISM", 143, 151], ["interleukin (IL)-2", "GENE_OR_GENE_PRODUCT", 357, 375], ["IL-7", "GENE_OR_GENE_PRODUCT", 377, 381], ["granulocyte-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 383, 420], ["G-CSF", "GENE_OR_GENE_PRODUCT", 422, 427], ["granulocyte-monocyte stimulating factor", "GENE_OR_GENE_PRODUCT", 430, 469], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 471, 477], ["interferon-\u03b3-inducible protein 10", "GENE_OR_GENE_PRODUCT", 480, 513], ["IP-10", "GENE_OR_GENE_PRODUCT", 515, 520], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 523, 557], ["MCP-1", "GENE_OR_GENE_PRODUCT", 559, 564], ["macrophage inflammatory protein 1-\u03b1", "GENE_OR_GENE_PRODUCT", 567, 602], ["MIP1-\u03b1", "GENE_OR_GENE_PRODUCT", 604, 610], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 617, 640], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 642, 647], ["IL-1\u03b2", "PROTEIN", 76, 81], ["IL-6", "PROTEIN", 86, 90], ["cytokine", "PROTEIN", 219, 227], ["inflammatory cytokines", "PROTEIN", 333, 355], ["interleukin (IL)-2, IL-7", "PROTEIN", 357, 381], ["granulocyte-colony stimulating factor", "PROTEIN", 383, 420], ["CSF", "PROTEIN", 424, 427], ["granulocyte-monocyte stimulating factor", "PROTEIN", 430, 469], ["GM", "PROTEIN", 471, 473], ["CSF", "PROTEIN", 474, 477], ["interferon-\u03b3-inducible protein 10 (IP-10", "PROTEIN", 480, 520], ["monocyte chemoattractant protein 1 (MCP-1", "PROTEIN", 523, 564], ["macrophage inflammatory protein 1", "PROTEIN", 567, 600], ["\u03b1", "PROTEIN", 601, 602], ["MIP1", "PROTEIN", 604, 608], ["\u03b1", "PROTEIN", 609, 610], ["tumor necrosis factor", "PROTEIN", 617, 638], ["TNF", "PROTEIN", 642, 645], ["patients", "SPECIES", 143, 151], ["therapies", "TREATMENT", 11, 20], ["target hyperinflammation", "PROBLEM", 26, 50], ["IL", "TEST", 76, 78], ["COVID", "TEST", 157, 162], ["a cytokine profile", "PROBLEM", 217, 235], ["secondary hemophagocytic lymphohistiocytosis", "PROBLEM", 255, 299], ["increased levels", "PROBLEM", 305, 321], ["several inflammatory cytokines", "PROBLEM", 325, 355], ["interleukin (IL)", "TEST", 357, 373], ["IL", "TEST", 377, 379], ["granulocyte", "TEST", 383, 394], ["colony stimulating factor", "TEST", 395, 420], ["G-CSF", "TEST", 422, 427], ["granulocyte", "TEST", 430, 441], ["monocyte stimulating factor", "TEST", 442, 469], ["GM", "TEST", 471, 473], ["CSF", "TEST", 474, 477], ["interferon", "TEST", 480, 490], ["inducible protein", "TEST", 493, 510], ["IP", "TEST", 515, 517], ["monocyte chemoattractant protein", "TEST", 523, 555], ["MCP", "TEST", 559, 562], ["macrophage inflammatory protein", "TEST", 567, 598], ["MIP1", "TEST", 604, 608], ["tumor necrosis factor", "PROBLEM", 617, 638], ["TNF", "TEST", 642, 645], ["may be", "UNCERTAINTY", 51, 57], ["effective", "OBSERVATION_MODIFIER", 58, 67], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 265, 299], ["several", "OBSERVATION_MODIFIER", 325, 332], ["inflammatory", "OBSERVATION_MODIFIER", 333, 345], ["granulocyte", "ANATOMY", 383, 394], ["granulocyte", "ANATOMY", 430, 441], ["macrophage", "ANATOMY", 567, 577], ["inflammatory", "OBSERVATION", 578, 590], ["tumor necrosis", "OBSERVATION", 617, 631]]], ["Additionally, increased levels of ferritin and IL-6 have been shown to correlate with a worse prognosis [(4\u201311); Supplementary Table 1].", [["ferritin", "GENE_OR_GENE_PRODUCT", 34, 42], ["IL-6", "GENE_OR_GENE_PRODUCT", 47, 51], ["ferritin", "PROTEIN", 34, 42], ["IL-6", "PROTEIN", 47, 51], ["ferritin", "TEST", 34, 42], ["IL", "TEST", 47, 49], ["a worse prognosis", "PROBLEM", 86, 103], ["increased", "OBSERVATION_MODIFIER", 14, 23]]], ["These observations underline that COVID-19 is a complex disease capable to combine different patterns of inflammatory biomarkers.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 34, 42], ["These observations", "TEST", 0, 18], ["COVID", "TEST", 34, 39], ["a complex disease", "PROBLEM", 46, 63], ["inflammatory biomarkers", "PROBLEM", 105, 128], ["inflammatory", "OBSERVATION", 105, 117]]], ["Indeed, most of the infections can trigger the release of IL-1\u03b2 from the inflammasome (12) followed by the production of IL-6 that increases the circulating levels of C-reactive protein, the prototypical acute-phase reactant (13).", [["infections", "DISEASE", 20, 30], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 167, 185], ["IL-1\u03b2", "PROTEIN", 58, 63], ["IL-6", "PROTEIN", 121, 125], ["C-reactive protein", "PROTEIN", 167, 185], ["the infections", "PROBLEM", 16, 30], ["IL", "TEST", 58, 60], ["C-reactive protein", "TEST", 167, 185], ["infections", "OBSERVATION", 20, 30]]], ["In viral infections, including COVID-19, elevated levels of the pro-inflammatory cytokine IL-18, that derives from the inflammasome as IL-1\u03b2, are found along with high levels of ferritin (13), thus replicating the events commonly observed in the macrophage activation syndrome (14).", [["macrophage", "ANATOMY", 246, 256], ["viral infections", "DISEASE", 3, 19], ["IL-18", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 135, 140], ["ferritin (13)", "GENE_OR_GENE_PRODUCT", 178, 191], ["macrophage", "CELL", 246, 256], ["pro-inflammatory cytokine IL-18", "PROTEIN", 64, 95], ["IL-1\u03b2", "PROTEIN", 135, 140], ["ferritin (13)", "PROTEIN", 178, 191], ["viral infections", "PROBLEM", 3, 19], ["COVID", "TEST", 31, 36], ["elevated levels", "PROBLEM", 41, 56], ["the pro-inflammatory cytokine IL", "TEST", 60, 92], ["the inflammasome as IL", "TEST", 115, 137], ["high levels of ferritin", "PROBLEM", 163, 186], ["the macrophage activation syndrome", "PROBLEM", 242, 276], ["viral", "OBSERVATION_MODIFIER", 3, 8], ["infections", "OBSERVATION", 9, 19], ["macrophage activation syndrome", "OBSERVATION", 246, 276]]], ["Altogether, these findings support the hypothesis that a maladaptive hyperinflammatory response to the virus orchestrated by IL-6, IL-1\u03b2, and eventually GM-CSF\u2014referred to as cytokine storm\u2014rather than the virus itself may drive the lung damage leading to hypoxia and acute respiratory failure.", [["lung", "ANATOMY", 233, 237], ["respiratory", "ANATOMY", 274, 285], ["GM", "CHEMICAL", 153, 155], ["lung damage", "DISEASE", 233, 244], ["hypoxia", "DISEASE", 256, 263], ["acute respiratory failure", "DISEASE", 268, 293], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 131, 136], ["GM-CSF\u2014referred", "GENE_OR_GENE_PRODUCT", 153, 168], ["lung", "ORGAN", 233, 237], ["IL-6", "PROTEIN", 125, 129], ["IL-1\u03b2", "PROTEIN", 131, 136], ["cytokine", "PROTEIN", 175, 183], ["the hypothesis", "PROBLEM", 35, 49], ["a maladaptive hyperinflammatory response", "PROBLEM", 55, 95], ["the virus", "PROBLEM", 99, 108], ["IL", "TEST", 125, 127], ["cytokine storm\u2014rather", "TREATMENT", 175, 196], ["the virus", "PROBLEM", 202, 211], ["the lung damage", "PROBLEM", 229, 244], ["hypoxia", "PROBLEM", 256, 263], ["acute respiratory failure", "PROBLEM", 268, 293], ["lung", "ANATOMY", 233, 237], ["damage", "OBSERVATION", 238, 244], ["hypoxia", "OBSERVATION", 256, 263], ["acute", "OBSERVATION_MODIFIER", 268, 273], ["respiratory failure", "OBSERVATION", 274, 293]]], ["Immunomodulation may be beneficial in the treatment of hyperinflammation-associated conditions.Role of IL-1\u03b2 and IL-6 in Hyperinflammation in COVID-19Data supporting the role of hyperinflammation in sepsis-related acute respiratory distress syndrome (ARDS) are derived from a sub-group analysis of a phase 3 randomized controlled trial of IL-1 receptor antagonist (anakinra), which showed significant survival benefit in patients treated with anakinra compared to placebo (15).", [["respiratory", "ANATOMY", 220, 231], ["hyperinflammation", "DISEASE", 55, 72], ["Hyperinflammation", "DISEASE", 121, 138], ["hyperinflammation", "DISEASE", 178, 195], ["sepsis", "DISEASE", 199, 205], ["acute respiratory distress syndrome", "DISEASE", 214, 249], ["ARDS", "DISEASE", 251, 255], ["anakinra", "CHEMICAL", 365, 373], ["anakinra", "CHEMICAL", 443, 451], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["COVID-19Data", "CELL", 142, 154], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 339, 363], ["anakinra", "SIMPLE_CHEMICAL", 365, 373], ["patients", "ORGANISM", 421, 429], ["anakinra", "SIMPLE_CHEMICAL", 443, 451], ["IL-1\u03b2", "PROTEIN", 103, 108], ["IL-6", "PROTEIN", 113, 117], ["patients", "SPECIES", 421, 429], ["Immunomodulation", "TREATMENT", 0, 16], ["hyperinflammation", "PROBLEM", 55, 72], ["associated conditions", "PROBLEM", 73, 94], ["IL", "TEST", 103, 105], ["IL", "TEST", 113, 115], ["Hyperinflammation", "PROBLEM", 121, 138], ["COVID", "TEST", 142, 147], ["hyperinflammation", "PROBLEM", 178, 195], ["sepsis", "PROBLEM", 199, 205], ["acute respiratory distress syndrome", "PROBLEM", 214, 249], ["ARDS", "PROBLEM", 251, 255], ["IL-1 receptor antagonist", "TREATMENT", 339, 363], ["anakinra", "TREATMENT", 443, 451], ["sepsis", "OBSERVATION", 199, 205], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory distress", "OBSERVATION", 220, 240], ["significant", "OBSERVATION_MODIFIER", 389, 400], ["survival benefit", "OBSERVATION", 401, 417]]], ["IL-1\u03b2 is an upstream pro-inflammatory cytokine that is released following activation of the inflammasome in response to infection and/or injury (16).Role of IL-1\u03b2 and IL-6 in Hyperinflammation in COVID-19IL-6 is a pleiotropic cytokine that influences several processes, such as acute-phase protein generation, inflammation, and antigen-specific immune responses (17).", [["infection", "DISEASE", 120, 129], ["Hyperinflammation", "DISEASE", 175, 192], ["COVID-19IL-6", "CHEMICAL", 196, 208], ["inflammation", "DISEASE", 310, 322], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 157, 162], ["IL-6", "GENE_OR_GENE_PRODUCT", 167, 171], ["COVID-19IL-6", "GENE_OR_GENE_PRODUCT", 196, 208], ["IL-1\u03b2", "PROTEIN", 0, 5], ["upstream pro-inflammatory cytokine", "PROTEIN", 12, 46], ["IL-1\u03b2", "PROTEIN", 157, 162], ["IL-6", "PROTEIN", 167, 171], ["pleiotropic cytokine", "PROTEIN", 214, 234], ["an upstream pro-inflammatory cytokine", "TREATMENT", 9, 46], ["the inflammasome", "PROBLEM", 88, 104], ["infection", "PROBLEM", 120, 129], ["injury", "PROBLEM", 137, 143], ["IL", "TEST", 157, 159], ["IL", "TEST", 167, 169], ["Hyperinflammation", "TEST", 175, 192], ["COVID", "TEST", 196, 201], ["a pleiotropic cytokine", "PROBLEM", 212, 234], ["acute-phase protein generation", "PROBLEM", 278, 308], ["inflammation", "PROBLEM", 310, 322], ["antigen", "TEST", 328, 335], ["pro-inflammatory cytokine", "OBSERVATION", 21, 46], ["infection", "OBSERVATION", 120, 129], ["acute", "OBSERVATION_MODIFIER", 278, 283], ["inflammation", "OBSERVATION", 310, 322]]], ["In the innate immune response, IL-6 is produced by myeloid cells [e.g., macrophages and dendritic cells (DCs)] following the recognition of sterile or non-sterile stimuli through toll-like receptors at the site of infection or tissue injury.", [["myeloid cells", "ANATOMY", 51, 64], ["macrophages", "ANATOMY", 72, 83], ["dendritic cells", "ANATOMY", 88, 103], ["DCs", "ANATOMY", 105, 108], ["tissue", "ANATOMY", 227, 233], ["infection", "DISEASE", 214, 223], ["tissue injury", "DISEASE", 227, 240], ["IL-6", "GENE_OR_GENE_PRODUCT", 31, 35], ["myeloid cells", "CELL", 51, 64], ["macrophages", "CELL", 72, 83], ["dendritic cells", "CELL", 88, 103], ["DCs", "CELL", 105, 108], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 179, 198], ["tissue", "TISSUE", 227, 233], ["IL-6", "PROTEIN", 31, 35], ["myeloid cells", "CELL_TYPE", 51, 64], ["macrophages", "CELL_TYPE", 72, 83], ["dendritic cells", "CELL_TYPE", 88, 103], ["DCs", "CELL_TYPE", 105, 108], ["toll-like receptors", "PROTEIN", 179, 198], ["IL", "TEST", 31, 33], ["myeloid cells", "PROBLEM", 51, 64], ["macrophages", "PROBLEM", 72, 83], ["dendritic cells", "PROBLEM", 88, 103], ["sterile or non-sterile stimuli", "TREATMENT", 140, 170], ["infection", "PROBLEM", 214, 223], ["tissue injury", "PROBLEM", 227, 240], ["myeloid cells", "OBSERVATION", 51, 64], ["dendritic cells", "OBSERVATION", 88, 103], ["infection", "OBSERVATION", 214, 223], ["tissue", "ANATOMY", 227, 233], ["injury", "OBSERVATION", 234, 240]]], ["In the adaptive immune response, IL-6 is a critical modulator of plasma B-cell differentiation and antibody production (18).", [["plasma B-cell", "ANATOMY", 65, 78], ["IL-6", "GENE_OR_GENE_PRODUCT", 33, 37], ["plasma B-cell", "CELL", 65, 78], ["IL-6", "PROTEIN", 33, 37], ["plasma B-cell differentiation", "TEST", 65, 94], ["antibody production", "TEST", 99, 118], ["immune response", "OBSERVATION", 16, 31], ["cell differentiation", "OBSERVATION", 74, 94]]], ["A deregulated IL-6 expression is involved in the pathogenesis of several disorders, such as chronic inflammatory diseases, autoimmune diseases, and tumor development (19, 20).", [["tumor", "ANATOMY", 148, 153], ["chronic inflammatory diseases", "DISEASE", 92, 121], ["autoimmune diseases", "DISEASE", 123, 142], ["tumor", "DISEASE", 148, 153], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["tumor", "CANCER", 148, 153], ["IL-6", "PROTEIN", 14, 18], ["A deregulated IL-6 expression", "TREATMENT", 0, 29], ["several disorders", "PROBLEM", 65, 82], ["chronic inflammatory diseases", "PROBLEM", 92, 121], ["autoimmune diseases", "PROBLEM", 123, 142], ["tumor development", "PROBLEM", 148, 165], ["deregulated", "OBSERVATION_MODIFIER", 2, 13], ["IL", "OBSERVATION_MODIFIER", 14, 16], ["several", "OBSERVATION_MODIFIER", 65, 72], ["disorders", "OBSERVATION", 73, 82], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["inflammatory", "OBSERVATION", 100, 112], ["autoimmune diseases", "OBSERVATION", 123, 142], ["tumor", "OBSERVATION", 148, 153]]], ["Cytokine release syndrome (CRS) represents an on-target effect of chimeric antigen receptor (CAR) T-cell therapy and consists of a systemic inflammatory response due to a massive cytokine release, including IL-6, GM-CSF, and interferon-\u03b3, following the in vivo activation of CAR T-cells (21, 22).", [["T-cell", "ANATOMY", 98, 104], ["CAR T-cells", "ANATOMY", 275, 286], ["CRS", "DISEASE", 27, 30], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["chimeric antigen receptor", "GENE_OR_GENE_PRODUCT", 66, 91], ["IL-6", "GENE_OR_GENE_PRODUCT", 207, 211], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 213, 219], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 225, 237], ["CAR T-cells", "CELL", 275, 286], ["Cytokine", "PROTEIN", 0, 8], ["chimeric antigen receptor", "PROTEIN", 66, 91], ["CAR", "PROTEIN", 93, 96], ["cytokine", "PROTEIN", 179, 187], ["IL-6", "PROTEIN", 207, 211], ["GM", "PROTEIN", 213, 215], ["CSF", "PROTEIN", 216, 219], ["interferon-\u03b3", "PROTEIN", 225, 237], ["CAR T-cells", "CELL_TYPE", 275, 286], ["Cytokine release syndrome", "PROBLEM", 0, 25], ["chimeric antigen receptor (CAR) T-cell therapy", "TREATMENT", 66, 112], ["a systemic inflammatory response", "PROBLEM", 129, 161], ["a massive cytokine release", "PROBLEM", 169, 195], ["IL", "TEST", 207, 209], ["GM-CSF", "TEST", 213, 219], ["interferon", "TREATMENT", 225, 235], ["systemic", "OBSERVATION_MODIFIER", 131, 139], ["inflammatory", "OBSERVATION", 140, 152], ["massive cytokine", "OBSERVATION", 171, 187]]], ["The incidence of CRS after CAR T-cell therapy ranges from 50 to 100% with 13\u201348% of patients having severe CRS (23).", [["T-cell", "ANATOMY", 31, 37], ["CRS", "DISEASE", 17, 20], ["CRS", "DISEASE", 107, 110], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["CRS", "TEST", 17, 20], ["CAR T-cell therapy", "TREATMENT", 27, 45], ["severe CRS", "PROBLEM", 100, 110], ["severe", "OBSERVATION_MODIFIER", 100, 106]]], ["Tocilizumab, an IL-6 receptor blocker, has been approved for the treatment of severe CRS after CAR T-cell therapy in light of its association with a rapid improvement of clinical manifestations and a decrease in the aforementioned cytokines along with a low toxicity for CAR T-cells (18).Role of IL-1\u03b2 and IL-6 in Hyperinflammation in COVID-19Different trials are recruiting patients with COVID-19 pneumonia to test whether IL-6 receptor blockers (tocilizumab, sirukumab, and sarilumab: ChiCTR2000029765, NCT04306705, NCT04315480, NCT04317092; NCT04315298, NCT04322773, and NCT04321993) and an IL-1 receptor blocker (anakinra, NCT04324021, NCT04364009, NCT04412291, NCT04366232, NCT04357366, NCT04341584, NCT04339712, and NCT04362943) improve COVID-19 pneumonia outcomes.", [["T-cell", "ANATOMY", 99, 105], ["CAR T-cells", "ANATOMY", 271, 282], ["Tocilizumab", "CHEMICAL", 0, 11], ["CRS", "DISEASE", 85, 88], ["toxicity", "DISEASE", 258, 266], ["Hyperinflammation", "DISEASE", 314, 331], ["pneumonia", "DISEASE", 398, 407], ["tocilizumab", "CHEMICAL", 448, 459], ["sirukumab", "CHEMICAL", 461, 470], ["sarilumab", "CHEMICAL", 476, 485], ["anakinra", "CHEMICAL", 617, 625], ["pneumonia", "DISEASE", 752, 761], ["Tocilizumab", "CHEMICAL", 0, 11], ["sirukumab", "CHEMICAL", 461, 470], ["sarilumab", "CHEMICAL", 476, 485], ["ChiCTR2000029765", "CHEMICAL", 487, 503], ["NCT04306705", "CHEMICAL", 505, 516], ["NCT04315480", "CHEMICAL", 518, 529], ["NCT04317092", "CHEMICAL", 531, 542], ["NCT04315298", "CHEMICAL", 544, 555], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 16, 29], ["CAR T-cell", "CELL", 95, 105], ["CAR T-cells", "CELL", 271, 282], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 296, 301], ["IL-6", "GENE_OR_GENE_PRODUCT", 306, 310], ["patients", "ORGANISM", 375, 383], ["IL-6 receptor blockers", "SIMPLE_CHEMICAL", 424, 446], ["tocilizumab", "SIMPLE_CHEMICAL", 448, 459], ["sirukumab", "SIMPLE_CHEMICAL", 461, 470], ["sarilumab", "SIMPLE_CHEMICAL", 476, 485], ["IL-1 receptor blocker", "SIMPLE_CHEMICAL", 594, 615], ["anakinra", "SIMPLE_CHEMICAL", 617, 625], ["cytokines", "PROTEIN", 231, 240], ["CAR T-cells", "CELL_TYPE", 271, 282], ["IL-1\u03b2", "PROTEIN", 296, 301], ["IL-6", "PROTEIN", 306, 310], ["patients", "SPECIES", 375, 383], ["Tocilizumab", "TREATMENT", 0, 11], ["an IL-6 receptor blocker", "TREATMENT", 13, 37], ["severe CRS", "PROBLEM", 78, 88], ["CAR T-cell therapy", "TREATMENT", 95, 113], ["clinical manifestations", "PROBLEM", 170, 193], ["a decrease in the aforementioned cytokines", "PROBLEM", 198, 240], ["a low toxicity", "PROBLEM", 252, 266], ["IL", "TEST", 296, 298], ["COVID", "TEST", 389, 394], ["pneumonia", "PROBLEM", 398, 407], ["IL", "TEST", 424, 426], ["receptor blockers", "TREATMENT", 429, 446], ["tocilizumab", "TEST", 448, 459], ["an IL", "TEST", 591, 596], ["anakinra", "TEST", 617, 625], ["COVID", "TEST", 743, 748], ["pneumonia outcomes", "PROBLEM", 752, 770], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["rapid", "OBSERVATION_MODIFIER", 149, 154], ["improvement", "OBSERVATION_MODIFIER", 155, 166], ["decrease", "OBSERVATION_MODIFIER", 200, 208], ["pneumonia", "OBSERVATION", 398, 407], ["pneumonia", "OBSERVATION", 752, 761]]], ["The identification and treatment of hyperinflammation using existing therapies with understood safety profiles that are either in clinical development or approved for other indications represent a valid option to cope with the immediate need to reduce the rising mortality of COVID-19.GM-CSF: a Key Mediator of Inflammation and InjuryIn an attempt to approach hyperinflammation upstream of both IL-1 and IL-6 and to target neutrophils as well as macrophages, GM-CSF may be considered as an appealing mediator.", [["neutrophils", "ANATOMY", 423, 434], ["macrophages", "ANATOMY", 446, 457], ["hyperinflammation", "DISEASE", 36, 53], ["GM", "CHEMICAL", 285, 287], ["GM", "CHEMICAL", 459, 461], ["COVID-19", "CHEMICAL", 276, 284], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 285, 291], ["IL-1", "GENE_OR_GENE_PRODUCT", 395, 399], ["IL-6", "GENE_OR_GENE_PRODUCT", 404, 408], ["neutrophils", "CELL", 423, 434], ["macrophages", "CELL", 446, 457], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 459, 465], ["IL-1 and IL-6", "PROTEIN", 395, 408], ["neutrophils", "CELL_TYPE", 423, 434], ["macrophages", "CELL_TYPE", 446, 457], ["The identification", "TEST", 0, 18], ["treatment", "TREATMENT", 23, 32], ["hyperinflammation", "PROBLEM", 36, 53], ["existing therapies", "TREATMENT", 60, 78], ["a valid option", "TREATMENT", 195, 209], ["COVID", "TEST", 276, 281], ["Inflammation", "PROBLEM", 311, 323], ["InjuryIn", "PROBLEM", 328, 336], ["both IL", "TEST", 390, 397], ["IL", "TEST", 404, 406], ["neutrophils", "TEST", 423, 434], ["macrophages", "TEST", 446, 457], ["GM-CSF", "TEST", 459, 465], ["CSF", "OBSERVATION", 288, 291], ["Inflammation", "OBSERVATION", 311, 323]]], ["GM-CSF is generally perceived as a pro-inflammatory cytokine and is produced by many cells, including macrophages, T-cells, fibroblasts, endothelial cells, epithelial cells, and tumor cells (24), with most of the production occurring at sites of inflammation (25).", [["cells", "ANATOMY", 85, 90], ["macrophages", "ANATOMY", 102, 113], ["T-cells", "ANATOMY", 115, 122], ["fibroblasts", "ANATOMY", 124, 135], ["endothelial cells", "ANATOMY", 137, 154], ["epithelial cells", "ANATOMY", 156, 172], ["tumor cells", "ANATOMY", 178, 189], ["sites", "ANATOMY", 237, 242], ["GM", "CHEMICAL", 0, 2], ["tumor", "DISEASE", 178, 183], ["inflammation", "DISEASE", 246, 258], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["cells", "CELL", 85, 90], ["macrophages", "CELL", 102, 113], ["T-cells", "CELL", 115, 122], ["fibroblasts", "CELL", 124, 135], ["endothelial cells", "CELL", 137, 154], ["epithelial cells", "CELL", 156, 172], ["tumor cells", "CELL", 178, 189], ["GM", "PROTEIN", 0, 2], ["CSF", "PROTEIN", 3, 6], ["pro-inflammatory cytokine", "PROTEIN", 35, 60], ["macrophages", "CELL_TYPE", 102, 113], ["T-cells", "CELL_TYPE", 115, 122], ["fibroblasts", "CELL_TYPE", 124, 135], ["endothelial cells", "CELL_TYPE", 137, 154], ["epithelial cells", "CELL_TYPE", 156, 172], ["tumor cells", "CELL_TYPE", 178, 189], ["GM-CSF", "TEST", 0, 6], ["a pro-inflammatory cytokine", "TEST", 33, 60], ["many cells", "PROBLEM", 80, 90], ["macrophages", "PROBLEM", 102, 113], ["T-cells", "PROBLEM", 115, 122], ["fibroblasts", "PROBLEM", 124, 135], ["endothelial cells", "TEST", 137, 154], ["epithelial cells", "PROBLEM", 156, 172], ["tumor cells", "PROBLEM", 178, 189], ["the production", "PROBLEM", 209, 223], ["inflammation", "PROBLEM", 246, 258], ["CSF", "OBSERVATION", 3, 6], ["pro-inflammatory cytokine", "OBSERVATION", 35, 60], ["many cells", "OBSERVATION", 80, 90], ["macrophages", "ANATOMY", 102, 113], ["fibroblasts", "ANATOMY", 124, 135], ["endothelial cells", "OBSERVATION", 137, 154], ["epithelial cells", "OBSERVATION", 156, 172], ["tumor cells", "OBSERVATION", 178, 189], ["inflammation", "OBSERVATION", 246, 258]]], ["GM-CSF signals are mediated by the GM-CSF receptor (GM-CSF-R) consisting of a specific ligand-binding \u03b1-chain (GM CSF-R\u03b1) and a signal-transducing \u03b2-chain (GM CSF-R\u03b2) (Figure 1A).", [["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["GM-CSF receptor", "GENE_OR_GENE_PRODUCT", 35, 50], ["GM-CSF-R", "GENE_OR_GENE_PRODUCT", 52, 60], ["ligand-binding \u03b1-chain", "GENE_OR_GENE_PRODUCT", 87, 109], ["GM CSF-R\u03b1", "GENE_OR_GENE_PRODUCT", 111, 120], ["GM CSF-R\u03b2", "GENE_OR_GENE_PRODUCT", 156, 165], ["Figure 1A", "GENE_OR_GENE_PRODUCT", 168, 177], ["CSF", "PROTEIN", 3, 6], ["GM-CSF receptor", "PROTEIN", 35, 50], ["GM", "PROTEIN", 52, 54], ["CSF", "PROTEIN", 55, 58], ["R", "PROTEIN", 59, 60], ["specific ligand-binding \u03b1-chain", "PROTEIN", 78, 109], ["CSF", "PROTEIN", 114, 117], ["R\u03b1", "PROTEIN", 118, 120], ["signal-transducing \u03b2-chain", "PROTEIN", 128, 154], ["GM CSF", "PROTEIN", 156, 162], ["R\u03b2", "PROTEIN", 163, 165], ["Figure 1A", "PROTEIN", 168, 177], ["CSF signals", "TEST", 3, 14], ["the GM", "TEST", 31, 37], ["CSF receptor", "TEST", 38, 50], ["a specific ligand", "TEST", 76, 93], ["GM CSF", "TEST", 111, 117], ["a signal", "TEST", 126, 134]]], ["Downstream signaling of GM-CSF-R includes Janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB), extracellular signal-regulated kinase (ERK), and the phosphoinositide 3-kinase (PI3K)-Akt pathway (26\u201329).", [["B cells", "ANATOMY", 179, 186], ["GM", "CHEMICAL", 24, 26], ["GM-CSF-R", "GENE_OR_GENE_PRODUCT", 24, 32], ["Janus kinase 2", "GENE_OR_GENE_PRODUCT", 42, 56], ["JAK2", "GENE_OR_GENE_PRODUCT", 58, 62], ["signal transducer and activator of transcription 5", "GENE_OR_GENE_PRODUCT", 64, 114], ["STAT5", "GENE_OR_GENE_PRODUCT", 116, 121], ["kappa-light-chain-enhancer of activated B cells", "GENE_OR_GENE_PRODUCT", 139, 186], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 188, 193], ["extracellular signal-regulated kinase", "GENE_OR_GENE_PRODUCT", 196, 233], ["ERK", "GENE_OR_GENE_PRODUCT", 235, 238], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 249, 274], ["PI3K", "GENE_OR_GENE_PRODUCT", 276, 280], ["Akt", "GENE_OR_GENE_PRODUCT", 282, 285], ["GM-CSF-R", "PROTEIN", 24, 32], ["Janus kinase 2", "PROTEIN", 42, 56], ["JAK2", "PROTEIN", 58, 62], ["signal transducer and activator of transcription 5", "PROTEIN", 64, 114], ["STAT5", "PROTEIN", 116, 121], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 124, 186], ["NF-\u03baB", "PROTEIN", 188, 193], ["extracellular signal-regulated kinase", "PROTEIN", 196, 233], ["ERK", "PROTEIN", 235, 238], ["phosphoinositide 3-kinase", "PROTEIN", 249, 274], ["PI3K", "PROTEIN", 276, 280], ["Akt", "PROTEIN", 282, 285], ["GM-CSF", "TEST", 24, 30], ["Janus kinase", "TEST", 42, 54], ["signal transducer", "TEST", 64, 81], ["activator of transcription", "TEST", 86, 112], ["nuclear factor kappa-light", "TEST", 124, 150], ["activated B cells", "TEST", 169, 186], ["NF", "TEST", 188, 190], ["extracellular signal", "TEST", 196, 216], ["ERK", "TEST", 235, 238], ["the phosphoinositide", "TEST", 245, 265], ["PI3K", "TEST", 276, 280], ["Akt pathway", "TEST", 282, 293]]], ["Importantly, ERK activity is responsible for GM-CSF-mediated human monocyte survival in vitro (27).", [["monocyte", "ANATOMY", 67, 75], ["GM", "CHEMICAL", 45, 47], ["ERK", "GENE_OR_GENE_PRODUCT", 13, 16], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 45, 51], ["human", "ORGANISM", 61, 66], ["monocyte", "CELL", 67, 75], ["ERK", "PROTEIN", 13, 16], ["CSF", "PROTEIN", 48, 51], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["ERK activity", "TEST", 13, 25], ["GM", "TEST", 45, 47], ["CSF", "TEST", 48, 51]]], ["Interferon regulatory factor 4 (IRF4) is a hemopoietic-specific transcription factor that has been involved in the induction of DC-like properties in monocytes treated with GM-CSF (30, 31).", [["hemopoietic", "ANATOMY", 43, 54], ["DC", "ANATOMY", 128, 130], ["monocytes", "ANATOMY", 150, 159], ["GM", "CHEMICAL", 173, 175], ["Interferon regulatory factor 4", "GENE_OR_GENE_PRODUCT", 0, 30], ["IRF4", "GENE_OR_GENE_PRODUCT", 32, 36], ["monocytes", "CELL", 150, 159], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 173, 179], ["Interferon regulatory factor 4", "PROTEIN", 0, 30], ["IRF4", "PROTEIN", 32, 36], ["transcription factor", "PROTEIN", 64, 84], ["DC", "CELL_TYPE", 128, 130], ["monocytes", "CELL_TYPE", 150, 159], ["Interferon regulatory factor", "TREATMENT", 0, 28], ["a hemopoietic-specific transcription factor", "PROBLEM", 41, 84], ["hemopoietic", "ANATOMY", 43, 54], ["monocytes", "ANATOMY", 150, 159]]], ["Recently, Achuthan et al. found that GM-CSF is capable to up-regulate IRF4 expression via Jumonji domain-containing protein D3 (JMJD3) demethylase in monocytes/macrophages (32).", [["monocytes", "ANATOMY", 150, 159], ["macrophages", "ANATOMY", 160, 171], ["GM", "CHEMICAL", 37, 39], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 37, 43], ["IRF4", "GENE_OR_GENE_PRODUCT", 70, 74], ["Jumonji domain-containing protein D3 (JMJD3) demethylase", "GENE_OR_GENE_PRODUCT", 90, 146], ["monocytes", "CELL", 150, 159], ["macrophages", "CELL", 160, 171], ["CSF", "PROTEIN", 40, 43], ["IRF4", "PROTEIN", 70, 74], ["Jumonji domain-containing protein D3 (JMJD3) demethylase", "PROTEIN", 90, 146], ["monocytes", "CELL_TYPE", 150, 159], ["macrophages", "CELL_TYPE", 160, 171], ["Jumonji domain", "TEST", 90, 104], ["protein D3 (JMJD3) demethylase in monocytes/macrophages", "TREATMENT", 116, 171], ["CSF", "ANATOMY", 40, 43], ["Jumonji", "ANATOMY", 90, 97], ["monocytes", "ANATOMY", 150, 159], ["macrophages", "ANATOMY", 160, 171]]], ["Increased levels of IRF4 are responsible for the production of chemokine (C-C motif) ligand 17 (CCL7), which is involved in inflammation and tissue remodeling, as occurs in arthritis (29).", [["tissue", "ANATOMY", 141, 147], ["inflammation", "DISEASE", 124, 136], ["arthritis", "DISEASE", 173, 182], ["IRF4", "GENE_OR_GENE_PRODUCT", 20, 24], ["C-C motif) ligand 17", "GENE_OR_GENE_PRODUCT", 74, 94], ["CCL7", "GENE_OR_GENE_PRODUCT", 96, 100], ["tissue", "TISSUE", 141, 147], ["IRF4", "PROTEIN", 20, 24], ["chemokine (C-C motif) ligand 17", "PROTEIN", 63, 94], ["CCL7", "PROTEIN", 96, 100], ["Increased levels of IRF4", "PROBLEM", 0, 24], ["chemokine (C-C motif) ligand", "TEST", 63, 91], ["inflammation", "PROBLEM", 124, 136], ["tissue remodeling", "PROBLEM", 141, 158], ["arthritis", "PROBLEM", 173, 182], ["IRF4", "OBSERVATION", 20, 24], ["inflammation", "OBSERVATION", 124, 136], ["tissue", "ANATOMY", 141, 147], ["remodeling", "OBSERVATION", 148, 158], ["arthritis", "OBSERVATION", 173, 182]]], ["The GM-CSF-IRF4 signaling was also described to up-regulate major histocompatibility complex (MHC) class II expression in mouse bone marrow cultures and macrophages (33, 34).GM-CSF: a Key Mediator of Inflammation and InjuryGM-CSF levels are low or undetectable in normal conditions; however, any immune trigger can rapidly increase concentrations, as it has been seen in the lungs of patients with asthma or within the synovial fluid of patients with arthritis (35).", [["bone marrow cultures", "ANATOMY", 128, 148], ["macrophages", "ANATOMY", 153, 164], ["lungs", "ANATOMY", 375, 380], ["synovial fluid", "ANATOMY", 419, 433], ["GM", "CHEMICAL", 4, 6], ["GM", "CHEMICAL", 174, 176], ["asthma", "DISEASE", 398, 404], ["arthritis", "DISEASE", 451, 460], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 4, 10], ["IRF4", "GENE_OR_GENE_PRODUCT", 11, 15], ["mouse", "ORGANISM", 122, 127], ["bone marrow cultures", "CELL", 128, 148], ["macrophages", "CELL", 153, 164], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 174, 180], ["InjuryGM-CSF", "GENE_OR_GENE_PRODUCT", 217, 229], ["lungs", "ORGAN", 375, 380], ["patients", "ORGANISM", 384, 392], ["synovial fluid", "ORGANISM_SUBSTANCE", 419, 433], ["patients", "ORGANISM", 437, 445], ["CSF", "PROTEIN", 7, 10], ["IRF4", "PROTEIN", 11, 15], ["major histocompatibility complex (MHC) class II", "PROTEIN", 60, 107], ["mouse bone marrow cultures", "CELL_LINE", 122, 148], ["macrophages", "CELL_TYPE", 153, 164], ["CSF", "PROTEIN", 177, 180], ["CSF", "PROTEIN", 226, 229], ["mouse", "SPECIES", 122, 127], ["patients", "SPECIES", 384, 392], ["patients", "SPECIES", 437, 445], ["mouse", "SPECIES", 122, 127], ["The GM", "TEST", 0, 6], ["mouse bone marrow cultures", "TEST", 122, 148], ["macrophages", "TEST", 153, 164], ["Inflammation", "PROBLEM", 200, 212], ["InjuryGM", "TEST", 217, 225], ["CSF levels", "TEST", 226, 236], ["any immune trigger", "PROBLEM", 292, 310], ["asthma", "PROBLEM", 398, 404], ["arthritis", "PROBLEM", 451, 460], ["CSF", "ANATOMY", 7, 10], ["bone marrow", "ANATOMY", 128, 139], ["macrophages", "ANATOMY", 153, 164], ["CSF", "OBSERVATION", 177, 180], ["Inflammation", "OBSERVATION", 200, 212], ["low", "OBSERVATION_MODIFIER", 241, 244], ["normal conditions", "OBSERVATION_MODIFIER", 264, 281], ["lungs", "ANATOMY", 375, 380], ["asthma", "OBSERVATION", 398, 404], ["synovial", "ANATOMY", 419, 427], ["fluid", "OBSERVATION", 428, 433], ["arthritis", "OBSERVATION", 451, 460]]], ["Bacterial endotoxins and inflammatory cytokines (e.g., IL-1\u03b2, IL-6, and TNF-\u03b1) potently induce GM-CSF (25).", [["GM", "CHEMICAL", 95, 97], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-6", "GENE_OR_GENE_PRODUCT", 62, 66], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 95, 101], ["inflammatory cytokines", "PROTEIN", 25, 47], ["IL", "PROTEIN", 55, 57], ["IL-6", "PROTEIN", 62, 66], ["TNF", "PROTEIN", 72, 75], ["Bacterial endotoxins", "PROBLEM", 0, 20], ["inflammatory cytokines", "PROBLEM", 25, 47], ["IL", "TEST", 55, 57], ["IL", "TEST", 62, 64], ["TNF", "TEST", 72, 75], ["CSF", "TEST", 98, 101], ["endotoxins", "OBSERVATION", 10, 20], ["inflammatory cytokines", "OBSERVATION", 25, 47]]], ["Indeed, increased mRNA expression for TNF-\u03b1, IL-1\u03b2, and IL-6 were reported in monocytes/macrophages treated with GM-CSF (32).", [["monocytes", "ANATOMY", 78, 87], ["macrophages", "ANATOMY", 88, 99], ["GM", "CHEMICAL", 113, 115], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["monocytes", "CELL", 78, 87], ["macrophages", "CELL", 88, 99], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 113, 119], ["TNF", "PROTEIN", 38, 41], ["IL-1\u03b2", "PROTEIN", 45, 50], ["IL-6", "PROTEIN", 56, 60], ["monocytes", "CELL_TYPE", 78, 87], ["macrophages", "CELL_TYPE", 88, 99], ["increased mRNA expression", "PROBLEM", 8, 33], ["TNF", "TEST", 38, 41], ["IL", "TEST", 45, 47], ["IL", "TEST", 56, 58], ["monocytes", "TEST", 78, 87], ["macrophages", "ANATOMY", 88, 99]]], ["These findings led to hypothesize that GM-CSF is part of the inflammatory milieu of some inflammatory/autoimmune reactions.", [["GM", "CHEMICAL", 39, 41], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 39, 45], ["CSF", "PROTEIN", 42, 45], ["GM", "TEST", 39, 41], ["CSF", "PROBLEM", 42, 45], ["some inflammatory/autoimmune reactions", "PROBLEM", 84, 122], ["inflammatory", "OBSERVATION_MODIFIER", 61, 73], ["some", "OBSERVATION_MODIFIER", 84, 88], ["inflammatory", "OBSERVATION", 89, 101], ["autoimmune", "OBSERVATION", 102, 112]]], ["GM-CSF would work as a co-regulator along with TNF-\u03b1, IL-6, and IL-1, as part of a positive feed-forward inflammatory loop involving monocytes/macrophages, fibroblasts, and endothelial cells (36\u201338), but also DCs and Th cells (39\u201341).", [["monocytes", "ANATOMY", 133, 142], ["macrophages", "ANATOMY", 143, 154], ["fibroblasts", "ANATOMY", 156, 167], ["endothelial cells", "ANATOMY", 173, 190], ["36\u201338", "ANATOMY", 192, 197], ["DCs", "ANATOMY", 209, 212], ["Th cells", "ANATOMY", 217, 225], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-6", "GENE_OR_GENE_PRODUCT", 54, 58], ["IL-1", "GENE_OR_GENE_PRODUCT", 64, 68], ["monocytes", "CELL", 133, 142], ["macrophages", "CELL", 143, 154], ["fibroblasts", "CELL", 156, 167], ["endothelial cells", "CELL", 173, 190], ["36\u201338", "CELL", 192, 197], ["DCs", "CELL", 209, 212], ["Th cells", "CELL", 217, 225], ["CSF", "PROTEIN", 3, 6], ["TNF", "PROTEIN", 47, 50], ["IL-1", "PROTEIN", 64, 68], ["monocytes", "CELL_TYPE", 133, 142], ["macrophages", "CELL_TYPE", 143, 154], ["fibroblasts", "CELL_TYPE", 156, 167], ["endothelial cells", "CELL_TYPE", 173, 190], ["DCs", "CELL_TYPE", 209, 212], ["Th cells", "CELL_TYPE", 217, 225], ["a co-regulator", "TEST", 21, 35], ["TNF", "TEST", 47, 50], ["IL", "TEST", 54, 56], ["forward inflammatory loop", "PROBLEM", 97, 122], ["monocytes", "TEST", 133, 142], ["macrophages", "PROBLEM", 143, 154], ["fibroblasts", "PROBLEM", 156, 167], ["endothelial cells", "TEST", 173, 190], ["inflammatory loop", "OBSERVATION", 105, 122], ["macrophages", "ANATOMY", 143, 154], ["endothelial cells", "ANATOMY", 173, 190]]], ["IL-6, however, was found to induce intestinal and splenic production of GM-CSF (42), thus promoting systemic effects, like an increase in splenic macrophage precursors.", [["intestinal", "ANATOMY", 35, 45], ["splenic", "ANATOMY", 50, 57], ["splenic macrophage", "ANATOMY", 138, 156], ["GM", "CHEMICAL", 72, 74], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["intestinal", "ORGAN", 35, 45], ["splenic", "ORGAN", 50, 57], ["GM-CSF (42)", "GENE_OR_GENE_PRODUCT", 72, 83], ["splenic macrophage", "CELL", 138, 156], ["IL-6", "PROTEIN", 0, 4], ["splenic macrophage precursors", "CELL_TYPE", 138, 167], ["intestinal and splenic production of GM-CSF", "PROBLEM", 35, 78], ["an increase in splenic macrophage precursors", "PROBLEM", 123, 167], ["intestinal", "ANATOMY", 35, 45], ["splenic", "ANATOMY", 50, 57], ["systemic effects", "OBSERVATION", 100, 116], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["splenic", "ANATOMY", 138, 145], ["macrophage precursors", "OBSERVATION", 146, 167]]], ["The importance of IL-1\u03b2 and the IL-1 receptor/myeloid differentiation primary response (MyD88) signaling axis appears of importance in the regulation of GM-CSF by CD4+ and \u03b3\u03b4 T cells (43).", [["CD4+ and \u03b3\u03b4 T cells", "ANATOMY", 163, 182], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 32, 45], ["myeloid differentiation primary response", "GENE_OR_GENE_PRODUCT", 46, 86], ["MyD88", "GENE_OR_GENE_PRODUCT", 88, 93], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 153, 159], ["CD4", "GENE_OR_GENE_PRODUCT", 163, 166], ["IL-1\u03b2", "PROTEIN", 18, 23], ["MyD88", "PROTEIN", 88, 93], ["CSF", "PROTEIN", 156, 159], ["CD4", "PROTEIN", 163, 166], ["\u03b3\u03b4 T cells", "CELL_TYPE", 172, 182], ["IL", "TREATMENT", 18, 20], ["the IL", "TREATMENT", 28, 34], ["myeloid", "ANATOMY", 46, 53]]], ["IL-1\u03b2, together with TNF-\u03b1, can also promote monocyte viability via GM-CSF while not inducing any specific macrophage polarization (44).GM-CSF: a Key Mediator of Inflammation and InjuryIncreased levels of GM-CSF have been found in the bronchoalveolar fluid of patients with ARDS compared with healthy controls (45, 46).", [["monocyte", "ANATOMY", 45, 53], ["macrophage", "ANATOMY", 107, 117], ["bronchoalveolar fluid", "ANATOMY", 235, 256], ["GM", "CHEMICAL", 68, 70], ["GM", "CHEMICAL", 136, 138], ["GM", "CHEMICAL", 205, 207], ["ARDS", "DISEASE", 274, 278], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["monocyte", "CELL", 45, 53], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 68, 74], ["macrophage", "CELL", 107, 117], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 136, 142], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 205, 211], ["bronchoalveolar fluid", "ORGANISM_SUBSTANCE", 235, 256], ["patients", "ORGANISM", 260, 268], ["IL-1\u03b2", "PROTEIN", 0, 5], ["TNF", "PROTEIN", 21, 24], ["CSF", "PROTEIN", 71, 74], ["GM", "PROTEIN", 205, 207], ["CSF", "PROTEIN", 208, 211], ["patients", "SPECIES", 260, 268], ["TNF", "TEST", 21, 24], ["GM-CSF", "TEST", 68, 74], ["Inflammation", "PROBLEM", 162, 174], ["Injury", "PROBLEM", 179, 185], ["GM-CSF", "TEST", 205, 211], ["ARDS", "PROBLEM", 274, 278], ["monocyte viability", "OBSERVATION", 45, 63], ["CSF", "OBSERVATION", 139, 142], ["Inflammation", "OBSERVATION", 162, 174], ["Injury", "OBSERVATION", 179, 185], ["bronchoalveolar fluid", "OBSERVATION", 235, 256], ["ARDS", "OBSERVATION", 274, 278]]], ["Higher levels were observed in the early phases (1\u20133 days) with a progressive decrease in late stages (day 14) (46).", [["a progressive decrease in late stages", "PROBLEM", 64, 101], ["progressive", "OBSERVATION_MODIFIER", 66, 77], ["decrease", "OBSERVATION_MODIFIER", 78, 86], ["late stages", "OBSERVATION_MODIFIER", 90, 101]]], ["GM-CSF may indirectly contribute to ARDS by the suppression of neutrophil apoptosis (45, 46) as activated neutrophils play a major role in the microvascular damage contributing to lung damage (47, 48).GM-CSF: a Key Mediator of Inflammation and InjuryLimited evidence describes a regulatory role for GM-CSF through the promotion of DC differentiation to a tolerogenic profile, thus increasing the number and function of regulatory T-cells (49).", [["neutrophil", "ANATOMY", 63, 73], ["neutrophils", "ANATOMY", 106, 117], ["microvascular", "ANATOMY", 143, 156], ["lung", "ANATOMY", 180, 184], ["DC", "ANATOMY", 331, 333], ["regulatory T-cells", "ANATOMY", 419, 437], ["GM", "CHEMICAL", 0, 2], ["ARDS", "DISEASE", 36, 40], ["microvascular damage", "DISEASE", 143, 163], ["lung damage", "DISEASE", 180, 191], ["GM", "CHEMICAL", 201, 203], ["GM", "CHEMICAL", 299, 301], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["neutrophil", "CELL", 63, 73], ["neutrophils", "CELL", 106, 117], ["microvascular", "TISSUE", 143, 156], ["lung", "ORGAN", 180, 184], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 201, 207], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 299, 305], ["DC", "CELL", 331, 333], ["T-cells", "CELL", 430, 437], ["CSF", "PROTEIN", 3, 6], ["neutrophil", "CELL_TYPE", 63, 73], ["activated neutrophils", "CELL_TYPE", 96, 117], ["CSF", "PROTEIN", 204, 207], ["GM", "PROTEIN", 299, 301], ["CSF", "PROTEIN", 302, 305], ["DC", "CELL_TYPE", 331, 333], ["regulatory T-cells", "CELL_TYPE", 419, 437], ["CSF", "PROBLEM", 3, 6], ["ARDS", "PROBLEM", 36, 40], ["neutrophil apoptosis", "PROBLEM", 63, 83], ["activated neutrophils", "PROBLEM", 96, 117], ["the microvascular damage", "PROBLEM", 139, 163], ["lung damage", "PROBLEM", 180, 191], ["Inflammation", "PROBLEM", 227, 239], ["GM-CSF", "TEST", 299, 305], ["CSF", "OBSERVATION", 3, 6], ["may indirectly contribute to", "UNCERTAINTY", 7, 35], ["ARDS", "OBSERVATION", 36, 40], ["neutrophil apoptosis", "OBSERVATION", 63, 83], ["microvascular", "ANATOMY", 143, 156], ["damage", "OBSERVATION", 157, 163], ["lung", "ANATOMY", 180, 184], ["damage", "OBSERVATION", 185, 191], ["CSF", "OBSERVATION", 204, 207], ["Inflammation", "OBSERVATION", 227, 239]]], ["This can also lead to T-cell hypo-responsiveness and/or anergy (50).", [["T-cell", "ANATOMY", 22, 28], ["T-cell", "CELL", 22, 28], ["T-cell hypo-responsiveness", "PROBLEM", 22, 48], ["cell hypo-responsiveness", "OBSERVATION", 24, 48]]], ["The mechanisms underlying pro-inflammatory and immunomodulatory phenotypes of GM-CSF are not fully understood and need to be further investigated.", [["GM", "CHEMICAL", 78, 80], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 78, 84], ["immunomodulatory phenotypes of GM-CSF", "PROBLEM", 47, 84], ["pro-inflammatory", "OBSERVATION_MODIFIER", 26, 42]]], ["These properties are hypothesized to depend on the dose and the presence of other cytokines in the setting of the immune response.", [["cytokines", "PROTEIN", 82, 91], ["other cytokines", "PROBLEM", 76, 91], ["the immune response", "PROBLEM", 110, 129], ["cytokines", "OBSERVATION", 82, 91], ["immune response", "OBSERVATION", 114, 129]]], ["At lower doses, GM-CSF stimulates the tolerogenesis of myeloid cells involved in the regulatory T-cell homeostasis (49), while at higher doses GM-CSF causes myeloproliferation, leading to a sustained immune response (51).GM-CSF: a Key Mediator of Inflammation and InjuryGM-CSF-derived signals are critically involved in the differentiation of macrophages and in the proliferation and activation of other immune cells.", [["myeloid cells", "ANATOMY", 55, 68], ["T-cell", "ANATOMY", 96, 102], ["macrophages", "ANATOMY", 343, 354], ["immune cells", "ANATOMY", 404, 416], ["GM", "CHEMICAL", 16, 18], ["GM", "CHEMICAL", 143, 145], ["GM", "CHEMICAL", 221, 223], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 16, 22], ["myeloid cells", "CELL", 55, 68], ["T-cell", "CELL", 96, 102], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 143, 149], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 221, 227], ["InjuryGM-CSF", "GENE_OR_GENE_PRODUCT", 264, 276], ["macrophages", "CELL", 343, 354], ["immune cells", "CELL", 404, 416], ["CSF", "PROTEIN", 19, 22], ["myeloid cells", "CELL_TYPE", 55, 68], ["CSF", "PROTEIN", 146, 149], ["CSF", "PROTEIN", 224, 227], ["CSF", "PROTEIN", 273, 276], ["macrophages", "CELL_TYPE", 343, 354], ["immune cells", "CELL_TYPE", 404, 416], ["GM", "TEST", 16, 18], ["CSF stimulates", "TEST", 19, 33], ["myeloid cells", "PROBLEM", 55, 68], ["myeloproliferation", "PROBLEM", 157, 175], ["a sustained immune response", "PROBLEM", 188, 215], ["Inflammation", "PROBLEM", 247, 259], ["InjuryGM", "TEST", 264, 272], ["macrophages", "PROBLEM", 343, 354], ["the proliferation", "PROBLEM", 362, 379], ["other immune cells", "PROBLEM", 398, 416], ["myeloid cells", "OBSERVATION", 55, 68], ["CSF", "OBSERVATION", 224, 227], ["Inflammation", "OBSERVATION", 247, 259], ["macrophages", "OBSERVATION", 343, 354], ["proliferation", "OBSERVATION_MODIFIER", 366, 379], ["immune cells", "OBSERVATION", 404, 416]]], ["Alveolar macrophages (AMs) are essential to clear respiratory microbes (52, 53), and their depletion has been associated with increased disease severity in murine models of influenza infection (54, 55).", [["Alveolar macrophages", "ANATOMY", 0, 20], ["AMs", "ANATOMY", 22, 25], ["respiratory", "ANATOMY", 50, 61], ["influenza infection", "DISEASE", 173, 192], ["Alveolar macrophages", "CELL", 0, 20], ["AMs", "CELL", 22, 25], ["murine", "ORGANISM", 156, 162], ["Alveolar macrophages", "CELL_TYPE", 0, 20], ["AMs", "CELL_TYPE", 22, 25], ["murine", "SPECIES", 156, 162], ["Alveolar macrophages", "PROBLEM", 0, 20], ["their depletion", "PROBLEM", 85, 100], ["increased disease severity", "PROBLEM", 126, 152], ["influenza infection", "PROBLEM", 173, 192], ["macrophages", "OBSERVATION", 9, 20], ["clear", "OBSERVATION_MODIFIER", 44, 49], ["respiratory microbes", "OBSERVATION", 50, 70], ["depletion", "OBSERVATION", 91, 100], ["associated with", "UNCERTAINTY", 110, 125], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["disease", "OBSERVATION", 136, 143], ["murine models", "OBSERVATION_MODIFIER", 156, 169], ["influenza", "OBSERVATION_MODIFIER", 173, 182], ["infection", "OBSERVATION", 183, 192]]], ["Therefore, several pre-clinical studies reported that the intranasal administration of GM-CSF prior to inducing an experimental viral infection conferred resistance to respiratory pathogens through an increased proliferation of AMs [(56, 57); Figure 1B].", [["respiratory", "ANATOMY", 168, 179], ["AMs", "ANATOMY", 228, 231], ["GM", "CHEMICAL", 87, 89], ["viral infection", "DISEASE", 128, 143], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 87, 93], ["AMs", "CELL", 228, 231], ["AMs", "CELL_TYPE", 228, 231], ["several pre-clinical studies", "TEST", 11, 39], ["the intranasal administration", "TREATMENT", 54, 83], ["GM-CSF", "TREATMENT", 87, 93], ["an experimental viral infection", "PROBLEM", 112, 143], ["respiratory pathogens", "PROBLEM", 168, 189], ["an increased proliferation of AMs", "PROBLEM", 198, 231], ["infection", "OBSERVATION", 134, 143], ["increased", "OBSERVATION_MODIFIER", 201, 210], ["proliferation", "OBSERVATION_MODIFIER", 211, 224]]], ["This is probably due to an enhanced clearance of the virus, thus limiting the direct damage provided by the virus itself.", [["an enhanced clearance of the virus", "PROBLEM", 24, 58], ["the direct damage", "PROBLEM", 74, 91], ["probably due to", "UNCERTAINTY", 8, 23], ["enhanced", "OBSERVATION_MODIFIER", 27, 35], ["clearance", "OBSERVATION", 36, 45], ["virus", "OBSERVATION", 53, 58], ["virus", "OBSERVATION", 108, 113]]], ["Recently, a subset of AMs, the nerve-associated interstitial alveolar macrophages (NAMs), have been identified and characterized in human and murine lung (58).", [["AMs", "ANATOMY", 22, 25], ["nerve", "ANATOMY", 31, 36], ["interstitial alveolar macrophages", "ANATOMY", 48, 81], ["NAMs", "ANATOMY", 83, 87], ["lung", "ANATOMY", 149, 153], ["AMs", "CELL", 22, 25], ["interstitial alveolar macrophages", "CELL", 48, 81], ["NAMs", "MULTI-TISSUE_STRUCTURE", 83, 87], ["human", "ORGANISM", 132, 137], ["murine", "ORGANISM", 142, 148], ["lung", "ORGAN", 149, 153], ["AMs", "CELL_TYPE", 22, 25], ["nerve-associated interstitial alveolar macrophages", "CELL_TYPE", 31, 81], ["NAMs", "CELL_TYPE", 83, 87], ["human", "SPECIES", 132, 137], ["murine", "SPECIES", 142, 148], ["human", "SPECIES", 132, 137], ["interstitial alveolar macrophages", "PROBLEM", 48, 81], ["nerve", "ANATOMY", 31, 36], ["interstitial", "ANATOMY_MODIFIER", 48, 60], ["alveolar macrophages", "OBSERVATION", 61, 81], ["lung", "ANATOMY", 149, 153]]], ["NAMs seem to originate from the yolk sac and, differently from the other AMs, require colony-stimulating factor 1 (CSF1) and not GM-CSF for development and maintenance in adulthood.", [["yolk sac", "ANATOMY", 32, 40], ["AMs", "ANATOMY", 73, 76], ["GM", "CHEMICAL", 129, 131], ["NAMs", "GENE_OR_GENE_PRODUCT", 0, 4], ["yolk sac", "ORGAN", 32, 40], ["AMs", "CELL", 73, 76], ["colony-stimulating factor 1", "GENE_OR_GENE_PRODUCT", 86, 113], ["CSF1", "GENE_OR_GENE_PRODUCT", 115, 119], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 129, 135], ["NAMs", "PROTEIN", 0, 4], ["AMs", "CELL_TYPE", 73, 76], ["colony-stimulating factor 1", "PROTEIN", 86, 113], ["CSF1", "PROTEIN", 115, 119], ["GM", "PROTEIN", 129, 131], ["CSF", "PROTEIN", 132, 135], ["colony-stimulating factor", "TEST", 86, 111], ["GM", "TEST", 129, 131], ["yolk sac", "ANATOMY", 32, 40]]], ["Mouse models of influenza virus infection on selectively NAM-depleted animals suggest a central role for NAMs in the negative regulation of virus-induced inflammation, whereas the other GM-CSF-dependent AMs display a pro-inflammatory profile (58).", [["AMs", "ANATOMY", 203, 206], ["influenza virus infection", "DISEASE", 16, 41], ["NAM", "CHEMICAL", 57, 60], ["inflammation", "DISEASE", 154, 166], ["GM", "CHEMICAL", 186, 188], ["Mouse", "ORGANISM", 0, 5], ["influenza virus", "ORGANISM", 16, 31], ["NAM", "GENE_OR_GENE_PRODUCT", 57, 60], ["NAMs", "GENE_OR_GENE_PRODUCT", 105, 109], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 186, 192], ["AMs", "CELL", 203, 206], ["NAMs", "PROTEIN", 105, 109], ["CSF", "PROTEIN", 189, 192], ["AMs", "CELL_TYPE", 203, 206], ["Mouse", "SPECIES", 0, 5], ["influenza virus", "SPECIES", 16, 31], ["influenza virus", "SPECIES", 16, 31], ["influenza virus infection", "PROBLEM", 16, 41], ["virus", "PROBLEM", 140, 145], ["induced inflammation", "PROBLEM", 146, 166], ["the other GM", "TEST", 176, 188], ["a pro-inflammatory profile", "TEST", 215, 241], ["influenza virus", "OBSERVATION", 16, 31], ["central", "ANATOMY_MODIFIER", 88, 95], ["inflammation", "OBSERVATION", 154, 166]]], ["In addition, GM-CSF receptor activation triggers stimulation of multiple downstream signaling pathways, including JAK2/STAT5, the mitogen-activated protein kinase (MAPK), and the PI3K, all fundamental in activation and differentiation of myeloid cells [(25, 37); Figure 1A].GM-CSF: a Key Mediator of Inflammation and InjuryAlong with its key role in inflammation, GM-CSF is critical in lung physiology.", [["myeloid cells", "ANATOMY", 238, 251], ["lung", "ANATOMY", 386, 390], ["GM", "CHEMICAL", 13, 15], ["GM", "CHEMICAL", 274, 276], ["inflammation", "DISEASE", 350, 362], ["GM", "CHEMICAL", 364, 366], ["GM-CSF receptor", "GENE_OR_GENE_PRODUCT", 13, 28], ["JAK2", "GENE_OR_GENE_PRODUCT", 114, 118], ["STAT5", "GENE_OR_GENE_PRODUCT", 119, 124], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 130, 162], ["MAPK", "GENE_OR_GENE_PRODUCT", 164, 168], ["PI3K", "GENE_OR_GENE_PRODUCT", 179, 183], ["myeloid cells", "CELL", 238, 251], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 274, 280], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 364, 370], ["lung", "ORGAN", 386, 390], ["CSF receptor", "PROTEIN", 16, 28], ["JAK2", "PROTEIN", 114, 118], ["STAT5", "PROTEIN", 119, 124], ["mitogen-activated protein kinase", "PROTEIN", 130, 162], ["MAPK", "PROTEIN", 164, 168], ["PI3K", "PROTEIN", 179, 183], ["myeloid cells", "CELL_TYPE", 238, 251], ["CSF", "PROTEIN", 277, 280], ["CSF", "PROTEIN", 367, 370], ["GM", "TEST", 13, 15], ["CSF receptor activation", "TEST", 16, 39], ["multiple downstream signaling pathways", "PROBLEM", 64, 102], ["JAK2", "TEST", 114, 118], ["STAT5", "TEST", 119, 124], ["the mitogen", "TEST", 126, 137], ["activated protein kinase", "TEST", 138, 162], ["MAPK", "TEST", 164, 168], ["the PI3K", "TEST", 175, 183], ["myeloid cells", "TEST", 238, 251], ["Inflammation", "PROBLEM", 300, 312], ["InjuryAlong", "PROBLEM", 317, 328], ["inflammation", "PROBLEM", 350, 362], ["PI3K", "ANATOMY", 179, 183], ["myeloid cells", "OBSERVATION", 238, 251], ["CSF", "OBSERVATION", 277, 280], ["Inflammation", "OBSERVATION", 300, 312], ["inflammation", "OBSERVATION", 350, 362], ["lung", "ANATOMY", 386, 390]]], ["This has been clearly highlighted by GM-CSF-deficient and GM-CSF receptor-deficient mice which develop pulmonary alveolar proteinosis (PAP) because AMs require GM-CSF to differentiate (59).", [["pulmonary alveolar", "ANATOMY", 103, 121], ["AMs", "ANATOMY", 148, 151], ["GM", "CHEMICAL", 37, 39], ["GM", "CHEMICAL", 58, 60], ["pulmonary alveolar proteinosis", "DISEASE", 103, 133], ["GM", "CHEMICAL", 160, 162], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 37, 43], ["GM-CSF receptor", "GENE_OR_GENE_PRODUCT", 58, 73], ["mice", "ORGANISM", 84, 88], ["pulmonary alveolar", "MULTI-TISSUE_STRUCTURE", 103, 121], ["AMs", "MULTI-TISSUE_STRUCTURE", 148, 151], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 160, 166], ["CSF", "PROTEIN", 40, 43], ["CSF receptor", "PROTEIN", 61, 73], ["AMs", "CELL_TYPE", 148, 151], ["CSF", "PROTEIN", 163, 166], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["GM", "TEST", 37, 39], ["GM", "TEST", 58, 60], ["CSF receptor", "TEST", 61, 73], ["deficient mice", "PROBLEM", 74, 88], ["pulmonary alveolar proteinosis", "PROBLEM", 103, 133], ["PAP", "TEST", 135, 138], ["GM-CSF", "TEST", 160, 166], ["pulmonary", "ANATOMY", 103, 112], ["alveolar", "ANATOMY_MODIFIER", 113, 121], ["proteinosis", "OBSERVATION", 122, 133]]], ["The poor differentiation of these macrophages is responsible for the accumulation of surfactant proteins, saturated phosphatidylcholine, and cholesterol, leading to PAP.", [["macrophages", "ANATOMY", 34, 45], ["phosphatidylcholine", "CHEMICAL", 116, 135], ["cholesterol", "CHEMICAL", 141, 152], ["phosphatidylcholine", "CHEMICAL", 116, 135], ["cholesterol", "CHEMICAL", 141, 152], ["macrophages", "CELL", 34, 45], ["saturated phosphatidylcholine", "SIMPLE_CHEMICAL", 106, 135], ["cholesterol", "SIMPLE_CHEMICAL", 141, 152], ["PAP", "GENE_OR_GENE_PRODUCT", 165, 168], ["macrophages", "CELL_TYPE", 34, 45], ["surfactant proteins", "PROTEIN", 85, 104], ["PAP", "PROTEIN", 165, 168], ["these macrophages", "PROBLEM", 28, 45], ["surfactant proteins", "TREATMENT", 85, 104], ["saturated phosphatidylcholine", "TREATMENT", 106, 135], ["cholesterol", "TREATMENT", 141, 152], ["PAP", "TEST", 165, 168], ["poor differentiation", "OBSERVATION_MODIFIER", 4, 24], ["macrophages", "OBSERVATION", 34, 45], ["responsible for", "UNCERTAINTY", 49, 64], ["surfactant proteins", "OBSERVATION", 85, 104]]], ["Indeed, local expression of GM-CSF in the lung is able to restore normal surfactant homeostasis and clearance in the setting of PAP (60).", [["lung", "ANATOMY", 42, 46], ["GM", "CHEMICAL", 28, 30], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 28, 34], ["lung", "ORGAN", 42, 46], ["surfactant", "SIMPLE_CHEMICAL", 73, 83], ["PAP", "GENE_OR_GENE_PRODUCT", 128, 131], ["GM", "PROTEIN", 28, 30], ["CSF", "PROTEIN", 31, 34], ["GM-CSF in the lung", "PROBLEM", 28, 46], ["PAP", "TEST", 128, 131], ["CSF", "OBSERVATION", 31, 34], ["lung", "ANATOMY", 42, 46], ["surfactant homeostasis", "OBSERVATION", 73, 95]]], ["Additionally, GM-CSF-deficient mice show a persistent, low-grade inflammation resulting from inappropriate responses to commensal microbes.", [["GM", "CHEMICAL", 14, 16], ["inflammation", "DISEASE", 65, 77], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 14, 20], ["mice", "ORGANISM", 31, 35], ["CSF", "PROTEIN", 17, 20], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["GM-CSF", "TEST", 14, 20], ["a persistent, low-grade inflammation", "PROBLEM", 41, 77], ["persistent", "OBSERVATION_MODIFIER", 43, 53], ["low-grade", "OBSERVATION_MODIFIER", 55, 64], ["inflammation", "OBSERVATION", 65, 77], ["commensal microbes", "OBSERVATION", 120, 138]]], ["This chronic inflammation predisposes mice to develop different kinds of tumors (61).", [["tumors", "ANATOMY", 73, 79], ["inflammation", "DISEASE", 13, 25], ["tumors", "DISEASE", 73, 79], ["mice", "ORGANISM", 38, 42], ["tumors", "CANCER", 73, 79], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["This chronic inflammation", "PROBLEM", 0, 25], ["different kinds of tumors", "PROBLEM", 54, 79], ["chronic", "OBSERVATION_MODIFIER", 5, 12], ["inflammation", "OBSERVATION", 13, 25], ["tumors", "OBSERVATION", 73, 79]]], ["To date, no function-altering GM-CSF mutations have been identified in humans.", [["GM", "CHEMICAL", 30, 32], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 30, 36], ["humans", "ORGANISM", 71, 77], ["CSF", "PROTEIN", 33, 36], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["altering GM-CSF mutations", "PROBLEM", 21, 46]]], ["However, an autoimmune form of PAP can develop in humans and is associated with high levels of neutralizing GM-CSF autoantibodies that inhibit GM-CSF signaling (62).", [["GM", "CHEMICAL", 108, 110], ["GM", "CHEMICAL", 143, 145], ["PAP", "GENE_OR_GENE_PRODUCT", 31, 34], ["humans", "ORGANISM", 50, 56], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 108, 114], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 143, 149], ["neutralizing GM-CSF autoantibodies", "PROTEIN", 95, 129], ["CSF", "PROTEIN", 146, 149], ["humans", "SPECIES", 50, 56], ["humans", "SPECIES", 50, 56], ["an autoimmune form of PAP", "PROBLEM", 9, 34], ["neutralizing GM", "TEST", 95, 110], ["CSF autoantibodies", "TEST", 111, 129], ["GM", "TEST", 143, 145], ["CSF signaling", "TEST", 146, 159], ["autoimmune", "OBSERVATION", 12, 22]]], ["A congenital form of PAP ending up with a complete inhibition of the macrophage clearance of surfactant has also been described and is caused by mutations in CSF2RA or CSF2RB, the genes encoding the GM-CSF-R\u03b1 and GM-CSF-R\u03b2 chains (63).GM-CSF: a Key Mediator of Inflammation and InjuryIncreased circulating levels of GM-CSF have been recently described in patients with COVID-19 compared to healthy controls (4).", [["macrophage", "ANATOMY", 69, 79], ["GM", "CHEMICAL", 235, 237], ["GM", "CHEMICAL", 316, 318], ["PAP", "GENE_OR_GENE_PRODUCT", 21, 24], ["macrophage", "CELL", 69, 79], ["CSF2RA", "GENE_OR_GENE_PRODUCT", 158, 164], ["CSF2RB", "GENE_OR_GENE_PRODUCT", 168, 174], ["GM-CSF-R\u03b1", "GENE_OR_GENE_PRODUCT", 199, 208], ["GM-CSF-R\u03b2 chains", "GENE_OR_GENE_PRODUCT", 213, 229], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 235, 241], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 316, 322], ["patients", "ORGANISM", 355, 363], ["CSF2RA", "PROTEIN", 158, 164], ["CSF2RB", "PROTEIN", 168, 174], ["GM", "PROTEIN", 199, 201], ["CSF", "PROTEIN", 202, 205], ["R\u03b1", "PROTEIN", 206, 208], ["GM", "PROTEIN", 213, 215], ["CSF", "PROTEIN", 216, 219], ["R\u03b2 chains", "PROTEIN", 220, 229], ["GM", "PROTEIN", 316, 318], ["CSF", "PROTEIN", 319, 322], ["patients", "SPECIES", 355, 363], ["A congenital form of PAP", "PROBLEM", 0, 24], ["the macrophage clearance of surfactant", "TREATMENT", 65, 103], ["mutations in CSF2RA", "PROBLEM", 145, 164], ["the GM", "TEST", 195, 201], ["CSF", "TEST", 202, 205], ["Inflammation", "PROBLEM", 261, 273], ["Injury", "PROBLEM", 278, 284], ["Increased circulating levels of GM-CSF", "PROBLEM", 284, 322], ["COVID", "TEST", 369, 374], ["congenital", "OBSERVATION", 2, 12], ["PAP", "OBSERVATION", 21, 24], ["macrophage", "OBSERVATION", 69, 79], ["CSF", "ANATOMY", 202, 205], ["CSF", "ANATOMY", 216, 219], ["CSF", "OBSERVATION", 238, 241], ["Inflammation", "OBSERVATION", 261, 273], ["Injury", "OBSERVATION", 278, 284], ["Increased", "OBSERVATION_MODIFIER", 284, 293]]], ["A paper from China appearing on the preprint online platform bioRxiv reported that in patients with COVID-19, especially those admitted to the ICU, CD4+ T lymphocytes were rapidly activated in the lung to pathogenic T helper (Th) 1 cells and generated GM-CSF and IL-6.", [["CD4+ T lymphocytes", "ANATOMY", 148, 166], ["lung", "ANATOMY", 197, 201], ["T helper (Th) 1 cells", "ANATOMY", 216, 237], ["patients", "ORGANISM", 86, 94], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["lung", "ORGAN", 197, 201], ["T helper (Th) 1 cells", "CELL", 216, 237], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 252, 258], ["IL-6", "GENE_OR_GENE_PRODUCT", 263, 267], ["CD4", "PROTEIN", 148, 151], ["T lymphocytes", "CELL_TYPE", 153, 166], ["pathogenic T helper (Th) 1 cells", "CELL_TYPE", 205, 237], ["GM-CSF and IL-6", "PROTEIN", 252, 267], ["patients", "SPECIES", 86, 94], ["COVID", "TEST", 100, 105], ["CD4", "TEST", 148, 151], ["T lymphocytes", "PROBLEM", 153, 166], ["GM", "TEST", 252, 254], ["IL", "TEST", 263, 265], ["lung", "ANATOMY", 197, 201], ["CSF", "ANATOMY", 255, 258]]], ["This potent pro-inflammatory environment strongly induced CD14+CD16+ monocytes, which also released GM-CSF and IL-6, further worsening the cytokine storm.", [["CD14+CD16+ monocytes", "ANATOMY", 58, 78], ["CD14", "GENE_OR_GENE_PRODUCT", 58, 62], ["CD16", "GENE_OR_GENE_PRODUCT", 63, 67], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 100, 106], ["IL-6", "GENE_OR_GENE_PRODUCT", 111, 115], ["CD14", "PROTEIN", 58, 62], ["CD16", "PROTEIN", 63, 67], ["monocytes", "CELL_TYPE", 69, 78], ["GM-CSF and IL-6", "PROTEIN", 100, 115], ["cytokine", "PROTEIN", 139, 147], ["CD14", "TEST", 58, 62], ["CD16", "TEST", 63, 67], ["monocytes", "TEST", 69, 78], ["GM", "TEST", 100, 102], ["CSF", "TEST", 103, 106], ["IL", "TEST", 111, 113], ["further worsening the cytokine storm", "PROBLEM", 117, 153], ["worsening", "OBSERVATION_MODIFIER", 125, 134], ["cytokine storm", "OBSERVATION", 139, 153]]], ["These aberrant and numerous GM-CSF+-IL-6+ cells may enter the lungs and explain the detrimental actions provided by hyperinflammation in the most severe and even fatal cases (64).GM-CSF as a Therapeutic Strategy in COVID-19 PneumoniaIn light of the results in animal studies following the intranasal administration of GM-CSF in the setting of respiratory infections, two human recombinant GM-CSF (hrGM-CSF), sargramostim and molgramostim, were investigated in humans (65\u201367).", [["IL-6+ cells", "ANATOMY", 36, 47], ["lungs", "ANATOMY", 62, 67], ["respiratory", "ANATOMY", 343, 354], ["hyperinflammation", "DISEASE", 116, 133], ["GM", "CHEMICAL", 179, 181], ["GM", "CHEMICAL", 318, 320], ["respiratory infections", "DISEASE", 343, 365], ["GM", "CHEMICAL", 389, 391], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 28, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 36, 40], ["lungs", "ORGAN", 62, 67], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 179, 185], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 318, 324], ["human", "ORGANISM", 371, 376], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 389, 395], ["hrGM-CSF", "GENE_OR_GENE_PRODUCT", 397, 405], ["sargramostim", "SIMPLE_CHEMICAL", 408, 420], ["molgramostim", "SIMPLE_CHEMICAL", 425, 437], ["humans", "ORGANISM", 460, 466], ["GM-CSF+-IL-6+ cells", "CELL_LINE", 28, 47], ["CSF", "PROTEIN", 392, 395], ["hrGM", "PROTEIN", 397, 401], ["CSF", "PROTEIN", 402, 405], ["human", "SPECIES", 371, 376], ["humans", "SPECIES", 460, 466], ["human", "SPECIES", 371, 376], ["humans", "SPECIES", 460, 466], ["CSF+-IL", "TEST", 31, 38], ["hyperinflammation", "PROBLEM", 116, 133], ["COVID", "TEST", 215, 220], ["animal studies", "TEST", 260, 274], ["the intranasal administration", "TREATMENT", 285, 314], ["GM-CSF", "TREATMENT", 318, 324], ["respiratory infections", "PROBLEM", 343, 365], ["CSF (hrGM", "TEST", 392, 401], ["sargramostim", "TEST", 408, 420], ["aberrant", "OBSERVATION_MODIFIER", 6, 14], ["numerous", "OBSERVATION_MODIFIER", 19, 27], ["GM", "OBSERVATION_MODIFIER", 28, 30], ["lungs", "ANATOMY", 62, 67], ["most severe", "OBSERVATION_MODIFIER", 141, 152], ["respiratory", "ANATOMY", 343, 354], ["infections", "OBSERVATION", 355, 365]]], ["Sargramostim was tested in a randomized, double-blind, placebo-controlled clinical trial in patients with acute lung injury/ARDS (67).", [["lung", "ANATOMY", 112, 116], ["Sargramostim", "CHEMICAL", 0, 12], ["acute lung injury", "DISEASE", 106, 123], ["ARDS", "DISEASE", 124, 128], ["Sargramostim", "CHEMICAL", 0, 12], ["Sargramostim", "SIMPLE_CHEMICAL", 0, 12], ["patients", "ORGANISM", 92, 100], ["lung", "ORGAN", 112, 116], ["patients", "SPECIES", 92, 100], ["Sargramostim", "TREATMENT", 0, 12], ["double-blind", "TREATMENT", 41, 53], ["placebo", "TREATMENT", 55, 62], ["acute lung injury", "PROBLEM", 106, 123], ["ARDS", "PROBLEM", 124, 128], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["lung", "ANATOMY", 112, 116], ["injury", "OBSERVATION", 117, 123], ["ARDS", "OBSERVATION", 124, 128]]], ["The drug was administered as an intravenous infusion once daily for 14 days at a dosage of 250 \u03bcg/m2.", [["intravenous", "ANATOMY", 32, 43], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 43], ["an intravenous infusion", "TREATMENT", 29, 52]]], ["The study showed no significant difference in the number of ventilator-free days, organ failure-free days, and 28-day mortality between the hrGM-CSF and placebo groups; there was also no difference in the number of serious adverse events (67).", [["organ", "ANATOMY", 82, 87], ["organ failure", "DISEASE", 82, 95], ["hrGM", "CHEMICAL", 140, 144], ["organ", "ORGAN", 82, 87], ["hrGM-CSF", "GENE_OR_GENE_PRODUCT", 140, 148], ["The study", "TEST", 0, 9], ["organ failure", "PROBLEM", 82, 95], ["serious adverse events", "PROBLEM", 215, 237], ["no", "UNCERTAINTY", 17, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["difference", "OBSERVATION_MODIFIER", 32, 42], ["organ", "ANATOMY", 82, 87], ["failure", "OBSERVATION", 88, 95], ["no", "UNCERTAINTY", 184, 186], ["difference", "OBSERVATION_MODIFIER", 187, 197]]], ["A randomized, double-blind, placebo-controlled phase II study tested the effects of low-dose hrGM-CSF (molgramostim, 3 \u03bcg/kg daily) for 5 days in patients in addition to the standard of care in critically ill patients with severe sepsis and respiratory dysfunction (65).", [["respiratory", "ANATOMY", 241, 252], ["hrGM", "CHEMICAL", 93, 97], ["molgramostim", "CHEMICAL", 103, 115], ["critically ill", "DISEASE", 194, 208], ["sepsis", "DISEASE", 230, 236], ["respiratory dysfunction", "DISEASE", 241, 264], ["molgramostim", "CHEMICAL", 103, 115], ["hrGM-CSF", "SIMPLE_CHEMICAL", 93, 101], ["molgramostim", "SIMPLE_CHEMICAL", 103, 115], ["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 209, 217], ["double-blind", "TREATMENT", 14, 26], ["placebo-controlled phase II study", "TEST", 28, 61], ["low-dose hrGM", "TREATMENT", 84, 97], ["CSF (molgramostim", "TREATMENT", 98, 115], ["severe sepsis", "PROBLEM", 223, 236], ["respiratory dysfunction", "PROBLEM", 241, 264], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["sepsis", "OBSERVATION", 230, 236], ["respiratory dysfunction", "OBSERVATION", 241, 264]]], ["The study found that hrGM-CSF was associated with an improvement in gas exchange and functional activation of pulmonary macrophages; however, there was no improvement in 30-day survival (65).", [["pulmonary macrophages", "ANATOMY", 110, 131], ["hrGM-CSF", "GENE_OR_GENE_PRODUCT", 21, 29], ["pulmonary macrophages", "CELL", 110, 131], ["hrGM", "PROTEIN", 21, 25], ["pulmonary macrophages", "CELL_TYPE", 110, 131], ["The study", "TEST", 0, 9], ["hrGM", "TEST", 21, 25], ["CSF", "PROBLEM", 26, 29], ["gas exchange", "TEST", 68, 80], ["pulmonary macrophages", "PROBLEM", 110, 131], ["improvement", "OBSERVATION_MODIFIER", 53, 64], ["gas exchange", "OBSERVATION", 68, 80], ["pulmonary", "ANATOMY", 110, 119], ["macrophages", "OBSERVATION", 120, 131], ["no", "UNCERTAINTY", 152, 154], ["improvement", "OBSERVATION_MODIFIER", 155, 166]]], ["In another randomized, double-blind, placebo-controlled clinical trial in patients with bacterial and fungal abdominal sepsis, molgramostim 3 \u03bcg/kg daily for 4 days was administered in addition to standard of care.", [["abdominal", "ANATOMY", 109, 118], ["fungal abdominal sepsis", "DISEASE", 102, 125], ["molgramostim", "CHEMICAL", 127, 139], ["patients", "ORGANISM", 74, 82], ["abdominal", "ORGANISM_SUBDIVISION", 109, 118], ["patients", "SPECIES", 74, 82], ["double-blind", "TREATMENT", 23, 35], ["placebo", "TREATMENT", 37, 44], ["bacterial and fungal abdominal sepsis", "PROBLEM", 88, 125], ["molgramostim", "TREATMENT", 127, 139], ["fungal", "OBSERVATION_MODIFIER", 102, 108], ["abdominal", "ANATOMY", 109, 118], ["sepsis", "OBSERVATION", 119, 125]]], ["The treatment group had a reduction in the rate of infectious complications and in the length of hospitalization (66).GM-CSF as a Therapeutic Strategy in COVID-19 PneumoniaIn the early phases of viral infections, GM-CSF's role may be protective as it helps limit virus-related injury.", [["GM", "CHEMICAL", 118, 120], ["viral infections", "DISEASE", 195, 211], ["GM", "CHEMICAL", 213, 215], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 118, 124], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 213, 219], ["a reduction", "TREATMENT", 24, 35], ["infectious complications", "PROBLEM", 51, 75], ["COVID", "TEST", 154, 159], ["viral infections", "PROBLEM", 195, 211], ["injury", "PROBLEM", 277, 283], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["infectious", "OBSERVATION", 51, 61], ["early phases", "OBSERVATION_MODIFIER", 179, 191], ["viral infections", "OBSERVATION", 195, 211]]], ["For this reason, an inhaled formulation of sargramostim is being tested in patients with COVID-19-related acute hypoxic respiratory failure (NCT04326920).Inhibition of GM-CSF Signaling in COVID-19 PneumoniaIn later stages of COVID-19, the severity of the illness appears to be driven by the inappropriate release of several cytokines, such as IL-6 and GM-CSF.", [["respiratory", "ANATOMY", 120, 131], ["sargramostim", "CHEMICAL", 43, 55], ["COVID-19", "CHEMICAL", 89, 97], ["hypoxic respiratory failure", "DISEASE", 112, 139], ["GM", "CHEMICAL", 168, 170], ["illness", "DISEASE", 255, 262], ["sargramostim", "CHEMICAL", 43, 55], ["sargramostim", "SIMPLE_CHEMICAL", 43, 55], ["patients", "ORGANISM", 75, 83], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 168, 174], ["COVID-19", "CELL", 225, 233], ["IL-6", "GENE_OR_GENE_PRODUCT", 343, 347], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 352, 358], ["GM", "PROTEIN", 168, 170], ["CSF", "PROTEIN", 171, 174], ["cytokines", "PROTEIN", 324, 333], ["IL-6", "PROTEIN", 343, 347], ["GM", "PROTEIN", 352, 354], ["CSF", "PROTEIN", 355, 358], ["patients", "SPECIES", 75, 83], ["an inhaled formulation of sargramostim", "TREATMENT", 17, 55], ["COVID", "TEST", 89, 94], ["acute hypoxic respiratory failure", "PROBLEM", 106, 139], ["GM", "TEST", 168, 170], ["COVID", "TEST", 188, 193], ["COVID", "TEST", 225, 230], ["the illness", "PROBLEM", 251, 262], ["IL", "TEST", 343, 345], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["hypoxic", "OBSERVATION_MODIFIER", 112, 119], ["respiratory failure", "OBSERVATION", 120, 139], ["illness", "OBSERVATION", 255, 262], ["CSF", "ANATOMY", 355, 358]]], ["These mediators are involved in the inflammatory lung injury, predisposing patients to respiratory failure and eventually ARDS.", [["lung", "ANATOMY", 49, 53], ["respiratory", "ANATOMY", 87, 98], ["lung injury", "DISEASE", 49, 60], ["respiratory failure", "DISEASE", 87, 106], ["ARDS", "DISEASE", 122, 126], ["lung", "ORGAN", 49, 53], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["the inflammatory lung injury", "PROBLEM", 32, 60], ["respiratory failure", "PROBLEM", 87, 106], ["ARDS", "PROBLEM", 122, 126], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48], ["lung", "ANATOMY", 49, 53], ["injury", "OBSERVATION", 54, 60], ["respiratory failure", "OBSERVATION", 87, 106], ["ARDS", "OBSERVATION", 122, 126]]], ["Therefore, inhibition of GM-CSF signaling may be a reasonable treatment in this stage of disease.", [["GM", "CHEMICAL", 25, 27], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 25, 31], ["CSF", "PROTEIN", 28, 31], ["GM-CSF signaling", "TREATMENT", 25, 41], ["a reasonable treatment", "TREATMENT", 49, 71], ["disease", "PROBLEM", 89, 96], ["disease", "OBSERVATION", 89, 96]]], ["This is supported by pre-clinical data in CRS showing that GM-CSF blockade reduced CAR T-cell therapy-related toxicity by preventing CRS development without affecting its therapeutic activity (68).Inhibition of GM-CSF Signaling in COVID-19 PneumoniaMavrilimumab is a high-affinity monoclonal IgG4 antibody against GM-CSF-R\u03b1 [(69); Figure 1C].", [["T-cell", "ANATOMY", 87, 93], ["GM", "CHEMICAL", 59, 61], ["toxicity", "DISEASE", 110, 118], ["CRS", "DISEASE", 133, 136], ["GM", "CHEMICAL", 211, 213], ["COVID-19 PneumoniaMavrilimumab", "CHEMICAL", 231, 261], ["GM", "CHEMICAL", 314, 316], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 59, 65], ["CAR T-cell", "CELL", 83, 93], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 211, 217], ["COVID-19 PneumoniaMavrilimumab", "SIMPLE_CHEMICAL", 231, 261], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 314, 320], ["GM", "PROTEIN", 211, 213], ["CSF", "PROTEIN", 214, 217], ["high-affinity monoclonal IgG4 antibody", "PROTEIN", 267, 305], ["GM", "PROTEIN", 314, 316], ["CSF", "PROTEIN", 317, 320], ["CRS", "TEST", 42, 45], ["GM", "TEST", 59, 61], ["CSF blockade", "TREATMENT", 62, 74], ["CAR T-cell therapy", "TREATMENT", 83, 101], ["related toxicity", "PROBLEM", 102, 118], ["CRS development", "PROBLEM", 133, 148], ["GM", "TEST", 211, 213], ["CSF Signaling", "TEST", 214, 227], ["COVID", "TEST", 231, 236], ["PneumoniaMavrilimumab", "TEST", 240, 261], ["monoclonal IgG4 antibody", "TEST", 281, 305], ["GM", "TEST", 314, 316], ["CSF", "TEST", 317, 320]]], ["The efficacy and safety of mavrilimumab have been studied in rheumatoid arthritis (RA) and showed promising results.", [["mavrilimumab", "CHEMICAL", 27, 39], ["rheumatoid arthritis", "DISEASE", 61, 81], ["RA", "DISEASE", 83, 85], ["mavrilimumab", "CHEMICAL", 27, 39], ["mavrilimumab", "SIMPLE_CHEMICAL", 27, 39], ["mavrilimumab", "TREATMENT", 27, 39], ["rheumatoid arthritis", "PROBLEM", 61, 81], ["rheumatoid", "OBSERVATION_MODIFIER", 61, 71], ["arthritis", "OBSERVATION", 72, 81]]], ["In a phase 2b multicenter placebo-controlled study, patients with moderate-to-severe RA were randomized to receive different dose levels of mavrilimumab (30, 100, and 150 mg subcutaneously every 2 weeks) or placebo.", [["RA", "DISEASE", 85, 87], ["mavrilimumab", "CHEMICAL", 140, 152], ["mavrilimumab", "CHEMICAL", 140, 152], ["patients", "ORGANISM", 52, 60], ["mavrilimumab", "SIMPLE_CHEMICAL", 140, 152], ["patients", "SPECIES", 52, 60], ["controlled study", "TEST", 34, 50], ["moderate-to-severe RA", "PROBLEM", 66, 87], ["different dose levels", "TREATMENT", 115, 136], ["mavrilimumab", "TREATMENT", 140, 152], ["placebo", "TREATMENT", 207, 214], ["moderate", "OBSERVATION_MODIFIER", 66, 74], ["RA", "ANATOMY", 85, 87]]], ["Mavrilimumab at a dose of 150 mg subcutaneously every 2 weeks was the most effective in improving clinical and laboratory disease activity (70).", [["Mavrilimumab", "CHEMICAL", 0, 12], ["Mavrilimumab", "CHEMICAL", 0, 12], ["Mavrilimumab", "SIMPLE_CHEMICAL", 0, 12], ["Mavrilimumab", "TREATMENT", 0, 12]]], ["No substantial differences in adverse events or severe adverse events were observed between groups (70).", [["adverse events", "PROBLEM", 30, 44], ["severe adverse events", "PROBLEM", 48, 69], ["substantial", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["severe", "OBSERVATION_MODIFIER", 48, 54]]], ["These results on safety and efficacy were confirmed in a phase 2 double-blind randomized trial evaluating the use of mavrilimumab at a dose of 100 mg subcutaneously every other week in long-standing RA patients (71).", [["mavrilimumab", "CHEMICAL", 117, 129], ["RA", "DISEASE", 199, 201], ["mavrilimumab", "CHEMICAL", 117, 129], ["mavrilimumab", "SIMPLE_CHEMICAL", 117, 129], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["mavrilimumab", "TREATMENT", 117, 129]]], ["A post-hoc analysis of these studies has shown that the administration of mavrilimumab was associated with a significant downregulation of the macrophage-derived chemokine C-C motif chemokine ligand 22 (CCL22) and IL-6 (72), related to a direct inhibition of the proinflammatory cytokine release from myeloid cells.", [["myeloid cells", "ANATOMY", 301, 314], ["mavrilimumab", "CHEMICAL", 74, 86], ["mavrilimumab", "CHEMICAL", 74, 86], ["mavrilimumab", "SIMPLE_CHEMICAL", 74, 86], ["macrophage", "CELL", 143, 153], ["C-C motif chemokine ligand 22", "GENE_OR_GENE_PRODUCT", 172, 201], ["CCL22", "GENE_OR_GENE_PRODUCT", 203, 208], ["IL-6", "GENE_OR_GENE_PRODUCT", 214, 218], ["myeloid cells", "CELL", 301, 314], ["chemokine C-C motif chemokine ligand 22", "PROTEIN", 162, 201], ["CCL22", "PROTEIN", 203, 208], ["proinflammatory cytokine", "PROTEIN", 263, 287], ["myeloid cells", "CELL_TYPE", 301, 314], ["A post-hoc analysis", "TEST", 0, 19], ["these studies", "TEST", 23, 36], ["mavrilimumab", "TREATMENT", 74, 86], ["the macrophage", "TEST", 139, 153], ["chemokine C", "TEST", 162, 173], ["motif chemokine ligand", "TEST", 176, 198], ["CCL22", "TEST", 203, 208], ["IL", "TEST", 214, 216], ["the proinflammatory cytokine release", "TREATMENT", 259, 295], ["myeloid cells", "PROBLEM", 301, 314], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["downregulation", "OBSERVATION", 121, 135], ["macrophage", "ANATOMY", 143, 153], ["proinflammatory cytokine", "OBSERVATION", 263, 287], ["myeloid cells", "OBSERVATION", 301, 314]]], ["Mavrilimumab also showed a decreased expression of IL-22/IL-17-associated transcripts, the latter suggesting an indirect suppressive effect of mavrilimumab on T cell activation (72).", [["T cell", "ANATOMY", 159, 165], ["Mavrilimumab", "CHEMICAL", 0, 12], ["mavrilimumab", "CHEMICAL", 143, 155], ["Mavrilimumab", "CHEMICAL", 0, 12], ["mavrilimumab", "CHEMICAL", 143, 155], ["Mavrilimumab", "SIMPLE_CHEMICAL", 0, 12], ["IL-22", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-17", "GENE_OR_GENE_PRODUCT", 57, 62], ["mavrilimumab", "SIMPLE_CHEMICAL", 143, 155], ["T cell", "CELL", 159, 165], ["IL", "TEST", 51, 53], ["mavrilimumab on T cell activation", "TREATMENT", 143, 176], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["expression", "OBSERVATION_MODIFIER", 37, 47], ["suppressive effect", "OBSERVATION", 121, 139]]], ["Moreover, a sustained suppression of serum markers of disease activity, such as C-reactive protein and IL-6, was observed in RA patients treated with mavrilimumab (73).", [["serum", "ANATOMY", 37, 42], ["RA", "DISEASE", 125, 127], ["mavrilimumab", "CHEMICAL", 150, 162], ["mavrilimumab", "CHEMICAL", 150, 162], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 80, 98], ["IL-6", "GENE_OR_GENE_PRODUCT", 103, 107], ["patients", "ORGANISM", 128, 136], ["mavrilimumab", "SIMPLE_CHEMICAL", 150, 162], ["serum markers", "PROTEIN", 37, 50], ["C-reactive protein", "PROTEIN", 80, 98], ["IL-6", "PROTEIN", 103, 107], ["patients", "SPECIES", 128, 136], ["a sustained suppression of serum markers of disease activity", "PROBLEM", 10, 70], ["C-reactive protein", "TEST", 80, 98], ["IL", "TEST", 103, 105], ["mavrilimumab", "TREATMENT", 150, 162], ["RA", "ANATOMY", 125, 127]]], ["Mavrilimumab is currently under investigation for the treatment of giant cell arteritis (NCT03827018).Inhibition of GM-CSF Signaling in COVID-19 PneumoniaA prospective interventional single-center cohort study tested the efficacy and safety of mavrilimumab in patients with severe COVID-19 pneumonia and evidence of hyperinflammation in Italy (74).", [["giant cell", "ANATOMY", 67, 77], ["Mavrilimumab", "CHEMICAL", 0, 12], ["giant cell arteritis", "DISEASE", 67, 87], ["GM", "CHEMICAL", 116, 118], ["mavrilimumab", "CHEMICAL", 244, 256], ["COVID", "DISEASE", 281, 286], ["pneumonia", "DISEASE", 290, 299], ["hyperinflammation", "DISEASE", 316, 333], ["Mavrilimumab", "CHEMICAL", 0, 12], ["mavrilimumab", "CHEMICAL", 244, 256], ["Mavrilimumab", "SIMPLE_CHEMICAL", 0, 12], ["giant cell", "CELL", 67, 77], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 116, 122], ["mavrilimumab", "SIMPLE_CHEMICAL", 244, 256], ["patients", "ORGANISM", 260, 268], ["CSF", "PROTEIN", 119, 122], ["patients", "SPECIES", 260, 268], ["Mavrilimumab", "TREATMENT", 0, 12], ["giant cell arteritis", "PROBLEM", 67, 87], ["COVID", "TEST", 136, 141], ["cohort study", "TEST", 197, 209], ["mavrilimumab", "TREATMENT", 244, 256], ["severe COVID", "PROBLEM", 274, 286], ["pneumonia", "PROBLEM", 290, 299], ["hyperinflammation", "PROBLEM", 316, 333], ["giant cell arteritis", "OBSERVATION", 67, 87], ["severe", "OBSERVATION_MODIFIER", 274, 280], ["pneumonia", "OBSERVATION", 290, 299], ["evidence of", "UNCERTAINTY", 304, 315], ["hyperinflammation", "OBSERVATION", 316, 333]]], ["Thirteen non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation were treated with a single intravenous dose of mavrilimumab 6 mg/kg upon admission to the hospital.", [["intravenous", "ANATOMY", 126, 137], ["COVID", "DISEASE", 58, 63], ["pneumonia", "DISEASE", 67, 76], ["hyperinflammation", "DISEASE", 81, 98], ["mavrilimumab", "CHEMICAL", 146, 158], ["mavrilimumab", "CHEMICAL", 146, 158], ["patients", "ORGANISM", 37, 45], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 137], ["mavrilimumab", "SIMPLE_CHEMICAL", 146, 158], ["patients", "SPECIES", 37, 45], ["severe COVID", "PROBLEM", 51, 63], ["pneumonia", "PROBLEM", 67, 76], ["hyperinflammation", "PROBLEM", 81, 98], ["a single intravenous dose of mavrilimumab", "TREATMENT", 117, 158], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["pneumonia", "OBSERVATION", 67, 76]]], ["Twenty-six non-mechanically ventilated patients with severe COVID-19 pneumonia and hyperinflammation and with similar baseline characteristics were evaluated as a control-group.", [["COVID", "DISEASE", 60, 65], ["pneumonia", "DISEASE", 69, 78], ["hyperinflammation", "DISEASE", 83, 100], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["severe COVID", "PROBLEM", 53, 65], ["pneumonia", "PROBLEM", 69, 78], ["hyperinflammation", "PROBLEM", 83, 100], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["pneumonia", "OBSERVATION", 69, 78]]], ["All patients received similar standard of care therapy, including antivirals and antibiotics.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["care therapy", "TREATMENT", 42, 54], ["antivirals", "TREATMENT", 66, 76], ["antibiotics", "TREATMENT", 81, 92]]], ["Over the course of the 28-day follow-up period, mavrilimumab-treated patients experienced earlier and improved clinical outcomes than control-group patients, including earlier weaning from supplemental oxygen and shorter hospitalizations.", [["mavrilimumab", "CHEMICAL", 48, 60], ["oxygen", "CHEMICAL", 202, 208], ["mavrilimumab", "CHEMICAL", 48, 60], ["oxygen", "CHEMICAL", 202, 208], ["mavrilimumab", "SIMPLE_CHEMICAL", 48, 60], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 148, 156], ["oxygen", "SIMPLE_CHEMICAL", 202, 208], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 148, 156], ["mavrilimumab", "TREATMENT", 48, 60], ["earlier weaning", "TREATMENT", 168, 183], ["supplemental oxygen", "TREATMENT", 189, 208]]], ["Death occurred in 0% (n = 0/13) of mavrilimumab-treated patients by day 28 compared to 27% (n = 7/26) of control-group patients (74).", [["Death", "DISEASE", 0, 5], ["mavrilimumab", "CHEMICAL", 35, 47], ["mavrilimumab", "CHEMICAL", 35, 47], ["mavrilimumab", "SIMPLE_CHEMICAL", 35, 47], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 119, 127], ["Death", "PROBLEM", 0, 5], ["mavrilimumab", "TREATMENT", 35, 47]]], ["These data are consistent with the hypothesis that excessive host immune response driven by T cells and monocytes may have a central role in the pathogenesis of COVID-19 pneumonia.", [["T cells", "ANATOMY", 92, 99], ["monocytes", "ANATOMY", 104, 113], ["pneumonia", "DISEASE", 170, 179], ["T cells", "CELL", 92, 99], ["monocytes", "CELL", 104, 113], ["COVID-19", "ORGANISM", 161, 169], ["T cells", "CELL_TYPE", 92, 99], ["monocytes", "CELL_TYPE", 104, 113], ["These data", "TEST", 0, 10], ["the hypothesis", "PROBLEM", 31, 45], ["excessive host immune response", "PROBLEM", 51, 81], ["COVID", "TEST", 161, 166], ["pneumonia", "PROBLEM", 170, 179], ["consistent with", "UNCERTAINTY", 15, 30], ["central", "OBSERVATION_MODIFIER", 125, 132], ["pneumonia", "OBSERVATION", 170, 179]]], ["A randomized controlled trial is being designed and is now active (Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation [COMBAT-19], NCT04397497).Inhibition of GM-CSF Signaling in COVID-19 PneumoniaFive monoclonal antibodies targeting GM-CSF (gimsilumab, otilimab, namilumab, lenzilumab, and TJ003234) are in development and are currently under investigation mainly for the treatment of RA.", [["Pneumonia", "DISEASE", 99, 108], ["Hyper-inflammation", "DISEASE", 113, 131], ["GM", "CHEMICAL", 172, 174], ["GM", "CHEMICAL", 247, 249], ["gimsilumab", "CHEMICAL", 255, 265], ["otilimab", "CHEMICAL", 267, 275], ["namilumab", "CHEMICAL", 277, 286], ["lenzilumab", "CHEMICAL", 288, 298], ["TJ003234", "CHEMICAL", 304, 312], ["RA", "DISEASE", 399, 401], ["gimsilumab", "CHEMICAL", 255, 265], ["otilimab", "CHEMICAL", 267, 275], ["namilumab", "CHEMICAL", 277, 286], ["lenzilumab", "CHEMICAL", 288, 298], ["TJ003234", "CHEMICAL", 304, 312], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 172, 178], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 247, 253], ["gimsilumab", "SIMPLE_CHEMICAL", 255, 265], ["otilimab", "SIMPLE_CHEMICAL", 267, 275], ["namilumab", "SIMPLE_CHEMICAL", 277, 286], ["lenzilumab", "SIMPLE_CHEMICAL", 288, 298], ["TJ003234", "SIMPLE_CHEMICAL", 304, 312], ["GM", "PROTEIN", 172, 174], ["CSF", "PROTEIN", 175, 178], ["COVID-19 PneumoniaFive monoclonal antibodies", "PROTEIN", 192, 236], ["A randomized controlled trial", "TREATMENT", 0, 29], ["Mavrilimumab", "TEST", 67, 79], ["Severe COVID", "PROBLEM", 83, 95], ["Pneumonia", "PROBLEM", 99, 108], ["Hyper-inflammation", "PROBLEM", 113, 131], ["GM", "TEST", 172, 174], ["CSF Signaling", "TEST", 175, 188], ["COVID", "TEST", 192, 197], ["PneumoniaFive monoclonal antibodies", "TEST", 201, 236], ["GM", "TEST", 247, 249], ["CSF", "TEST", 250, 253], ["gimsilumab", "TEST", 255, 265], ["otilimab", "TEST", 267, 275], ["namilumab", "TEST", 277, 286], ["lenzilumab", "TEST", 288, 298], ["the treatment of RA", "TREATMENT", 382, 401], ["active", "OBSERVATION_MODIFIER", 59, 65], ["Severe", "OBSERVATION_MODIFIER", 83, 89], ["Pneumonia", "OBSERVATION", 99, 108], ["RA", "ANATOMY", 399, 401]]], ["Recently, TJ003234 (also known as TJM2) obtained the US Food and Drug Administration (FDA) clearance to start a clinical study for COVID-19 associated CRS (I-Mab)1.", [["TJ003234", "CHEMICAL", 10, 18], ["CRS", "DISEASE", 151, 154], ["TJ003234", "CHEMICAL", 10, 18], ["TJ003234", "SIMPLE_CHEMICAL", 10, 18], ["a clinical study", "TEST", 110, 126], ["COVID", "TEST", 131, 136]]], ["Additionally, lenzilumab has received FDA approval for compassionate use in COVID-19 patients (FDA)2, while a phase 3 study is ongoing.", [["lenzilumab", "CHEMICAL", 14, 24], ["lenzilumab", "CHEMICAL", 14, 24], ["lenzilumab", "SIMPLE_CHEMICAL", 14, 24], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["a phase 3 study", "TEST", 108, 123]]], ["A clinical trial has also been approved for gimsilumab for the treatment of COVID-19 and is now enrolling patients in the US (NCT04351243) (Figure 1C).", [["gimsilumab", "CHEMICAL", 44, 54], ["COVID-19", "CHEMICAL", 76, 84], ["gimsilumab", "CHEMICAL", 44, 54], ["gimsilumab", "SIMPLE_CHEMICAL", 44, 54], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["gimsilumab", "TREATMENT", 44, 54], ["COVID", "TEST", 76, 81], ["the US", "TEST", 118, 124]]], ["In addition, CSL311 is a monoclonal antibody targeting the GM-CSF-R\u03b2, common to GM-CSF, IL-3, and IL-5.", [["CSL311", "CHEMICAL", 13, 19], ["CSL311", "CHEMICAL", 13, 19], ["CSL311", "SIMPLE_CHEMICAL", 13, 19], ["GM-CSF-R\u03b2", "GENE_OR_GENE_PRODUCT", 59, 68], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 80, 86], ["IL-3", "GENE_OR_GENE_PRODUCT", 88, 92], ["IL-5", "GENE_OR_GENE_PRODUCT", 98, 102], ["CSL311", "PROTEIN", 13, 19], ["monoclonal antibody", "PROTEIN", 25, 44], ["GM", "PROTEIN", 59, 61], ["CSF", "PROTEIN", 62, 65], ["R\u03b2", "PROTEIN", 66, 68], ["GM", "PROTEIN", 80, 82], ["CSF", "PROTEIN", 83, 86], ["IL", "PROTEIN", 98, 100], ["CSL311", "TEST", 13, 19], ["a monoclonal antibody", "TEST", 23, 44], ["the GM", "TEST", 55, 61], ["CSF", "TEST", 62, 65], ["GM", "TEST", 80, 82], ["CSF", "TEST", 83, 86], ["IL", "TEST", 88, 90], ["IL", "TEST", 98, 100], ["CSF", "ANATOMY", 83, 86]]], ["A phase 1 trial is evaluating the safety and tolerability of this drug in patients with asthma (Table 1).Inhibition of GM-CSF Signaling in COVID-19 PneumoniaBecause GM-CSF is a key mediator in pulmonary homeostasis, there is the theoretical concern that inhibition of GM-CSF signaling by either binding to GM-CSF or blocking the receptor may result in dysfunctional AMs, leading to PAP and development of new infections.", [["pulmonary", "ANATOMY", 193, 202], ["AMs", "ANATOMY", 366, 369], ["asthma", "DISEASE", 88, 94], ["GM", "CHEMICAL", 119, 121], ["GM", "CHEMICAL", 165, 167], ["GM", "CHEMICAL", 268, 270], ["GM", "CHEMICAL", 306, 308], ["infections", "DISEASE", 409, 419], ["patients", "ORGANISM", 74, 82], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 119, 125], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 165, 171], ["pulmonary", "ORGAN", 193, 202], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 268, 274], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 306, 312], ["AMs", "CELL", 366, 369], ["PAP", "GENE_OR_GENE_PRODUCT", 382, 385], ["GM", "PROTEIN", 119, 121], ["CSF", "PROTEIN", 122, 125], ["CSF", "PROTEIN", 168, 171], ["CSF", "PROTEIN", 271, 274], ["GM", "PROTEIN", 306, 308], ["CSF", "PROTEIN", 309, 312], ["AMs", "CELL_TYPE", 366, 369], ["patients", "SPECIES", 74, 82], ["this drug", "TREATMENT", 61, 70], ["asthma", "PROBLEM", 88, 94], ["GM", "TEST", 119, 121], ["CSF Signaling", "TEST", 122, 135], ["COVID", "TEST", 139, 144], ["CSF signaling", "TEST", 271, 284], ["GM", "TEST", 306, 308], ["CSF", "PROBLEM", 309, 312], ["dysfunctional AMs", "PROBLEM", 352, 369], ["PAP", "TEST", 382, 385], ["new infections", "PROBLEM", 405, 419], ["pulmonary", "ANATOMY", 193, 202], ["homeostasis", "OBSERVATION", 203, 214], ["new", "OBSERVATION_MODIFIER", 405, 408], ["infections", "OBSERVATION", 409, 419]]], ["Fortunately, there has yet to be a case of PAP reported with the use of anti-GM-CSF monoclonal antibodies.", [["PAP", "GENE_OR_GENE_PRODUCT", 43, 46], ["anti-GM-CSF", "GENE_OR_GENE_PRODUCT", 72, 83], ["PAP", "PROTEIN", 43, 46], ["anti-GM", "PROTEIN", 72, 79], ["CSF monoclonal antibodies", "PROTEIN", 80, 105], ["PAP", "TEST", 43, 46], ["anti-GM", "TREATMENT", 72, 79], ["CSF monoclonal antibodies", "TEST", 80, 105], ["monoclonal antibodies", "OBSERVATION", 84, 105]]], ["This may be due to the fact that patients with autoimmune PAP have to reach a \u201ccritical threshold\u201d of neutralizing antibodies to develop the disease, and the doses currently being utilized in clinical trials may not reach this threshold (79).", [["patients", "ORGANISM", 33, 41], ["PAP", "GENE_OR_GENE_PRODUCT", 58, 61], ["neutralizing antibodies", "PROTEIN", 102, 125], ["patients", "SPECIES", 33, 41], ["autoimmune PAP", "PROBLEM", 47, 61], ["neutralizing antibodies", "PROBLEM", 102, 125], ["the disease", "PROBLEM", 137, 148], ["may be due to", "UNCERTAINTY", 5, 18], ["disease", "OBSERVATION", 141, 148]]], ["This may actually be true for the chronic use where the low level of lung penetration of the 100\u2013150 mg subcutaneously every 2 weeks may not provide the level of necessary inhibition (80).", [["lung", "ANATOMY", 69, 73], ["subcutaneously", "ANATOMY", 104, 118], ["lung", "ORGAN", 69, 73], ["lung penetration of the", "TREATMENT", 69, 92], ["may actually be", "UNCERTAINTY", 5, 20], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["lung", "ANATOMY", 69, 73]]], ["However, in the case of COVID-19 pneumonia and hyperinflammation, the lung penetration of the drug may be critical.", [["lung", "ANATOMY", 70, 74], ["pneumonia", "DISEASE", 33, 42], ["hyperinflammation", "DISEASE", 47, 64], ["lung", "ORGAN", 70, 74], ["COVID-19 pneumonia", "PROBLEM", 24, 42], ["hyperinflammation", "PROBLEM", 47, 64], ["the lung penetration", "PROBLEM", 66, 86], ["pneumonia", "OBSERVATION", 33, 42], ["lung", "ANATOMY", 70, 74], ["penetration", "OBSERVATION_MODIFIER", 75, 86]]], ["This is the reason why the dose has been increased from 1.5\u20132 mg/kg subcutaneously to 6\u201310 mg/kg intravenously.", [["subcutaneously", "ANATOMY", 68, 82]]], ["This means that PAP should not necessarily be an issue in the COVID-19 treatment in that a single intravenous dose is being given and it will wear off in a month, while PAP is a disease caused by chronic inhibition over years.ConclusionsAs COVID-19 pneumonia is likely to be aggravated by a cytokine storm, immunomodulation gained importance as a possible therapeutic strategy to this disease.", [["intravenous", "ANATOMY", 98, 109], ["pneumonia", "DISEASE", 249, 258], ["COVID-19", "CHEMICAL", 62, 70], ["PAP", "GENE_OR_GENE_PRODUCT", 16, 19], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 109], ["PAP", "GENE_OR_GENE_PRODUCT", 169, 172], ["COVID-19", "ORGANISM", 240, 248], ["cytokine", "PROTEIN", 291, 299], ["PAP", "TEST", 16, 19], ["the COVID-19 treatment", "TREATMENT", 58, 80], ["a single intravenous dose", "TREATMENT", 89, 114], ["a disease", "PROBLEM", 176, 185], ["COVID", "TEST", 240, 245], ["pneumonia", "PROBLEM", 249, 258], ["a cytokine storm", "TREATMENT", 289, 305], ["this disease", "PROBLEM", 380, 392], ["should not necessarily be", "UNCERTAINTY", 20, 45], ["chronic", "OBSERVATION_MODIFIER", 196, 203], ["pneumonia", "OBSERVATION", 249, 258], ["likely to be", "UNCERTAINTY", 262, 274], ["cytokine storm", "OBSERVATION", 291, 305]]], ["A wealth of IL-6 and IL-1 blockade trials are ongoing and results are awaited.", [["IL-6", "GENE_OR_GENE_PRODUCT", 12, 16], ["IL-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["A wealth of IL", "TREATMENT", 0, 14], ["IL-1 blockade trials", "TREATMENT", 21, 41]]], ["However, an approach targeting hyperinflammation upstream of IL-1 and IL-6 as well as neutrophils and macrophages may be envisioned through GM-CSF signaling.", [["neutrophils", "ANATOMY", 86, 97], ["macrophages", "ANATOMY", 102, 113], ["GM", "CHEMICAL", 140, 142], ["IL-1", "GENE_OR_GENE_PRODUCT", 61, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 70, 74], ["neutrophils", "CELL", 86, 97], ["macrophages", "CELL", 102, 113], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 140, 146], ["IL-1 and IL-6", "PROTEIN", 61, 74], ["neutrophils", "CELL_TYPE", 86, 97], ["macrophages", "CELL_TYPE", 102, 113], ["CSF", "PROTEIN", 143, 146], ["an approach", "TEST", 9, 20], ["IL", "TEST", 61, 63], ["neutrophils", "TEST", 86, 97], ["macrophages", "TREATMENT", 102, 113]]], ["GM-CSF is an immunomodulatory cytokine that may help to clear respiratory microbes by stimulating AMs.", [["respiratory microbes", "ANATOMY", 62, 82], ["AMs", "ANATOMY", 98, 101], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["AMs", "CELL", 98, 101], ["GM", "PROTEIN", 0, 2], ["CSF", "PROTEIN", 3, 6], ["immunomodulatory cytokine", "PROTEIN", 13, 38], ["AMs", "CELL_TYPE", 98, 101], ["an immunomodulatory cytokine", "TREATMENT", 10, 38], ["CSF", "OBSERVATION", 3, 6]]], ["A clinical trial with a hrGM-CSF, sargramostim, will be conducted in COVID-19 patients with the rationale that it may help clear the SARS-CoV-2 earlier in the disease course.", [["SARS", "DISEASE", 133, 137], ["hrGM-CSF", "GENE_OR_GENE_PRODUCT", 24, 32], ["sargramostim", "SIMPLE_CHEMICAL", 34, 46], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["a hrGM", "TEST", 22, 28], ["the SARS", "PROBLEM", 129, 137], ["CoV", "TEST", 138, 141]]], ["However, in the later phase of COVID-19 lung injury, the marked elevation in GM-CSF levels as part of the cytokine storm during the onset of COVID-19 pneumonia suggests that GM-CSF may actually be deleterious at this stage of the disease.", [["lung", "ANATOMY", 40, 44], ["lung injury", "DISEASE", 40, 51], ["GM", "CHEMICAL", 77, 79], ["pneumonia", "DISEASE", 150, 159], ["GM", "CHEMICAL", 174, 176], ["lung", "ORGAN", 40, 44], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 77, 83], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 174, 180], ["GM", "PROTEIN", 77, 79], ["CSF", "PROTEIN", 80, 83], ["cytokine", "PROTEIN", 106, 114], ["COVID", "TEST", 31, 36], ["lung injury", "PROBLEM", 40, 51], ["the marked elevation", "PROBLEM", 53, 73], ["GM-CSF levels", "TEST", 77, 90], ["the cytokine storm", "PROBLEM", 102, 120], ["COVID", "TEST", 141, 146], ["pneumonia", "PROBLEM", 150, 159], ["GM-CSF", "PROBLEM", 174, 180], ["the disease", "PROBLEM", 226, 237], ["lung", "ANATOMY", 40, 44], ["injury", "OBSERVATION", 45, 51], ["marked", "OBSERVATION_MODIFIER", 57, 63], ["elevation", "OBSERVATION_MODIFIER", 64, 73], ["pneumonia", "OBSERVATION", 150, 159], ["disease", "OBSERVATION", 230, 237]]], ["Blocking GM-CSF signaling could therefore be an effective therapeutic strategy by reducing the cytokine storm, which leads to the progression of acute respiratory failure in patients with hyperinflammation.", [["respiratory", "ANATOMY", 151, 162], ["GM", "CHEMICAL", 9, 11], ["acute respiratory failure", "DISEASE", 145, 170], ["hyperinflammation", "DISEASE", 188, 205], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 9, 15], ["patients", "ORGANISM", 174, 182], ["CSF", "PROTEIN", 12, 15], ["cytokine", "PROTEIN", 95, 103], ["patients", "SPECIES", 174, 182], ["CSF signaling", "TEST", 12, 25], ["the cytokine storm", "TREATMENT", 91, 109], ["acute respiratory failure", "PROBLEM", 145, 170], ["hyperinflammation", "PROBLEM", 188, 205], ["cytokine storm", "OBSERVATION", 95, 109], ["progression", "OBSERVATION_MODIFIER", 130, 141], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory failure", "OBSERVATION", 151, 170], ["hyperinflammation", "OBSERVATION", 188, 205]]], ["Multiple clinical trials with inhibition of the GM-CSF pathway are either ongoing or under development.Author ContributionsAB, AV, and AA conceived the manuscript.", [["GM", "CHEMICAL", 48, 50], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 48, 54], ["CSF", "PROTEIN", 51, 54], ["the GM-CSF pathway", "TEST", 44, 62], ["AV", "ANATOMY", 127, 129]]], ["AB and AV drafted manuscript, figure, and tables.", [["AV", "ANATOMY", 7, 9]]], ["TW, EL, PC, BC, PR, KH, LK, BV, LD, and AA critically revised the manuscript.", [["BV", "ORGANISM_SUBSTANCE", 28, 30], ["TW", "TEST", 0, 2], ["EL", "TEST", 4, 6], ["PC", "TEST", 8, 10], ["BC", "TEST", 12, 14], ["PR", "TEST", 16, 18]]], ["All authors approved the final version.Conflict of InterestAB and AV received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 AHA Scientific Sessions (Philadelphia, PA, USA).", [["InterestAB", "TREATMENT", 51, 61], ["AV", "ANATOMY", 66, 68]]], ["TW was on a research advisory board for GSK.", [["GSK", "GENE_OR_GENE_PRODUCT", 40, 43], ["GSK", "PROTEIN", 40, 43]]], ["PC was on a scientific advisory board for Kiniksa Pharmaceuticals.", [["Kiniksa Pharmaceuticals", "TREATMENT", 42, 65]]], ["AA has served as a consultant to Kiniksa Pharmaceuticals Ltd.", [["AA", "CHEMICAL", 0, 2]]]]}